{
  "usdmVersion": "4.0",
  "generatedAt": "2026-01-23T03:53:18.863196",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "5ca8b349-7e57-4685-a80c-c599080085de",
    "instanceType": "Study",
    "versions": [
      {
        "id": "b2a61ddd-b82d-46b2-acf4-c98c1e4a6b85",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "08f96419-2723-4df1-9ea0-26f316bba1df",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "b118595e-1c82-4da4-83aa-3b23d4e27ca3",
              "standardCode": {
                "id": "0c8058ae-7102-49ec-b989-3a77f6e4f7dc",
                "code": "Open Label",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Open Label",
                "instanceType": "Code"
              },
              "instanceType": "AliasCode"
            },
            "randomizationType": {
              "code": "Randomized"
            },
            "arms": [
              {
                "id": "7f62ad37-b5a6-4608-b0c2-5d18d98be4a9",
                "name": "Arm A",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Atezolizumab 1200 mg IV infusion every 3 weeks (Q3W) and bevacizumab 15 mg/kg IV Q3W",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "a094b817-6f83-4965-a924-aeca1af62823",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              },
              {
                "id": "a8971b5e-ae01-4974-b52e-5191458147f0",
                "name": "Arm B",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Sorafenib 400 mg by mouth, twice a day (BID), continuously",
                "type": {
                  "id": "C174267",
                  "code": "C174267",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.12e",
                  "decode": "Active Comparator Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "3b37ad4f-9a64-4efc-bf47-0680f89a8692",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              }
            ],
            "studyCohorts": [
              {
                "id": "41c60cb7-d61b-4882-b654-c71a19dd96a3",
                "name": "Global Enrollment Phase",
                "instanceType": "StudyCohort",
                "characteristic": "Approximately 480 patients enrolled globally"
              },
              {
                "id": "8ccc85bb-5f6e-4c62-b275-ec5c942ccdb1",
                "name": "China Subpopulation",
                "instanceType": "StudyCohort",
                "characteristic": "Approximately 135 patients from mainland China, including those from the global phase and an extended China enrollment phase"
              }
            ],
            "studyCells": [
              {
                "id": "3003d916-5d3e-432b-90c5-f4ab763ec336",
                "armId": "7f62ad37-b5a6-4608-b0c2-5d18d98be4a9",
                "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd",
                "elementIds": [
                  "6840d248-1d13-4ca5-a457-6182b723cc99"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "75d24477-0c11-48dd-8fd6-7ceba78603b8",
                "armId": "7f62ad37-b5a6-4608-b0c2-5d18d98be4a9",
                "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50",
                "elementIds": [
                  "a65748d2-c84d-42f4-9344-86a230ad1b48"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "90ffd067-c862-468f-b30d-a9b7b9e97754",
                "armId": "7f62ad37-b5a6-4608-b0c2-5d18d98be4a9",
                "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34",
                "elementIds": [
                  "552c53c4-7966-4dd3-9e70-0ad54cbfcf44"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "2c94bb91-77bf-4887-b34e-6b0eca2a6f40",
                "armId": "a8971b5e-ae01-4974-b52e-5191458147f0",
                "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd",
                "elementIds": [
                  "ceb520e3-80aa-4c0c-aabd-3fc431707b7b"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "5d6fe3ef-b67e-49ec-93fb-e0d39f447cb6",
                "armId": "a8971b5e-ae01-4974-b52e-5191458147f0",
                "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50",
                "elementIds": [
                  "15fd3419-47cf-4a47-aeab-5118231906c8"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "cb3fb094-8ad4-432b-b91e-51c442a18f5c",
                "armId": "a8971b5e-ae01-4974-b52e-5191458147f0",
                "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34",
                "elementIds": [
                  "be445090-e988-4df1-9ac8-e1c944d2accf"
                ],
                "instanceType": "StudyCell"
              }
            ],
            "studyElements": [
              {
                "id": "6840d248-1d13-4ca5-a457-6182b723cc99",
                "name": "Arm A - Screening",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm A during Screening"
              },
              {
                "id": "a65748d2-c84d-42f4-9344-86a230ad1b48",
                "name": "Arm A - Treatment Phase",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm A during Treatment Phase"
              },
              {
                "id": "552c53c4-7966-4dd3-9e70-0ad54cbfcf44",
                "name": "Arm A - Survival Follow-Up",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm A during Survival Follow-Up"
              },
              {
                "id": "ceb520e3-80aa-4c0c-aabd-3fc431707b7b",
                "name": "Arm B - Screening",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm B during Screening"
              },
              {
                "id": "15fd3419-47cf-4a47-aeab-5118231906c8",
                "name": "Arm B - Treatment Phase",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm B during Treatment Phase"
              },
              {
                "id": "be445090-e988-4df1-9ac8-e1c944d2accf",
                "name": "Arm B - Survival Follow-Up",
                "instanceType": "StudyElement",
                "description": "Treatment period for Arm B during Survival Follow-Up"
              }
            ],
            "maskingRoles": [
              {
                "id": "2dc32529-1cfe-4df4-9a81-52ff601c4c9e",
                "text": "This is an Open Label study with no masking",
                "isMasked": false,
                "instanceType": "Masking"
              }
            ],
            "eligibilityCriteria": [
              {
                "id": "d36ebd57-55ef-49d2-97da-aa15d7606aad",
                "identifier": "1",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "27e7cd76-87d5-4416-a9ff-f741aad44a90",
                "instanceType": "EligibilityCriterion",
                "name": "Informed Consent",
                "nextId": "b3037378-b276-4221-bf99-200009f35324"
              },
              {
                "id": "b3037378-b276-4221-bf99-200009f35324",
                "identifier": "2",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "88e5b1d2-8aa2-42c4-b720-3fc9b2439cde",
                "instanceType": "EligibilityCriterion",
                "name": "Age Requirement",
                "previousId": "d36ebd57-55ef-49d2-97da-aa15d7606aad",
                "nextId": "f8901415-4eb5-481b-a8c5-d5e27f203b0b"
              },
              {
                "id": "f8901415-4eb5-481b-a8c5-d5e27f203b0b",
                "identifier": "3",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ebc6e647-9746-4c9c-a366-7ebc11906b82",
                "instanceType": "EligibilityCriterion",
                "name": "Compliance",
                "previousId": "b3037378-b276-4221-bf99-200009f35324",
                "nextId": "afbba4df-51a9-46a5-a9e3-0755c2964f3d"
              },
              {
                "id": "afbba4df-51a9-46a5-a9e3-0755c2964f3d",
                "identifier": "4",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "6a76a9c7-c9cc-4324-9c7b-e9341b0d7aaa",
                "instanceType": "EligibilityCriterion",
                "name": "HCC Diagnosis",
                "previousId": "f8901415-4eb5-481b-a8c5-d5e27f203b0b",
                "nextId": "55fceb17-57ba-446a-9ba0-c80aa18986ed"
              },
              {
                "id": "55fceb17-57ba-446a-9ba0-c80aa18986ed",
                "identifier": "5",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "09813e2e-7edf-4b6f-8f90-c1b019f601f0",
                "instanceType": "EligibilityCriterion",
                "name": "Disease Status",
                "previousId": "afbba4df-51a9-46a5-a9e3-0755c2964f3d",
                "nextId": "46a98d5c-1864-4fdf-a9ee-e41b8aa006eb"
              },
              {
                "id": "46a98d5c-1864-4fdf-a9ee-e41b8aa006eb",
                "identifier": "6",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "cd6d42d9-58c0-4ba9-aa79-d8a9ae991c42",
                "instanceType": "EligibilityCriterion",
                "name": "Prior Systemic Therapy",
                "previousId": "55fceb17-57ba-446a-9ba0-c80aa18986ed",
                "nextId": "1fad6e9c-a878-4695-9178-bb2923a7004e"
              },
              {
                "id": "1fad6e9c-a878-4695-9178-bb2923a7004e",
                "identifier": "7",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "76742451-36a3-4893-9594-6bc67258a599",
                "instanceType": "EligibilityCriterion",
                "name": "Measurable Disease",
                "previousId": "46a98d5c-1864-4fdf-a9ee-e41b8aa006eb",
                "nextId": "5a27337e-0479-4119-80cb-4667033fbf96"
              },
              {
                "id": "5a27337e-0479-4119-80cb-4667033fbf96",
                "identifier": "8",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "f1598a54-96f9-4945-a003-4831591d5ff5",
                "instanceType": "EligibilityCriterion",
                "name": "Prior Local Therapy",
                "previousId": "1fad6e9c-a878-4695-9178-bb2923a7004e",
                "nextId": "8fba4ce5-d553-4964-9dbb-7187872f1103"
              },
              {
                "id": "8fba4ce5-d553-4964-9dbb-7187872f1103",
                "identifier": "9",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c3d7cbc6-1f73-4dbd-a499-2d1499fdd984",
                "instanceType": "EligibilityCriterion",
                "name": "Tumor Tissue",
                "previousId": "5a27337e-0479-4119-80cb-4667033fbf96",
                "nextId": "36eba5ba-e5ad-45a7-b683-795cdb49b31a"
              },
              {
                "id": "36eba5ba-e5ad-45a7-b683-795cdb49b31a",
                "identifier": "10",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "dda1358d-3424-4009-b758-4d2687bcb75a",
                "instanceType": "EligibilityCriterion",
                "name": "ECOG Performance Status",
                "previousId": "8fba4ce5-d553-4964-9dbb-7187872f1103",
                "nextId": "e6760125-26ae-4564-b7c8-a86816818fca"
              },
              {
                "id": "e6760125-26ae-4564-b7c8-a86816818fca",
                "identifier": "11",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "2d51ae4d-6057-41c2-a194-a2358810b3ab",
                "instanceType": "EligibilityCriterion",
                "name": "Child-Pugh Class",
                "previousId": "36eba5ba-e5ad-45a7-b683-795cdb49b31a",
                "nextId": "8befd73c-5623-42f1-8ac2-f8c741b4717d"
              },
              {
                "id": "8befd73c-5623-42f1-8ac2-f8c741b4717d",
                "identifier": "12",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "38aef12f-f0ea-42c5-93a9-61e8fd83bf5e",
                "instanceType": "EligibilityCriterion",
                "name": "Hematologic and End-organ Function",
                "previousId": "e6760125-26ae-4564-b7c8-a86816818fca",
                "nextId": "34279899-3dc9-4a9a-bd53-9082930ea543"
              },
              {
                "id": "34279899-3dc9-4a9a-bd53-9082930ea543",
                "identifier": "13",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "914cd7bd-5004-424f-a7b4-ff461b49e4e8",
                "instanceType": "EligibilityCriterion",
                "name": "Toxicity Resolution",
                "previousId": "8befd73c-5623-42f1-8ac2-f8c741b4717d",
                "nextId": "0ad807ae-e033-40a4-ba76-92f186375703"
              },
              {
                "id": "0ad807ae-e033-40a4-ba76-92f186375703",
                "identifier": "14",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "123669be-0a8c-4fa1-92d0-e04ec7a9276a",
                "instanceType": "EligibilityCriterion",
                "name": "HIV Status",
                "previousId": "34279899-3dc9-4a9a-bd53-9082930ea543",
                "nextId": "546a5e6c-3dde-462b-ada4-b5e0d67995a8"
              },
              {
                "id": "546a5e6c-3dde-462b-ada4-b5e0d67995a8",
                "identifier": "15",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "3ffe45c5-a292-4f7c-9d81-89592fa34ee4",
                "instanceType": "EligibilityCriterion",
                "name": "Hepatitis Virology",
                "previousId": "0ad807ae-e033-40a4-ba76-92f186375703",
                "nextId": "ae45fa16-4f33-4d04-b891-469db11b6def"
              },
              {
                "id": "ae45fa16-4f33-4d04-b891-469db11b6def",
                "identifier": "16",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "683b5e04-8873-4b8f-87a1-34ae9d9c0c9e",
                "instanceType": "EligibilityCriterion",
                "name": "Active HBV Management",
                "previousId": "546a5e6c-3dde-462b-ada4-b5e0d67995a8",
                "nextId": "e92cea55-9a02-4376-95f6-2356b6ca4736"
              },
              {
                "id": "e92cea55-9a02-4376-95f6-2356b6ca4736",
                "identifier": "17",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "0cc2ee64-3655-47bc-8212-da6b640cd1d3",
                "instanceType": "EligibilityCriterion",
                "name": "Contraception - Women",
                "previousId": "ae45fa16-4f33-4d04-b891-469db11b6def",
                "nextId": "df279ad5-88ef-49c0-b155-73ff2f0195d8"
              },
              {
                "id": "df279ad5-88ef-49c0-b155-73ff2f0195d8",
                "identifier": "18",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "5eaf7e96-6728-478c-a36d-cebde93e244b",
                "instanceType": "EligibilityCriterion",
                "name": "Contraception - Men",
                "previousId": "e92cea55-9a02-4376-95f6-2356b6ca4736",
                "nextId": "6f3771d6-b936-48cd-8744-104d0eadf9f4"
              },
              {
                "id": "6f3771d6-b936-48cd-8744-104d0eadf9f4",
                "identifier": "19",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "6958a4ee-765c-44c3-bb38-01c8ca381fa6",
                "instanceType": "EligibilityCriterion",
                "name": "China Enrollment Phase",
                "previousId": "df279ad5-88ef-49c0-b155-73ff2f0195d8"
              },
              {
                "id": "cd8fb963-8a55-491c-b29a-a02d8e32516f",
                "identifier": "E1",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "3896273f-15b6-4b7c-8a31-b22f855950b6",
                "instanceType": "EligibilityCriterion",
                "name": "Leptomeningeal Disease",
                "nextId": "99abbbb0-297c-4cab-a3f2-f0178eedf4b2"
              },
              {
                "id": "99abbbb0-297c-4cab-a3f2-f0178eedf4b2",
                "identifier": "E2",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "41c260f1-dcc7-4f4f-bd1d-5afa8b2206c0",
                "instanceType": "EligibilityCriterion",
                "name": "Autoimmune Disease",
                "previousId": "cd8fb963-8a55-491c-b29a-a02d8e32516f",
                "nextId": "e744f22c-03e5-4cd2-85a6-52f7e951e520"
              },
              {
                "id": "e744f22c-03e5-4cd2-85a6-52f7e951e520",
                "identifier": "E3",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "7940ff64-ca19-4661-ba97-f19b38f17d55",
                "instanceType": "EligibilityCriterion",
                "name": "Pulmonary Conditions",
                "previousId": "99abbbb0-297c-4cab-a3f2-f0178eedf4b2",
                "nextId": "e16463a3-001b-419d-bc93-b9e3d9b70e6f"
              },
              {
                "id": "e16463a3-001b-419d-bc93-b9e3d9b70e6f",
                "identifier": "E4",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c34986ef-105d-4138-b689-86b6cf112fd5",
                "instanceType": "EligibilityCriterion",
                "name": "Active Tuberculosis",
                "previousId": "e744f22c-03e5-4cd2-85a6-52f7e951e520",
                "nextId": "6ca470e2-f05c-4c5f-bafc-26ad66818168"
              },
              {
                "id": "6ca470e2-f05c-4c5f-bafc-26ad66818168",
                "identifier": "E5",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "fd831336-84bd-43f1-9608-f8593c04d52b",
                "instanceType": "EligibilityCriterion",
                "name": "Cardiovascular Disease",
                "previousId": "e16463a3-001b-419d-bc93-b9e3d9b70e6f",
                "nextId": "ea119757-3e67-4773-a54d-d59e7be0e6ab"
              },
              {
                "id": "ea119757-3e67-4773-a54d-d59e7be0e6ab",
                "identifier": "E6",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "7e8f5c74-0700-4250-8e3c-6c0e481c03c3",
                "instanceType": "EligibilityCriterion",
                "name": "QT Interval",
                "previousId": "6ca470e2-f05c-4c5f-bafc-26ad66818168",
                "nextId": "5782d18f-26e0-4897-8047-07429df5024e"
              },
              {
                "id": "5782d18f-26e0-4897-8047-07429df5024e",
                "identifier": "E7",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "2e1fb6c8-7524-454f-9241-093d4d0dce61",
                "instanceType": "EligibilityCriterion",
                "name": "Electrolyte Disorder",
                "previousId": "ea119757-3e67-4773-a54d-d59e7be0e6ab",
                "nextId": "3b8d024e-0797-4c81-9795-d0808f86eebb"
              },
              {
                "id": "3b8d024e-0797-4c81-9795-d0808f86eebb",
                "identifier": "E8",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b421661a-2c6b-41d6-8e7b-10b3d4eef684",
                "instanceType": "EligibilityCriterion",
                "name": "Major Surgery",
                "previousId": "5782d18f-26e0-4897-8047-07429df5024e",
                "nextId": "c876a73d-e29f-4cd5-b192-141e25d91ae8"
              },
              {
                "id": "c876a73d-e29f-4cd5-b192-141e25d91ae8",
                "identifier": "E9",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a049e4ad-b6b1-4088-ba96-53d6aedb1978",
                "instanceType": "EligibilityCriterion",
                "name": "Other Malignancy",
                "previousId": "3b8d024e-0797-4c81-9795-d0808f86eebb",
                "nextId": "cf490d46-4a20-4b7c-97be-36a4e9a645e3"
              },
              {
                "id": "cf490d46-4a20-4b7c-97be-36a4e9a645e3",
                "identifier": "E10",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "9bb990f7-6299-48ec-9fdd-5fc03a07c6f0",
                "instanceType": "EligibilityCriterion",
                "name": "Severe Infection",
                "previousId": "c876a73d-e29f-4cd5-b192-141e25d91ae8",
                "nextId": "d1a9df84-5443-4d0b-90a3-0d7f077add9c"
              },
              {
                "id": "d1a9df84-5443-4d0b-90a3-0d7f077add9c",
                "identifier": "E11",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "f63cd517-49c4-4361-a9f8-bd101d8e0ff1",
                "instanceType": "EligibilityCriterion",
                "name": "Antibiotic Treatment",
                "previousId": "cf490d46-4a20-4b7c-97be-36a4e9a645e3",
                "nextId": "b5c64670-9705-49b2-9117-0b6de7767c62"
              },
              {
                "id": "b5c64670-9705-49b2-9117-0b6de7767c62",
                "identifier": "E12",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "54084945-ee57-472f-bc24-d15b29b708b8",
                "instanceType": "EligibilityCriterion",
                "name": "Transplantation",
                "previousId": "d1a9df84-5443-4d0b-90a3-0d7f077add9c",
                "nextId": "46a1d886-f67f-4e17-9426-f13506725806"
              },
              {
                "id": "46a1d886-f67f-4e17-9426-f13506725806",
                "identifier": "E13",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "bd7c6666-0439-4eaa-aa6b-2f12efa5eca2",
                "instanceType": "EligibilityCriterion",
                "name": "Other Contraindications",
                "previousId": "b5c64670-9705-49b2-9117-0b6de7767c62",
                "nextId": "1d14cb86-7e65-493e-bb1b-e87bfab306b6"
              },
              {
                "id": "1d14cb86-7e65-493e-bb1b-e87bfab306b6",
                "identifier": "E14",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "95abc6ee-7000-45d0-a077-87b5f1709220",
                "instanceType": "EligibilityCriterion",
                "name": "Live Vaccine",
                "previousId": "46a1d886-f67f-4e17-9426-f13506725806",
                "nextId": "91d3943d-33e9-4452-b8bc-030128913568"
              },
              {
                "id": "91d3943d-33e9-4452-b8bc-030128913568",
                "identifier": "E15",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "0b8b66c9-d85c-40e9-b9e3-57d78af35db5",
                "instanceType": "EligibilityCriterion",
                "name": "Anaphylactic Reactions",
                "previousId": "1d14cb86-7e65-493e-bb1b-e87bfab306b6",
                "nextId": "1d4aa846-486c-4e03-9e31-62e1d2f92d4c"
              },
              {
                "id": "1d4aa846-486c-4e03-9e31-62e1d2f92d4c",
                "identifier": "E16",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "df9a5c43-5160-48d0-a9e4-10bcb8809d8a",
                "instanceType": "EligibilityCriterion",
                "name": "Hypersensitivity",
                "previousId": "91d3943d-33e9-4452-b8bc-030128913568",
                "nextId": "cfa1e149-6e15-4446-b5cc-10df20b72a5d"
              },
              {
                "id": "cfa1e149-6e15-4446-b5cc-10df20b72a5d",
                "identifier": "E17",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "78c2180f-0bc0-47ea-8dca-4aee49411b91",
                "instanceType": "EligibilityCriterion",
                "name": "Pregnancy and Breastfeeding",
                "previousId": "1d4aa846-486c-4e03-9e31-62e1d2f92d4c",
                "nextId": "424d0aec-8260-4823-bda0-e3c5a71eb37e"
              },
              {
                "id": "424d0aec-8260-4823-bda0-e3c5a71eb37e",
                "identifier": "E18",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "7dec73d2-1a19-42c1-b97b-460cc98f7206",
                "instanceType": "EligibilityCriterion",
                "name": "Specific HCC Types",
                "previousId": "cfa1e149-6e15-4446-b5cc-10df20b72a5d",
                "nextId": "2ef71980-d771-4863-bf92-f006f0e4a057"
              },
              {
                "id": "2ef71980-d771-4863-bf92-f006f0e4a057",
                "identifier": "E19",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "f96e78ac-91c3-42c3-acc1-2f11cf23519c",
                "instanceType": "EligibilityCriterion",
                "name": "Varices",
                "previousId": "424d0aec-8260-4823-bda0-e3c5a71eb37e",
                "nextId": "e28ef5d0-8362-4626-9f6a-db44d2c84328"
              },
              {
                "id": "e28ef5d0-8362-4626-9f6a-db44d2c84328",
                "identifier": "E20",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1dc15812-dc82-4dc4-a929-e5feccec942e",
                "instanceType": "EligibilityCriterion",
                "name": "Prior Bleeding Event",
                "previousId": "2ef71980-d771-4863-bf92-f006f0e4a057",
                "nextId": "78681a72-ae60-437c-9b3e-23a05c042ad8"
              },
              {
                "id": "78681a72-ae60-437c-9b3e-23a05c042ad8",
                "identifier": "E21",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a5ae7fc0-27f0-488d-9eb5-f23f89f6ce60",
                "instanceType": "EligibilityCriterion",
                "name": "Ascites",
                "previousId": "e28ef5d0-8362-4626-9f6a-db44d2c84328",
                "nextId": "315d7410-101c-49d7-abb4-91dd4cf33091"
              },
              {
                "id": "315d7410-101c-49d7-abb4-91dd4cf33091",
                "identifier": "E22",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "578b4a62-41a4-499e-9aa1-bfaf46f17750",
                "instanceType": "EligibilityCriterion",
                "name": "Hepatic Encephalopathy",
                "previousId": "78681a72-ae60-437c-9b3e-23a05c042ad8",
                "nextId": "82f3e2f8-a0b3-49cf-8971-10575399add1"
              },
              {
                "id": "82f3e2f8-a0b3-49cf-8971-10575399add1",
                "identifier": "E23",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "31cf676d-ae1f-4478-825b-ffcc28dc1fbc",
                "instanceType": "EligibilityCriterion",
                "name": "HBV and HCV Coinfection",
                "previousId": "315d7410-101c-49d7-abb4-91dd4cf33091",
                "nextId": "f0edc852-614c-461b-b7f8-fc2db6e3b582"
              },
              {
                "id": "f0edc852-614c-461b-b7f8-fc2db6e3b582",
                "identifier": "E24",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "114c5965-4e50-4cf2-8637-9332aa48a5e8",
                "instanceType": "EligibilityCriterion",
                "name": "CNS Metastases",
                "previousId": "82f3e2f8-a0b3-49cf-8971-10575399add1",
                "nextId": "d6ba7a5d-3c44-456e-be3d-0a18d5b961b8"
              },
              {
                "id": "d6ba7a5d-3c44-456e-be3d-0a18d5b961b8",
                "identifier": "E25",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c0dee62f-9df1-403b-9a3a-d9d261d42e70",
                "instanceType": "EligibilityCriterion",
                "name": "Tumor-related Pain",
                "previousId": "f0edc852-614c-461b-b7f8-fc2db6e3b582"
              }
            ],
            "population": {
              "id": "498ad2e1-1125-418d-8f8a-c88ea6a91127",
              "name": "Study Population",
              "includesHealthySubjects": false,
              "criterionIds": [
                "d36ebd57-55ef-49d2-97da-aa15d7606aad",
                "b3037378-b276-4221-bf99-200009f35324",
                "f8901415-4eb5-481b-a8c5-d5e27f203b0b",
                "afbba4df-51a9-46a5-a9e3-0755c2964f3d",
                "55fceb17-57ba-446a-9ba0-c80aa18986ed",
                "46a98d5c-1864-4fdf-a9ee-e41b8aa006eb",
                "1fad6e9c-a878-4695-9178-bb2923a7004e",
                "5a27337e-0479-4119-80cb-4667033fbf96",
                "8fba4ce5-d553-4964-9dbb-7187872f1103",
                "36eba5ba-e5ad-45a7-b683-795cdb49b31a",
                "e6760125-26ae-4564-b7c8-a86816818fca",
                "8befd73c-5623-42f1-8ac2-f8c741b4717d",
                "34279899-3dc9-4a9a-bd53-9082930ea543",
                "0ad807ae-e033-40a4-ba76-92f186375703",
                "546a5e6c-3dde-462b-ada4-b5e0d67995a8",
                "ae45fa16-4f33-4d04-b891-469db11b6def",
                "e92cea55-9a02-4376-95f6-2356b6ca4736",
                "df279ad5-88ef-49c0-b155-73ff2f0195d8",
                "6f3771d6-b936-48cd-8744-104d0eadf9f4",
                "cd8fb963-8a55-491c-b29a-a02d8e32516f",
                "99abbbb0-297c-4cab-a3f2-f0178eedf4b2",
                "e744f22c-03e5-4cd2-85a6-52f7e951e520",
                "e16463a3-001b-419d-bc93-b9e3d9b70e6f",
                "6ca470e2-f05c-4c5f-bafc-26ad66818168",
                "ea119757-3e67-4773-a54d-d59e7be0e6ab",
                "5782d18f-26e0-4897-8047-07429df5024e",
                "3b8d024e-0797-4c81-9795-d0808f86eebb",
                "c876a73d-e29f-4cd5-b192-141e25d91ae8",
                "cf490d46-4a20-4b7c-97be-36a4e9a645e3",
                "d1a9df84-5443-4d0b-90a3-0d7f077add9c",
                "b5c64670-9705-49b2-9117-0b6de7767c62",
                "46a1d886-f67f-4e17-9426-f13506725806",
                "1d14cb86-7e65-493e-bb1b-e87bfab306b6",
                "91d3943d-33e9-4452-b8bc-030128913568",
                "1d4aa846-486c-4e03-9e31-62e1d2f92d4c",
                "cfa1e149-6e15-4446-b5cc-10df20b72a5d",
                "424d0aec-8260-4823-bda0-e3c5a71eb37e",
                "2ef71980-d771-4863-bf92-f006f0e4a057",
                "e28ef5d0-8362-4626-9f6a-db44d2c84328",
                "78681a72-ae60-437c-9b3e-23a05c042ad8",
                "315d7410-101c-49d7-abb4-91dd4cf33091",
                "82f3e2f8-a0b3-49cf-8971-10575399add1",
                "f0edc852-614c-461b-b7f8-fc2db6e3b582",
                "d6ba7a5d-3c44-456e-be3d-0a18d5b961b8"
              ],
              "instanceType": "StudyDesignPopulation",
              "description": "Target population defined by eligibility criteria"
            },
            "objectives": [
              {
                "id": "aa886d9f-3eac-408f-ba42-9f1185bbba0a",
                "name": "Primary Efficacy Objective",
                "text": "To evaluate the efficacy of atezolizumab in combination with bevacizumab compared with sorafenib on the basis of the co-primary efficacy endpoints of OS and IRF-assessed PFS according to RECIST v1.1.",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "1b47e68f-7105-4a35-becc-607aa619d2fc",
                  "b2f53daf-1070-4890-9231-4f496c304a6f"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "6c6816f7-7de4-40a8-aecb-60e0a70bbe0e",
                "name": "Secondary Efficacy Objective",
                "text": "Secondary Efficacy Endpoints",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "134df78b-f276-4dca-a744-b4325a1b394d"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "b18ddc24-dffb-494e-88c3-c548e24d8ea1",
                "name": "Safety Objective",
                "text": "Safety Analyses",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "2056fb9c-6408-4fd1-9e6a-2e3dd348e866"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "7ab5c33d-f5b1-471a-a45c-e5543e3d6e7a",
                "name": "Exploratory Efficacy Objective",
                "text": "Exploratory Efficacy Endpoints",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "ce43a917-e71a-466e-bffe-41c5f5114fa9"
                ],
                "instanceType": "Objective"
              }
            ],
            "endpoints": [
              {
                "id": "1b47e68f-7105-4a35-becc-607aa619d2fc",
                "name": "Overall Survival",
                "text": "Overall survival is defined as the time from the date of randomization to the date of death from any cause.",
                "level": {
                  "id": "C98772",
                  "code": "C98772",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "b2f53daf-1070-4890-9231-4f496c304a6f",
                "name": "IRF-Assessed Progression-Free Survival",
                "text": "Independent Review Facility-assessed PFS is defined as the time from randomization to the occurrence of disease progression as determined by the IRF according to RECIST v1.1, or death from any cause, whichever occurs first.",
                "level": {
                  "id": "C98772",
                  "code": "C98772",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "134df78b-f276-4dca-a744-b4325a1b394d",
                "name": "Secondary Efficacy Endpoints",
                "text": "Secondary Efficacy Endpoints (as listed in Section 6.4.2)",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "2056fb9c-6408-4fd1-9e6a-2e3dd348e866",
                "name": "Safety Endpoints",
                "text": "Safety Analyses (as listed in Section 6.5)",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "ce43a917-e71a-466e-bffe-41c5f5114fa9",
                "name": "Exploratory Efficacy Endpoints",
                "text": "Exploratory Efficacy Endpoints (as listed in Section 6.4.3)",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              }
            ],
            "estimands": [
              {
                "id": "1533949d-6f7b-44cc-b452-e78638ec5136",
                "name": "Primary Efficacy Estimand for Overall Survival",
                "populationSummary": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase) Summary measure: Hazard ratio (stratified).",
                "analysisPopulationId": "bcf298bf-0b32-4d00-a4d4-4bb704060e30",
                "variableOfInterestId": "1b47e68f-7105-4a35-becc-607aa619d2fc",
                "interventionIds": [
                  "56ffefee-1ad3-4d92-bbdc-7a10bb3bb841"
                ],
                "intercurrentEvents": [
                  {
                    "id": "156d9cc3-1bf7-4eed-aa7b-d5833cffc447",
                    "name": "Treatment discontinuation",
                    "text": "Discontinuation of study treatment due to toxicity or other reasons",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  },
                  {
                    "id": "6aac18bb-3771-4335-be18-a66dbc18c7cf",
                    "name": "Subsequent anti-cancer therapy",
                    "text": "Initiation of non-protocol anti-cancer therapies after progression",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Atezolizumab 1200 mg IV + Bevacizumab 15 mg/kg IV every 21 days vs Sorafenib 400 mg BID",
                "analysisPopulation": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase)",
                "variableOfInterest": "Time from randomization to death from any cause",
                "summaryMeasure": "Hazard ratio (stratified)"
              },
              {
                "id": "0b947a60-a5b0-4960-93b8-e46ba0ab024b",
                "name": "Primary Efficacy Estimand for Progression-Free Survival",
                "populationSummary": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase) Summary measure: Hazard ratio (stratified).",
                "analysisPopulationId": "587f119f-25d5-4e53-818f-7adb128ec2ce",
                "variableOfInterestId": "b2f53daf-1070-4890-9231-4f496c304a6f",
                "interventionIds": [
                  "0c95242c-d257-483e-8224-14250bb88caf"
                ],
                "intercurrentEvents": [
                  {
                    "id": "a8680630-c328-444a-a865-0ff14b2ebba5",
                    "name": "Treatment discontinuation",
                    "text": "Discontinuation of study treatment prior to progression",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  },
                  {
                    "id": "7ef01fef-5429-434b-8b39-15b6d7aeffc9",
                    "name": "Missing tumor assessments",
                    "text": "Patient has no post-baseline tumor assessments",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Atezolizumab 1200 mg IV + Bevacizumab 15 mg/kg IV every 21 days vs Sorafenib 400 mg BID",
                "analysisPopulation": "Adult patients with hepatocellular carcinoma meeting eligibility criteria (Global enrollment phase)",
                "variableOfInterest": "Time from randomization to IRF-assessed disease progression (RECIST v1.1) or death from any cause",
                "summaryMeasure": "Hazard ratio (stratified)"
              }
            ],
            "scheduleTimelines": [
              {
                "id": "67ef620e-236c-4715-810f-0a3b34120f76",
                "name": "Main Schedule Timeline",
                "mainTimeline": true,
                "instanceType": "ScheduleTimeline",
                "entryCondition": "Subject enrolled in study",
                "entryId": "7bf94b90-ea30-4217-acd8-c408b4b4e0fe",
                "instances": [
                  {
                    "id": "7bf94b90-ea30-4217-acd8-c408b4b4e0fe",
                    "activityIds": [
                      "95424f85-cacb-418c-a51f-405dd241e8be"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_1@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "14b719e7-4eae-470b-952f-7f3eb81d6203",
                    "activityIds": [
                      "1f86581c-8fca-4949-a962-2eee8dbd454b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "0465fb8c-f279-4a4b-97f2-634bb66c049d",
                    "activityIds": [
                      "08dbf4d9-7773-4dce-8dde-78683a3c8f87"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_3@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "ab18a351-0698-4f67-9c01-e380afd39f6f",
                    "activityIds": [
                      "25d75c60-587d-452d-aabf-0890d5992450"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "f2f5ce28-b743-4868-a01d-d0049ea0a38a",
                    "activityIds": [
                      "95f20827-374c-44ed-bf19-1a1bf8abac09"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "b4abad21-0c1f-4894-8c19-18263b269bd5",
                    "activityIds": [
                      "95f20827-374c-44ed-bf19-1a1bf8abac09"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "7714bb2f-257d-4e15-bb40-744a484e1da5",
                    "activityIds": [
                      "c6c141c9-bba2-47e6-9414-bea3c0135857"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "6424977f-4601-4d04-bbe9-bf465a397d89",
                    "activityIds": [
                      "c6c141c9-bba2-47e6-9414-bea3c0135857"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "a4c71fe0-1c39-4208-8cc6-33de722085d6",
                    "activityIds": [
                      "c6c141c9-bba2-47e6-9414-bea3c0135857"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "48ff2ecf-5466-4bfd-a6b5-cbaba9913fba",
                    "activityIds": [
                      "ce5762b2-32e2-460e-b3bf-fc1e51b8ff07"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "bf08cad5-06bd-4c60-b21a-a8ec738279e3",
                    "activityIds": [
                      "ce5762b2-32e2-460e-b3bf-fc1e51b8ff07"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "74e16af1-301f-4c1a-8bc4-326c1d3c87e5",
                    "activityIds": [
                      "ce5762b2-32e2-460e-b3bf-fc1e51b8ff07"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_5",
                    "encounterId": "89a5c41b-bf67-472a-8cf7-41a7578829ae",
                    "epochId": "5c47d6e5-58f4-4d1e-aa72-f3bb4555c433"
                  },
                  {
                    "id": "850cc669-254f-423a-b587-45b855ca5cd0",
                    "activityIds": [
                      "763973ad-b0bc-4bbe-bf6f-b683cea2db94"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "89504c9c-6fc9-4d7b-9877-99e04e819e51",
                    "activityIds": [
                      "763973ad-b0bc-4bbe-bf6f-b683cea2db94"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "1646e9b7-a587-45ee-ab8d-58fff1b23632",
                    "activityIds": [
                      "763973ad-b0bc-4bbe-bf6f-b683cea2db94"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_5",
                    "encounterId": "89a5c41b-bf67-472a-8cf7-41a7578829ae",
                    "epochId": "5c47d6e5-58f4-4d1e-aa72-f3bb4555c433"
                  },
                  {
                    "id": "4998d26a-ba0b-48cb-90d3-7ffbf92221f4",
                    "activityIds": [
                      "60004221-4821-455e-a413-9f55e93f5239"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "dda8c0f9-5ad1-42df-a5a5-5ff53d2c2edc",
                    "activityIds": [
                      "60004221-4821-455e-a413-9f55e93f5239"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "a31b8a32-749c-45bf-9be6-4e1a6f612043",
                    "activityIds": [
                      "60004221-4821-455e-a413-9f55e93f5239"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "1e98ced0-0dbe-48c8-aa91-2845f6643654",
                    "activityIds": [
                      "5eef4a97-c02b-4fb9-910a-9add09c89013"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "576fb323-b4e4-44ff-a869-1a4bdba85757",
                    "activityIds": [
                      "5eef4a97-c02b-4fb9-910a-9add09c89013"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "cb901b8b-7d76-4bf1-b569-b68a2747d7c8",
                    "activityIds": [
                      "5eef4a97-c02b-4fb9-910a-9add09c89013"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "73d392ff-d708-4072-8d44-34576cd41644",
                    "activityIds": [
                      "9fc0ff26-5fb7-4850-9e77-cdc4cc24cf88"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "c1cb4809-d931-40c4-bb1b-aa087ff84633",
                    "activityIds": [
                      "595631ed-5b13-4ba5-8b6a-b67dabe11674"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_12@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "31eb8744-ac6f-4da3-9178-fdab19047358",
                    "activityIds": [
                      "356adf92-7500-447d-b122-76bc02816824"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "e28bf89e-5fc3-4668-ae30-0b4e500bfb7f",
                    "activityIds": [
                      "7b4dc48e-8841-41d3-8b7a-d1b82b9ba3bd"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_14@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "50d6aab3-5c3b-4bcc-b640-d5f134cee7d9",
                    "activityIds": [
                      "7b4dc48e-8841-41d3-8b7a-d1b82b9ba3bd"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_14@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "8e03fbbf-bec4-4e3f-b07e-63ac3f441675",
                    "activityIds": [
                      "7b4dc48e-8841-41d3-8b7a-d1b82b9ba3bd"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_14@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "8263b919-b919-459f-ae19-7e1825f7c9a8",
                    "activityIds": [
                      "342637c8-3ba7-4142-8a2a-2c715b33bfd8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "b2f6a232-55d1-4885-86c3-4eb3554ae0f1",
                    "activityIds": [
                      "342637c8-3ba7-4142-8a2a-2c715b33bfd8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "33069d7a-fb08-48fe-9fe0-924b0c64b37a",
                    "activityIds": [
                      "342637c8-3ba7-4142-8a2a-2c715b33bfd8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "b146254f-d876-42cb-b707-b8bbd3c8f2f4",
                    "activityIds": [
                      "bb9bf26a-337e-448e-b9a3-dc0de7878578"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "d208a9c2-52b9-479e-b2af-e1a1f207790f",
                    "activityIds": [
                      "ecf70b4c-6605-4f42-9249-36d7e43a1f65"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "75c633cc-4101-4763-9126-a57e345b3d40",
                    "activityIds": [
                      "ecf70b4c-6605-4f42-9249-36d7e43a1f65"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "7a7d4f87-d9e1-4743-a817-23ddf8f56e69",
                    "activityIds": [
                      "ecf70b4c-6605-4f42-9249-36d7e43a1f65"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "2d98bb7d-9009-464d-b49b-51af2663e4a4",
                    "activityIds": [
                      "beffdadd-76cd-45e0-a3b9-3251f8c78b55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "b17cfb1a-3a74-4446-9653-520709e12541",
                    "activityIds": [
                      "beffdadd-76cd-45e0-a3b9-3251f8c78b55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "3f94be65-2f1f-4f9c-80b4-05767e2ab5ac",
                    "activityIds": [
                      "beffdadd-76cd-45e0-a3b9-3251f8c78b55"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "88bee622-a4d1-4eba-a708-47b9bc8274c0",
                    "activityIds": [
                      "ebe5f25a-8b43-47e6-bfbc-c1930fc5c382"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "bbe7ea6e-4b9c-44ef-8e96-ecd3c8cd040b",
                    "activityIds": [
                      "ebe5f25a-8b43-47e6-bfbc-c1930fc5c382"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "541e74cf-c433-4b58-af10-adab4e2bfd61",
                    "activityIds": [
                      "ebe5f25a-8b43-47e6-bfbc-c1930fc5c382"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "725c834b-d03b-40d4-afac-7ef5b11b22d6",
                    "activityIds": [
                      "f8a2de8e-cccf-4f46-8106-bb52e9f19316"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "bf307c6e-addf-4230-81c0-459c311598ab",
                    "activityIds": [
                      "f8a2de8e-cccf-4f46-8106-bb52e9f19316"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "2e4f50a8-970b-4572-96fa-7e79b87f5180",
                    "activityIds": [
                      "f8a2de8e-cccf-4f46-8106-bb52e9f19316"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "9bac07dc-1363-47d5-8b05-3f6ab4c793fc",
                    "activityIds": [
                      "84072a29-c6ae-4c5f-8195-aac59352bc2c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "20cd15e4-7b3d-4a45-b22b-7f893fd847d4",
                    "activityIds": [
                      "84072a29-c6ae-4c5f-8195-aac59352bc2c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "954192f2-2918-40e4-aeb7-6daabeca403b",
                    "activityIds": [
                      "84072a29-c6ae-4c5f-8195-aac59352bc2c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "f2dd3ba9-8194-44cd-97be-b62c3e53a249",
                    "activityIds": [
                      "b2c3814e-81f4-4171-bced-4f4499cf84fa"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_22@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "b19c4823-cd0c-4d66-9d21-f3d579d6d4f1",
                    "activityIds": [
                      "b2c3814e-81f4-4171-bced-4f4499cf84fa"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_22@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "4148c569-24c9-4846-8799-4178cb4c3d6d",
                    "activityIds": [
                      "b2c3814e-81f4-4171-bced-4f4499cf84fa"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_22@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "919b2019-1b86-4c1f-b63f-566a0bd1ad93",
                    "activityIds": [
                      "be23dffe-8490-4ada-a8ac-5fd694989cdb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_25@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "582a41d1-5d5f-4fb8-b2fd-1edc22a59086",
                    "activityIds": [
                      "5d475e85-5aba-4345-af1c-f3c5569ed8b1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_27@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "61111aca-ad5a-451c-8776-baa5e7e13de8",
                    "activityIds": [
                      "ba6a9168-9994-4f90-a10f-60e6ad357f3a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_28@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "048f49ad-6a5f-4351-a959-e5566d48bdb4",
                    "activityIds": [
                      "ba6a9168-9994-4f90-a10f-60e6ad357f3a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_28@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "33a8c82d-cf76-46fd-8029-6a862a3c6a83",
                    "activityIds": [
                      "ba6a9168-9994-4f90-a10f-60e6ad357f3a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_28@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "1ed9cce8-0645-4099-ac5b-7e173cb4357b",
                    "activityIds": [
                      "1cb596db-3995-4454-a9a6-2196bf8e2aff"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_29@enc_1",
                    "encounterId": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                    "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd"
                  },
                  {
                    "id": "eca480a3-6834-4fdb-b235-b42c8a2978a5",
                    "activityIds": [
                      "1cb596db-3995-4454-a9a6-2196bf8e2aff"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_29@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "b6b2c4d1-67c1-4b9f-9c40-cf710c1cdaa7",
                    "activityIds": [
                      "1cb596db-3995-4454-a9a6-2196bf8e2aff"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_29@enc_4",
                    "encounterId": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                    "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34"
                  },
                  {
                    "id": "871d39d2-3200-4407-b07f-117727068f0d",
                    "activityIds": [
                      "816e3ef5-8953-48e4-a4fd-aa8101ae6f2b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_30@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "690cbd21-ed4f-4740-ab37-97503d576b3b",
                    "activityIds": [
                      "55090bbc-c623-4797-86a4-5f8e56cccf2e"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_31@enc_3",
                    "encounterId": "d62382d2-d012-4f98-b65a-b5018df5315a",
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50"
                  },
                  {
                    "id": "797502f5-a9f4-41c7-82a8-3cea980a472e",
                    "activityIds": [
                      "828c269f-2bb0-4f00-a838-e6316bf9fe33"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_32@enc_5",
                    "encounterId": "89a5c41b-bf67-472a-8cf7-41a7578829ae",
                    "epochId": "5c47d6e5-58f4-4d1e-aa72-f3bb4555c433"
                  },
                  {
                    "id": "05d4503c-2b5a-4dc0-9400-e6ffb0bcbe10",
                    "name": "InformedConsent",
                    "description": "Event anchor: InformedConsent",
                    "activityIds": [
                      "95424f85-cacb-418c-a51f-405dd241e8be"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "f7dda289-281a-4b3f-8df8-4df73b284af7",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "4449cb8f-c79b-410f-a2f5-d562a80d1097",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 10
                      }
                    ],
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50",
                    "scheduledDay": 1
                  },
                  {
                    "id": "0d5ae2fc-5cc3-45c3-8e1c-e045e95f3d83",
                    "name": "Randomization",
                    "description": "Event anchor: Randomization",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "f7dda289-281a-4b3f-8df8-4df73b284af7",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "4449cb8f-c79b-410f-a2f5-d562a80d1097",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 40
                      }
                    ],
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50",
                    "scheduledDay": 1
                  },
                  {
                    "id": "42144572-50e0-4900-b31e-8e9e127b1e1c",
                    "name": "FirstDose",
                    "description": "Event anchor: FirstDose",
                    "activityIds": [
                      "816e3ef5-8953-48e4-a4fd-aa8101ae6f2b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "f7dda289-281a-4b3f-8df8-4df73b284af7",
                        "url": "http://example.org/usdm/anchorClassification",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "Event"
                      },
                      {
                        "id": "4449cb8f-c79b-410f-a2f5-d562a80d1097",
                        "url": "http://example.org/usdm/intraDayOrder",
                        "instanceType": "ExtensionAttribute",
                        "valueInteger": 60
                      }
                    ],
                    "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50",
                    "scheduledDay": 1
                  }
                ],
                "timings": [
                  {
                    "id": "9f82688e-0cb2-4ff1-8613-cbf62c5c331b",
                    "name": "ECOG Performance Status Assessment",
                    "type": {
                      "id": "ca0d6098-6f6a-4ee3-abbf-f000f3024e86",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P7D",
                    "valueLabel": "Day 7",
                    "relativeToFrom": {
                      "id": "0d7f5d92-83ea-41b1-b779-e74dd5641e98",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "f338bcdf-6c1d-4fe0-a4cb-38c9086eff96",
                    "instanceType": "Timing",
                    "windowLower": "-P7D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "81ed9284-6699-409a-8e09-342c54e04ec3",
                    "name": "Child-Pugh Class Assessment",
                    "type": {
                      "id": "3c0c5290-7e0e-49f2-9d98-3607f22f4b0c",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P7D",
                    "valueLabel": "Day 7",
                    "relativeToFrom": {
                      "id": "6e022e94-d654-41f0-b73f-410646740d4e",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "1ce4289b-32a5-4e5e-8434-fd99b1d6a331",
                    "instanceType": "Timing",
                    "windowLower": "-P7D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "fbed8fd0-2151-4d77-91fb-5cd4d39d5f34",
                    "name": "Hematologic and End-organ Labs",
                    "type": {
                      "id": "bf1f1c72-15a3-4412-a855-17b4cbbfaa08",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P7D",
                    "valueLabel": "Day 7",
                    "relativeToFrom": {
                      "id": "1d42318d-a7bd-48e6-aca2-0afb6a2cfe56",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "83ea85fc-b5fd-4eed-9ff3-c96f965643ac",
                    "instanceType": "Timing",
                    "windowLower": "-P7D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "32c24cfe-73ef-4030-a567-bf695844019d",
                    "name": "Tumor Tissue Submission",
                    "type": {
                      "id": "bf4183bd-beb5-4f7d-b380-583d616536a1",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P28D",
                    "valueLabel": "Day 28",
                    "relativeToFrom": {
                      "id": "8985377b-299c-4689-b2b7-32a0935d4731",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "c79cdadb-4e3c-49ba-a786-9529300ed5f2",
                    "instanceType": "Timing",
                    "windowLower": "-P28D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "e4ab866c-5805-4e2f-bce6-ea0c590706e0",
                    "name": "HBV DNA Testing",
                    "type": {
                      "id": "ac486b20-878e-456c-9f7d-8756aa0fc7d0",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P28D",
                    "valueLabel": "Day 28",
                    "relativeToFrom": {
                      "id": "cded4c03-82bb-46f5-a372-a8873ac75885",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "43e0104a-8fcd-4684-a10c-911e56d11148",
                    "instanceType": "Timing",
                    "windowLower": "-P28D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "c2f73247-6975-4d36-95ba-46b15da2974e",
                    "name": "Anti-HBV Treatment Initiation",
                    "type": {
                      "id": "b4a4accc-2744-47a3-b2ab-d3418e3c80c0",
                      "code": "C71149",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Before",
                      "instanceType": "Code"
                    },
                    "value": "P14D",
                    "valueLabel": "Day 14",
                    "relativeToFrom": {
                      "id": "015af8d2-3021-4777-a085-2cd1f28dd27e",
                      "code": "C71153",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Study Start",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "67e7125e-3be1-4ad3-8e90-2f939f23e349",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "-P14D"
                  },
                  {
                    "id": "374fa368-7e33-4447-9132-d123ed6ceaaf",
                    "name": "Serum Pregnancy Test",
                    "type": {
                      "id": "fe09fe1d-add7-4477-a8cb-f1eaa9ccc6c0",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P14D",
                    "valueLabel": "Day 14",
                    "relativeToFrom": {
                      "id": "dcb3a5f1-1472-4e03-9754-c37d6b06d31c",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "3e69dbb9-a47a-4ff4-8052-e0007f3d6d69",
                    "instanceType": "Timing",
                    "windowLower": "-P14D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "b25b64db-c56c-4944-8fec-abe565d732c9",
                    "name": "EGD Window",
                    "type": {
                      "id": "be0c8711-dad4-4d3e-a907-f232eafd5104",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P6D",
                    "valueLabel": "6 months",
                    "relativeToFrom": {
                      "id": "5b1817d7-e924-45d8-904e-09c9bd2609f2",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "7ef83de2-e7f0-44df-bafd-5f90cedb072d",
                    "instanceType": "Timing",
                    "windowLower": "-P180D",
                    "windowUpper": "P0D"
                  },
                  {
                    "id": "2af61207-c5e0-4772-9fbe-078a53579843",
                    "name": "Live Vaccine Exclusion",
                    "type": {
                      "id": "33a22b82-e333-45cb-86c2-cca9491ecc47",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P4W",
                    "valueLabel": "4 weeks",
                    "relativeToFrom": {
                      "id": "8f49172e-76ae-4d13-90b3-5ac7f51bc071",
                      "code": "C71155",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "First Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "f6c8db26-12f0-4901-9b3f-b47d0b4dfd69",
                    "instanceType": "Timing",
                    "windowLower": "-P28W",
                    "windowUpper": "P0W"
                  }
                ],
                "exits": [
                  {
                    "id": "49ff4fe7-8e95-4a72-baf0-01bf658afe6c",
                    "name": "Study Completion",
                    "exitType": "Completion",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Date when last patient last visit occurs or safety follow-up is received."
                  },
                  {
                    "id": "54acd9a1-3238-4911-82ed-d99839fcc95a",
                    "name": "Sponsor Termination",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "The Sponsor may decide to terminate the study at any time."
                  }
                ]
              }
            ],
            "encounters": [
              {
                "id": "d62382d2-d012-4f98-b65a-b5018df5315a",
                "name": "Day 1 of Each Cycle",
                "instanceType": "Encounter",
                "type": {
                  "id": "66dd66b8-67a5-4189-b4fe-3e73edf5c436",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50",
                "extensionAttributes": [
                  {
                    "id": "8fc3ef7b-2550-461a-9a5f-30b5ed2a02f5",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "af5ca7c5-a751-4da8-b3df-2b71fcac0f78",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "1f82544f-0f49-4d81-b347-936b6138f3a1",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 1
                  }
                ]
              },
              {
                "id": "97f0ccdc-8d38-41da-844e-2de2f6a1e377",
                "name": "Screening (-28 to -1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "0025f4c3-4095-4a04-a03c-b570d40499fa",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Visit",
                  "instanceType": "Code"
                },
                "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd",
                "extensionAttributes": [
                  {
                    "id": "5d80299a-9a72-4582-87b2-19022e2ba968",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "741a229a-2d88-49f5-8344-93e6cedbcf40",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "917c8542-9009-4d3f-94f4-c33d50d3849a",
                "name": "Screening (-7 to -1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "2206328e-c15e-417c-a9ee-d05ab782072a",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Visit",
                  "instanceType": "Code"
                },
                "epochId": "e7105d8f-d167-47e8-95d0-fc75e528cecd",
                "extensionAttributes": [
                  {
                    "id": "9b58af92-3881-4819-a1bd-5bf4b53f1f0f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a44ef573-13df-4069-9383-393fc65a7866",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "89a5c41b-bf67-472a-8cf7-41a7578829ae",
                "name": "Survival Follow-Up",
                "instanceType": "Encounter",
                "type": {
                  "id": "bc5bad67-e2d1-43af-9928-a348b8a62260",
                  "code": "C98777",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Visit",
                  "instanceType": "Code"
                },
                "epochId": "5c47d6e5-58f4-4d1e-aa72-f3bb4555c433",
                "extensionAttributes": [
                  {
                    "id": "dec7bce5-9cc2-4f3e-a059-c2018b890d9c",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "2ab7457d-92f4-45b2-b601-92034304a10f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "5fa06027-7bb4-44a6-b5f6-79fc726391a1",
                "name": "Treatment Discontinuation ( 30 Days after Last Dose)",
                "instanceType": "Encounter",
                "type": {
                  "id": "7d984d43-a1d3-4fb1-b209-113c838a04a2",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Visit",
                  "instanceType": "Code"
                },
                "epochId": "a3e8270f-e935-4c79-8d0e-e18360debd34",
                "extensionAttributes": [
                  {
                    "id": "dc6c22f4-ffb1-46a1-8bc9-60dce985ba87",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "60534a13-a89a-4941-a7fa-7950eeb23cb2",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              }
            ],
            "activities": [
              {
                "id": "595631ed-5b13-4ba5-8b6a-b67dabe11674",
                "name": "12-lead ECG",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "8bddcebe-06ee-4792-b636-03dd422df6cd",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "db10330a-1945-42af-aa59-5d256b610757",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "59e6b894-acfa-4247-9290-18db6bc2c544",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "1cb596db-3995-4454-a9a6-2196bf8e2aff",
                "name": "Adverse events",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "a8657d40-58d9-47f4-9be2-2e010ada3e95",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "9b393de5-7e64-4141-b7b0-2100651285d2",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "bf20e1b7-8b0b-4e4e-85f7-b40e3d5c1d07",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "5d475e85-5aba-4345-af1c-f3c5569ed8b1",
                "name": "Archival tumor tissue sample (or optional fresh biopsy if archival tissue is not available) for biomarkers",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "1bd3f1fe-7733-4bb1-badc-bc46a2124901",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a4f9d73f-fc0f-4957-a23b-5b76b3694ab2",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "cbafe7a7-54e0-4d73-8da3-6e4ad36ca599",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "4d12013a-84b8-4f26-ba10-017664d4a353",
                "name": "Blood Chemistry and Hematology",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "853eb2da-36da-4aac-b872-e4f28b81db7a",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "a054b6b6-722c-4dbc-a78b-1620a8ed138a",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "3160a18d-b36f-46ba-9990-11b556bca0f2",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "ebe5f25a-8b43-47e6-bfbc-c1930fc5c382",
                "name": "Coagulation panel (aPTT, INR)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "3ecf4843-bf2e-4b53-b786-d88a6656198e",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "be9d6239-ac9b-4b12-9ee1-005f70a29715",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "lab"
                  },
                  {
                    "id": "ca5b9bfc-2f97-4d06-9486-3ab57cef90b5",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "25d75c60-587d-452d-aabf-0890d5992450",
                "name": "Complete physical examination",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "7ba905c8-0987-447b-9724-73db58db9422",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "0174f202-07cf-46d2-87e3-bc3ca316faf5",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "54af8f07-1ab6-4f4e-b2f8-8614a0b6d07f",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "ba6a9168-9994-4f90-a10f-60e6ad357f3a",
                "name": "Concomitant medications",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "71b5f394-5c7b-4b67-9748-78359e8b1b82",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "5db29408-6699-42d7-a57d-3feecc512eac",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "896eb441-cfc4-48a2-a84e-99eccda83007",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "c6c141c9-bba2-47e6-9414-bea3c0135857",
                "name": "ECOG Performance Status",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "a879429e-4264-4129-af5c-85fac5b4a95c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "5b48feaa-c64f-4df3-be67-4fe9a0dc425a",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "01a10fdf-c44b-43d0-b88c-9d9c515c0a4a",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "356adf92-7500-447d-b122-76bc02816824",
                "name": "EGD",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "b13b8a58-dc92-408e-b742-9eefa6bdb819",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a1c30d94-06e1-4c6f-9449-9a35b104672c",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "81454331-66d1-4b91-af8e-861a8657fa07",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "6c953643-4a12-4a37-a3e6-1fdbe0db456d",
                "name": "Electrocardiogram",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "6c953643-4a12-4a37-a3e6-1fdbe0db456d",
                    "name": "Electrocardiogram",
                    "procedureType": "Diagnostic Procedure",
                    "code": {
                      "id": "ae42295f-c843-464a-8989-0ca01db311ff",
                      "code": "93000",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Electrocardiogram, routine ECG with at least 12 leads",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "ECG",
                    "description": "Recording of the electrical activity of the heart"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "743f8b9b-22b9-48a2-ad8b-2e9d8429d70b",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "9e5d049e-c625-49c4-be64-3c0857c41a2e",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "9be46c73-1f18-457b-9174-531be61a34b7",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "b5297265-2dd2-4411-8ca2-a7d7e1e01a54",
                "name": "Esophagogastroduodenoscopy",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "b5297265-2dd2-4411-8ca2-a7d7e1e01a54",
                    "name": "Esophagogastroduodenoscopy",
                    "procedureType": "Diagnostic Procedure",
                    "code": {
                      "id": "656806c7-c8f8-4ade-bdbb-7703e177adbe",
                      "code": "43235",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Upper gastrointestinal endoscopy",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "EGD",
                    "description": "Endoscopic examination of the esophagus, stomach, and duodenum"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "08c550a1-48a6-4294-8588-f73b55c8072d",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "eb568813-40e6-4aa8-a4ff-e307a98ef86e",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "f3fe06cd-b992-4601-ac6e-2543806dd1f5",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "bb9bf26a-337e-448e-b9a3-dc0de7878578",
                "name": "HIV, HBV, HCV serology",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ac5384b9-76c0-4610-bfba-480b59a898c4",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "afbed1b5-b676-4edd-aceb-adeb6c423805",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "lab"
                  },
                  {
                    "id": "c083b34c-e9aa-46ea-9aeb-5c1ee96696e8",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "9fc0ff26-5fb7-4850-9e77-cdc4cc24cf88",
                "name": "Height",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "cadf9e66-c33f-4630-8f06-f46afe71deed",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "113ebd45-f9c1-4c77-9de2-0117964672c5",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "2026d073-da82-44d4-8764-7077531a0dee",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "7b4dc48e-8841-41d3-8b7a-d1b82b9ba3bd",
                "name": "Hematology",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "847fa70e-bcdb-4911-98b8-aab5ac7a7de8",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "89702397-709d-4c2b-abc1-8410012cb7b0",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "lab"
                  },
                  {
                    "id": "5f113000-deb8-4d60-91b7-cd8e715c5c11",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "ee785402-4bf2-4ef8-9047-6f8edfdf719d",
                "name": "Intravenous Infusion",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "ee785402-4bf2-4ef8-9047-6f8edfdf719d",
                    "name": "Intravenous Infusion",
                    "procedureType": "Therapeutic Procedure",
                    "code": {
                      "id": "f90936eb-feb5-4317-b790-3a2b955b34d2",
                      "code": "96413",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Chemotherapy administration, intravenous infusion technique",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "IV Infusion",
                    "description": "Administration of atezolizumab or bevacizumab"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ac353219-f95f-4eea-904d-89c06795743e",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "2ba8619d-a059-4bf1-8f2d-9a0c557b4e34",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "5667a1ed-d5d7-448a-ad05-7c52fd0e4813",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "95f20827-374c-44ed-bf19-1a1bf8abac09",
                "name": "Limited physical examination",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "d7ea9c17-346a-4042-b57f-d639a5db437c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "93c65075-0992-411d-8085-462cb784f065",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "69f5e1c6-c901-46c1-a41a-60da3421f263",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "08dbf4d9-7773-4dce-8dde-78683a3c8f87",
                "name": "Medical, surgical, and cancer histories, including demographic information",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "e9625a64-88d6-4861-b4d3-607175ae3705",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ce870a5b-1177-440a-ad28-b8a43d0b7af6",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "f6f87632-3544-402c-8375-13c28fdde32b",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "ce5762b2-32e2-460e-b3bf-fc1e51b8ff07",
                "name": "Patient-reported outcomes",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "66ebfc87-9d98-47f5-a6dc-ad3c92ad1f0a",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "32f4cda7-443b-4cac-a0b3-9e4a37ffb6a4",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "b04dccca-e629-48e3-8333-4456d93b2075",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "be23dffe-8490-4ada-a8ac-5fd694989cdb",
                "name": "Pharmacodynamic samples for biomarkers",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "862e6845-c295-47f1-852f-c9a63ace6267",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "e477027e-8140-4353-a410-71c4e603e097",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "782690a7-df82-46d1-801f-55091a6a89cc",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "5a08249f-f960-4a84-b3f5-aa75d4fdddd7",
                "name": "Physical Examination",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "cbb93adc-bb61-4ec8-9e0b-67ecde666db9",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "9d58b419-6907-4e75-bafc-d4347422b743",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "385ba419-373f-4ef0-9824-aaed6432b2e9",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "be8cec6d-b362-41fb-a1f5-1f4ef8ee7e2a",
                "name": "Plasma sample for RBR (optional)",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "4cc33520-3419-4364-a8e4-15099dca8401",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f3d1f0ad-39d3-4475-b7e2-9d19fc4ae7c7",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "3d65ed36-2ab1-4a94-a095-49013f237668",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "b2c3814e-81f4-4171-bced-4f4499cf84fa",
                "name": "Pregnancy test",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "70f55e1a-6253-43a4-b06b-7b541a38f404",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures,soa"
                  },
                  {
                    "id": "82123ebc-672c-4063-87b5-7b477d891e7c",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "88bfe6ca-04b5-4dbe-b039-9487c7b9fb17",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "ecf70b4c-6605-4f42-9249-36d7e43a1f65",
                "name": "Quantitative HBsAg, HBV DNA, HCV RNA",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "da638c31-5df3-47e5-8a88-60dccd1d6487",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "698e3b23-4940-4788-967f-69a274cc3f75",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "e91ad8d7-dda9-4b95-b8db-5d4f313294f1",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "1f86581c-8fca-4949-a962-2eee8dbd454b",
                "name": "Review of eligibility criteria",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "65844499-8a6b-4d57-98f2-4faeb587ad83",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "25e820d3-4937-4c62-b7e2-b3ead7c73845",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "616a1ece-ffc8-4ef4-88e2-0e9c7e5b229d",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "90b616c2-771c-474d-9bb9-bc8a8bb3bd75",
                "name": "Serum ADA sample",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "9e3efd7e-e296-4c6f-be43-39eba1b03d14",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f355c71c-9bf7-423f-84d8-6c2f2ec8c313",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "7bde57ff-2837-4522-b902-3316eb24a577",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "b1780d68-2a23-4ca0-812c-40982e06a2d4",
                "name": "Serum PK sample",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "16a652de-d502-4f45-9973-5e1b70548747",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8109c8d2-11a5-40fe-a318-b6e779de3a72",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "6c6784b0-3d87-4297-bd2f-9a8524aab399",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "342637c8-3ba7-4142-8a2a-2c715b33bfd8",
                "name": "Serum chemistry",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "20698afe-1a29-43e7-8ad9-01c421e40e82",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "e9c94398-9a65-4888-a6ed-5ca6b1c0ed36",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "lab"
                  },
                  {
                    "id": "435de9b6-2b86-4eb0-a6b6-f1f9a30042fa",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "95424f85-cacb-418c-a51f-405dd241e8be",
                "name": "Signed Informed Consent Form",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "7e07e297-7da2-4ee7-9b53-56798f0a4973",
                    "url": "https://protocol2usdm.io/extensions/x-activityRawName",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "Signed Informed Consent Form(s)"
                  },
                  {
                    "id": "f2febaf5-8af3-4879-b83b-7b2296cccfed",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f49dd829-5439-4a73-a070-352ae5f7074a",
                    "url": "https://protocol2usdm.io/extensions/x-activityFootnoteRefs",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "s"
                  },
                  {
                    "id": "96e209ca-848d-4720-aed4-912cdfac892f",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "documentation"
                  },
                  {
                    "id": "1543c156-2616-4854-ab15-e8d596a34c6f",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "55090bbc-c623-4797-86a4-5f8e56cccf2e",
                "name": "Sorafenib dispensing",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "859e63dc-29a0-4fc3-8b5b-f3a2ceee23b6",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f85f33d3-92d2-470e-8872-e57051567ad0",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "409b1982-1ee8-4f23-9e83-58d08a87879a",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "816e3ef5-8953-48e4-a4fd-aa8101ae6f2b",
                "name": "Study treatment infusion",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "1c3da4d2-98b0-465e-a8f3-476c08338561",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "a5afb5b9-b0b5-4fed-88ba-56975883be24",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "administration"
                  },
                  {
                    "id": "2a361cde-56d9-4fcf-868e-96576a885522",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "828c269f-2bb0-4f00-a838-e6316bf9fe33",
                "name": "Survival and anti-cancer therapy follow-up",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "774a55a4-711b-4c45-9bba-b741c45957a8",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "39dd5454-f65c-43db-a0c7-5d1de5ec4982",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "b7825dd4-8bf6-4c58-8b2a-c5aa10ca2156",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "84072a29-c6ae-4c5f-8195-aac59352bc2c",
                "name": "TSH, free T3, free T4",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "971fd058-ac16-4f08-9080-45c9eb10d2e8",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "decd25b2-5f27-496a-9956-c0d71e472eda",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "ce85995d-9ffd-41cf-b51e-5259fca1b76e",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "65339cf5-6bf9-42bf-b4c1-a4e065717d5b",
                "name": "Tumor Biopsy",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "65339cf5-6bf9-42bf-b4c1-a4e065717d5b",
                    "name": "Tumor Biopsy",
                    "procedureType": "Biospecimen Collection",
                    "code": {
                      "id": "d27a4262-efa2-4a33-96fa-44a7abbe49b7",
                      "code": "47000",
                      "codeSystem": "CPT",
                      "codeSystemVersion": "",
                      "decode": "Biopsy of liver, needle; percutaneous",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Core Biopsy",
                    "description": "Collection of tumor tissue sample"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "53f6fc13-1ffa-45ee-95ed-957398b06c58",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "63067b2e-56f6-4a15-a902-cb9a31be6f1e",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "21ff9e9f-739e-4286-959b-fd065534e323",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "763973ad-b0bc-4bbe-bf6f-b683cea2db94",
                "name": "Tumor assessment",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "dbd164bc-7b9a-472c-bd9a-c5912080cfdc",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures,soa"
                  },
                  {
                    "id": "686d77d1-1bc3-406c-98d2-652e3c412d92",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "cb478e20-f45b-442b-8e0b-7fe69cfe3646",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "f8a2de8e-cccf-4f46-8106-bb52e9f19316",
                "name": "Urinalysis",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "b6d1ad7e-05da-48f0-8b44-72f94c869cd1",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f97b588f-8965-4fe0-bb56-860e175b0387",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "lab"
                  },
                  {
                    "id": "a23318a9-ef7b-4639-b638-747d0bc7afe4",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "db8703dc-a723-406e-9451-e0ef44ee0b25",
                "name": "Vital Signs Measurement",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "e81453ed-515c-4fb5-b9e2-31555682cb25",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "b6406dab-5b89-45f7-92ff-7a9d4211a63b",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "1ac02214-81d0-4007-ba23-855cb76e8a32",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "60004221-4821-455e-a413-9f55e93f5239",
                "name": "Vital signs",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "f0896553-fb18-4f18-9d59-4077371d09bd",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "74cbbdac-2407-481d-9b95-3fec675676d5",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "5a643bff-6da8-4492-bcc1-869201d7cd69",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "5eef4a97-c02b-4fb9-910a-9add09c89013",
                "name": "Weight",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "1743f6f4-ca36-47e7-beff-be6ad4b33dcb",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "54be8932-6f91-472e-aa47-c55947ea94d4",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "b1019b72-4db7-484c-ace3-8aa24041920a",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "beffdadd-76cd-45e0-a3b9-3251f8c78b55",
                "name": "-fetoprotein",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "71e3ad2e-34c7-47c0-a9ab-1bd81f9f9819",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "b5152afc-4b94-409a-8000-52eb7b422cd2",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "c5982708-ca97-40c5-8284-1f3f4c8cdf00",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              }
            ],
            "epochs": [
              {
                "id": "e7105d8f-d167-47e8-95d0-fc75e528cecd",
                "name": "Screening",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "eecf3c48-f4a5-4b8e-b26e-3721a111c44d",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "a12516b3-b49f-4c75-b952-3af1643bd0fb",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "6d5a7d1c-9b86-4f12-8d16-6b21ef37d172",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "eedec202-3136-4817-9eb8-8fee8ceda809",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "1"
                  }
                ]
              },
              {
                "id": "a3e8270f-e935-4c79-8d0e-e18360debd34",
                "name": "Treatment Discontinuation",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "2eb6575c-fe23-4d61-b4a5-a7683971ed1c",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "51d28359-0ff2-4b2b-8fca-be5d25abb4cc",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "b300c9dd-4f4f-4f48-a373-a6475201e13c",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "9bd9c322-3a78-40b7-b03d-7035450a897d",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "2"
                  }
                ]
              },
              {
                "id": "5c47d6e5-58f4-4d1e-aa72-f3bb4555c433",
                "name": "Survival Follow-Up",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "44ccece3-9db9-44e1-8357-9204cc5e442e",
                  "code": "C98781",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "9982f15a-2e1e-4402-94d9-9377d0f9c5f0",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "0fc35dd4-b025-45b9-b1aa-ae4e65ea3892",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "80626c4b-edfa-4c13-8877-5286d6a47775",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "3"
                  }
                ]
              },
              {
                "id": "16868fb2-3195-4dd6-a6ea-e7a3a0c2fb50",
                "name": "Treatment Phase (Q3W)",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "e978ee46-0b6a-41c2-82ab-9599c72d6aca",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "a4ed5cb8-9f21-4558-b136-9595a7f8a2f6",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "1b4a7d69-0ac6-46f3-beaa-941b562a4ba1",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "sub"
                  }
                ]
              }
            ],
            "activityGroups": [
              {
                "id": "43f4be9d-e5a6-42a8-99e1-8d570b7a88c2",
                "name": "General Assessments",
                "description": null,
                "childIds": [
                  "1f86581c-8fca-4949-a962-2eee8dbd454b",
                  "08dbf4d9-7773-4dce-8dde-78683a3c8f87",
                  "25d75c60-587d-452d-aabf-0890d5992450",
                  "95f20827-374c-44ed-bf19-1a1bf8abac09",
                  "c6c141c9-bba2-47e6-9414-bea3c0135857",
                  "ce5762b2-32e2-460e-b3bf-fc1e51b8ff07",
                  "763973ad-b0bc-4bbe-bf6f-b683cea2db94",
                  "60004221-4821-455e-a413-9f55e93f5239",
                  "5eef4a97-c02b-4fb9-910a-9add09c89013",
                  "9fc0ff26-5fb7-4850-9e77-cdc4cc24cf88",
                  "595631ed-5b13-4ba5-8b6a-b67dabe11674",
                  "356adf92-7500-447d-b122-76bc02816824"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Signed Informed Consent Form(s)",
                  "Review of eligibility criteria",
                  "Medical, surgical, and cancer histories, including demographic information",
                  "Complete physical examination",
                  "Limited physical examination",
                  "ECOG Performance Status",
                  "Patient-reported outcomes",
                  "Tumor assessment",
                  "Vital signs",
                  "Weight",
                  "Height",
                  "12-lead ECG",
                  "EGD"
                ]
              },
              {
                "id": "f29cee6a-2192-43a1-8cce-67e50e3608e6",
                "name": "Laboratory Assessments",
                "description": null,
                "childIds": [
                  "7b4dc48e-8841-41d3-8b7a-d1b82b9ba3bd",
                  "342637c8-3ba7-4142-8a2a-2c715b33bfd8",
                  "bb9bf26a-337e-448e-b9a3-dc0de7878578",
                  "ecf70b4c-6605-4f42-9249-36d7e43a1f65",
                  "beffdadd-76cd-45e0-a3b9-3251f8c78b55",
                  "ebe5f25a-8b43-47e6-bfbc-c1930fc5c382",
                  "f8a2de8e-cccf-4f46-8106-bb52e9f19316",
                  "84072a29-c6ae-4c5f-8195-aac59352bc2c",
                  "b2c3814e-81f4-4171-bced-4f4499cf84fa"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Hematology",
                  "Serum chemistry",
                  "HIV, HBV, HCV serology",
                  "Quantitative HBsAg, HBV DNA, HCV RNA",
                  "-fetoprotein",
                  "Coagulation panel (aPTT, INR)",
                  "Urinalysis",
                  "TSH, free T3, free T4",
                  "Pregnancy test"
                ]
              },
              {
                "id": "698106bf-4042-47b2-af87-2619eb2e0c62",
                "name": "Specialized Samples and Treatment",
                "description": null,
                "childIds": [
                  "be23dffe-8490-4ada-a8ac-5fd694989cdb",
                  "5d475e85-5aba-4345-af1c-f3c5569ed8b1",
                  "ba6a9168-9994-4f90-a10f-60e6ad357f3a",
                  "1cb596db-3995-4454-a9a6-2196bf8e2aff",
                  "816e3ef5-8953-48e4-a4fd-aa8101ae6f2b",
                  "55090bbc-c623-4797-86a4-5f8e56cccf2e",
                  "828c269f-2bb0-4f00-a838-e6316bf9fe33"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Serum PK sample",
                  "Serum ADA sample",
                  "Pharmacodynamic samples for biomarkers",
                  "Plasma sample for RBR (optional)",
                  "Archival tumor tissue sample (or optional fresh biopsy if archival tissue is not available) for biomarkers",
                  "Concomitant medications",
                  "Adverse events",
                  "Study treatment infusion",
                  "Sorafenib dispensing",
                  "Survival and anti-cancer therapy follow-up"
                ]
              }
            ],
            "notes": [
              {
                "id": "f54ac050-bb80-49b8-b805-49fbdcdaf962",
                "text": "a. The first dosing date (Cycle 1, Day 1) should occur within 3 business days from randomization, with the exception of the emergence of an adverse event for which dosing may be postponed. All visits and infusions thereafter may be administered with a window of  3 days.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "89eb7fd7-0d5c-46d5-a2c8-4e5f738dba28",
                "text": "b. Written informed consent can be obtained up to 30 days prior to study entry and is required before performing any study-specific tests or procedures. Results of standard of care tests or examinations performed prior to obtaining informed consent and per protocol relevant window may be used for screening assessments rather than repeating such tests. Screening local laboratory assessments obtained  96 hours prior to the initiation of study treatment do not have to be repeated for Cycle 1. Test results should be reviewed prior to administration of study treatment.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "7ca5d88c-a19d-4a78-bbac-cf5e84dd34eb",
                "text": "c. Patients will be asked to return to the clinic 30 days after the last dose of study treatment for an end-of-treatment visit. After this visit, serious adverse events and protocol defined adverse events of special interest, regardless of attribution, will be recorded until 90 days after the last dose of study treatment or until initiation of another systemic anti-cancer therapy, whichever occurs first. Ongoing adverse events thought to be related to study treatment will be followed until the event has resolved to baseline grade or better, the event is assessed by the investigator as stable, new anti-cancer treatment is initiated, the patient is lost to follow-up, the patient withdraws consent, or it is determined that the study treatment or participation is not the cause of the adverse event. Scans performed within 6 weeks prior to the treatment discontinuation visit do not need to be repeated.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "2e532b82-5ff7-44c0-bfbd-e376d2920e59",
                "text": "d. Cancer history includes stage, date of diagnosis, and prior anti-tumor treatment. Demographic information includes age and self-reported race/ethnicity. Reproductive status and smoking history should also be captured.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "fd283be8-b53c-45ed-92b5-7b805fedffa1",
                "text": "e. A complete physical examination at screening should include the evaluation of head, eye, ear, nose, and throat and cardiovascular, dermatologic, musculoskeletal, respiratory, gastrointestinal, genitourinary, and neurologic systems. Changes in abnormalities noted at baseline should be recorded at the end of the visit. New or worsened abnormalities should be recorded as adverse events if appropriate.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "d2a8e854-a018-448c-8eeb-e1ec463dd06a",
                "text": "f. A limited physical examination will be performed at other visits to assess changes from baseline abnormalities and any new abnormalities and to evaluate patient-reported symptoms. New or worsened abnormalities should be recorded as adverse events if appropriate.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "bf6c6911-86ef-489f-8787-feae2d05003c",
                "text": "g. ECOG Performance Status, limited physical examination, local laboratory assessments, and PROs may be obtained  96 hours before Day 1 of each cycle.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "9c82913b-e50f-4f3f-b94a-28a891f58a09",
                "text": "h. The EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D-5L questionnaires will be completed by all patients on paper starting on Day 1 of Cycle 1 and Day 1 of every cycle thereafter. All PRO questionnaires scheduled for administration during a clinic visit are required to be completed by the patient at the investigational site at the start of the clinic visit before discussion of the patient's health state, lab results or health record, before administration of study treatment, and/or prior to any other study assessment(s). This is to avoid any potential bias to patients' responses to ensure that the validity of the instrument is not compromised and that data quality meets regulatory requirements. Interview assessment by a member of the clinic staff will be allowed if the patient is not able to complete the measure on their own. Study personnel should review all questionnaires for completeness before the patient leaves the investigational site. During survival follow-up, all PRO questionnaires will be completed every 3 months (for 1 year), unless the patient withdraws consent or the Sponsor terminates the study. PRO questionnaires during the survival follow-up period may be completed at the investigational site should the patient come in for a clinic visit or be administered via interview in telephone calls.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "4d8b793a-2423-4cf9-9a56-54d9eedae0fe",
                "text": "i. All measurable and evaluable lesions should be assessed and documented at the screening visit. Radiologic imaging performed during the screening period should consist of 1) CT and/or MRI of the chest/abdomen/pelvis and brain, 2) bone scan or PET scan as clinically indicated, and 3) any other imaging studies (CT scan of the neck, plain films, etc.) as clinically indicated by the treating physician. The same radiographic procedures and technique must be used throughout the study for each patient (e.g., if the patient had CT chest/abdomen/pelvis performed during screening, then she should subsequently undergo CT performed with use of the same radiologic protocol throughout the remainder of the study). Results must be reviewed by the investigator before dosing at the next cycle. Tumor assessments will be performed at baseline, every 6 weeks ( 1 week) for the first 54 weeks following the initiation of study treatment, and every 9 weeks ( 1 week) thereafter, with additional scans as clinically indicated. All known sites of disease documented at screening should be re-assessed at each subsequent tumor evaluation. Tumor response will be evaluated by the investigator with use of RECIST version 1.1 and imRECIST. In the absence of disease progression, tumor assessments should continue regardless of whether patients discontinue study treatment or start new anti-cancer treatment, unless the patient dies, withdraws consent, or the study is terminated by the Sponsor, whichever occurs first.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "27734ddd-f87c-430d-afc4-a91602ec010c",
                "text": "j. Vital signs include heart rate, respiratory rate, blood pressure, and temperature. For patients randomized to Arm A, on days of study treatment administration (atezolizumab and bevacizumab), the patient's vital signs should be determined up to 60 minutes before all infusions. Vital signs will be measured at the end of bevacizumab infusion and 2 ( 1) hours after end of the infusion and will also be collected during and after every infusion of atezolizumab if clinically indicated.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "4d295a04-c11a-4a94-8c15-2230084a57a4",
                "text": "k. The dose of bevacizumab will be based on the patient's weight (in kilograms) measured  14 days prior to baseline (the initiation of study treatment) and will remain the same throughout the study unless there is a weight change of > 10% from baseline. If re-baseline is needed the latest baseline weight should always be used to calculate percent change in weight for all subsequent doses.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "82c93ea7-cf63-4f0b-b4e2-8c39ae014b22",
                "text": "l. Patients should be resting and in a supine position for at least 10 minutes prior to each ECG collection.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "94c15e08-6238-49f2-869b-af7cf843704a",
                "text": "m. All patients must undergo an EGD and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "b3fc32ea-dc7b-42f4-8b5a-e2f1a9092fd7",
                "text": "n. Hematology consists of CBC, including RBC count, hemoglobin, hematocrit, WBC count with differential (neutrophils, eosinophils, lymphocytes, monocytes, basophils, and other cells), and platelet count. A manual differential can be done if clinically indicated.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a17aec74-9fd2-4dbe-938b-72ea64c404dd",
                "text": "o. Serum chemistry includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, potassium, magnesium, chloride, glucose, BUN or urea, creatinine, total protein, albumin, phosphorus, calcium, total bilirubin, alkaline phosphatase, ALT, AST, and LDH.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "dca4b00e-53c4-4c73-b276-591dae3099b5",
                "text": "p. All patients will be tested for HIV locally prior to the inclusion into the study and if not in contradiction with local legislation; HIV-positive patients will be excluded from the clinical study. HBsAg, HBcAb, and HBsAb should be collected during screening and tested locally. HBV DNA must be collected prior to Cycle 1, Day 1 in patients who have negative serology for HBsAg and positive serology for anti-HBcAb.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "40ad5b25-8ccf-48b3-b16e-8bcfdf9912a5",
                "text": "q. Only if patient tests positive for HBsAg, HBcAb, quantitative HBsAg and HBV DNA will be tested during screening; Cycle 5, Day 1; Cycle 9, Day 1; and at treatment discontinuation. Quantitative HBsAg will be tested by central laboratory. If a patient tests positive for HCV antibody at screening, quantitative HCV RNA must be tested locally at screening, Cycle 5 Day 1, Cycle 9 Day 1, and at treatment discontinuation.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "298f0fa6-e2cf-4906-b2a2-41ba00fd7b1a",
                "text": "r. Urine dipstick includes specific gravity, pH, glucose, protein, ketones, and blood and should be repeated before every cycle during treatment. Urine dipstick for proteinuria must be < 2+ within 7 days prior to initiation of study treatment. Patients discovered to have  2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "01b5813b-0815-433d-b65c-7a804ec8ddcc",
                "text": "s. Serum pregnancy test within 14 days before Cycle 1, Day 1.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "72f27422-eee5-484b-abd8-732a282153c3",
                "text": "t. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "005c5ee8-a048-4dd7-a7e0-095aae2733a1",
                "text": "u. Concomitant medications include any prescription medications or over-the-counter medications. At screening, any medications the patient has used within the 7 days prior to initiation of study treatment should be documented. At subsequent visits, changes to current medications or medications used since the last documentation of medications will be recorded.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "f6b30192-137d-44f9-922b-18b31193d37c",
                "text": "v. After informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protocol-mandated intervention should be reported. After initiation of study drug, all adverse events will be reported until 30 days after the last dose of study treatment or until initiation of another anti-cancer therapy, whichever occurs first. Serious adverse events and adverse events of special interest will continue to be reported until 90 days after the last dose of study treatment or until initiation of new anti-cancer therapy, whichever occurs first. After this period, investigators should report any serious adverse events and adverse events of special interest that are believed to be related to prior treatment with study drug. The investigator should follow each adverse event until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, new systemic anti-cancer treatment is initiated, the patient is lost to follow-up, the patient withdraws consent, or it is determined that the study treatment or participation is not the cause of the adverse event. Every effort should be made to follow all serious adverse events considered to be related to study drug or study-related procedures until a final outcome can be reported.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "8828bfd7-e5d9-4a05-948a-640bb6063d14",
                "text": "w. The initial dose of atezolizumab will be delivered over 60 ( 15) minutes. If the first infusion is tolerated without infusion-associated adverse events, the second infusion may be delivered over 30 ( 10) minutes. If the 30-minute infusion is well-tolerated, all subsequent infusions may be delivered over 30 ( 10) minutes. The initial dose of bevacizumab will be delivered over 90 ( 15) minutes. If the first infusion is tolerated without infusion-associated adverse events, the second infusion may be delivered over 60 ( 10) minutes. If the 60-minute infusion is well-tolerated, all subsequent infusions may be delivered over 30 ( 10) minutes. For patients randomized to Arm A, atezolizumab will be administered first followed by bevacizumab, with a minimum of 5 minutes between dosing. In the absence of unacceptable toxicity, patients may continue study treatment until there is evidence of disease progression or lack of clinical benefit.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "5eb6b293-68ff-4281-834a-eb95570a5bba",
                "text": "x. Sorafenib is taken by mouth twice a day continuously.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "2b1fb9ce-e97d-48a6-b95c-6693db16089e",
                "text": "y. Survival follow-up information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 3 months ( 21 days) until death, loss to follow-up, or until study termination by the Sponsor. All patients will be followed for survival and new anti-cancer therapy (including targeted therapy and immunotherapy) information unless the patient requests to be withdrawn from follow-up; this request must be documented in the source documents and signed by the investigator. If the patient withdraws from study, the study staff may use a public information source (e.g., county records) to obtain information about survival status only.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "63f2c09e-96a1-4c66-91e6-495b450d8072",
                "text": "z. Local laboratory assessments from each cycle must be reviewed prior to study treatment administration for each cycle.",
                "instanceType": "CommentAnnotation"
              }
            ],
            "model": {
              "id": "c604fa83-ecd6-480d-ae14-b7c6b6f89aca",
              "code": "C82639",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Parallel Study",
              "instanceType": "Code"
            },
            "indications": [
              {
                "id": "b971eaa6-9fa7-4446-bf34-c718a63e1e5f",
                "name": "Hepatocellular Carcinoma",
                "isRareDisease": false,
                "instanceType": "Indication",
                "description": "Untreated locally advanced or metastatic hepatocellular carcinoma"
              }
            ],
            "procedures": [
              {
                "id": "6c953643-4a12-4a37-a3e6-1fdbe0db456d",
                "name": "Electrocardiogram",
                "procedureType": "Diagnostic Procedure",
                "code": {
                  "id": "ae42295f-c843-464a-8989-0ca01db311ff",
                  "code": "93000",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Electrocardiogram, routine ECG with at least 12 leads",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "ECG",
                "description": "Recording of the electrical activity of the heart"
              },
              {
                "id": "b5297265-2dd2-4411-8ca2-a7d7e1e01a54",
                "name": "Esophagogastroduodenoscopy",
                "procedureType": "Diagnostic Procedure",
                "code": {
                  "id": "656806c7-c8f8-4ade-bdbb-7703e177adbe",
                  "code": "43235",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Upper gastrointestinal endoscopy",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "EGD",
                "description": "Endoscopic examination of the esophagus, stomach, and duodenum"
              },
              {
                "id": "ee785402-4bf2-4ef8-9047-6f8edfdf719d",
                "name": "Intravenous Infusion",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "f90936eb-feb5-4317-b790-3a2b955b34d2",
                  "code": "96413",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Chemotherapy administration, intravenous infusion technique",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "IV Infusion",
                "description": "Administration of atezolizumab or bevacizumab"
              },
              {
                "id": "65339cf5-6bf9-42bf-b4c1-a4e065717d5b",
                "name": "Tumor Biopsy",
                "procedureType": "Biospecimen Collection",
                "code": {
                  "id": "d27a4262-efa2-4a33-96fa-44a7abbe49b7",
                  "code": "47000",
                  "codeSystem": "CPT",
                  "codeSystemVersion": "",
                  "decode": "Biopsy of liver, needle; percutaneous",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Core Biopsy",
                "description": "Collection of tumor tissue sample"
              }
            ],
            "analysisPopulations": [
              {
                "id": "498ad2e1-1125-418d-8f8a-c88ea6a91127",
                "name": "Intent-to-Treat Population",
                "text": "The ITT population is defined as all randomized patients, whether or not the patient has received the assigned study treatment.",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "ITT",
                "populationDescription": "The ITT population is defined as all randomized patients, whether or not the patient has received the assigned study treatment.",
                "criteria": "All randomized patients"
              },
              {
                "id": "e20fd7f9-7a75-4ca2-a50b-8d4b67821e31",
                "name": "Pharmacokinetic-Evaluable Population",
                "text": "The pharmacokinetic (PK)-evaluable population is defined as all patients who received any dose of study treatment and who have at least one post-baseline PK sample available.",
                "populationType": "PK/PD",
                "instanceType": "AnalysisPopulation",
                "label": "PK-evaluable",
                "populationDescription": "The pharmacokinetic (PK)-evaluable population is defined as all patients who received any dose of study treatment and who have at least one post-baseline PK sample available.",
                "criteria": "Received any dose AND has >=1 post-baseline PK sample"
              },
              {
                "id": "7df1ae80-41f8-40da-9be0-f812c15e9318",
                "name": "PRO-Evaluable Population",
                "text": "The patient-reported outcome (PRO)-evaluable population will include all randomized patients who have a baseline and at least 1 post-baseline assessment.",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "PRO-evaluable",
                "populationDescription": "The patient-reported outcome (PRO)-evaluable population will include all randomized patients who have a baseline and at least 1 post-baseline assessment.",
                "criteria": "Randomized AND has baseline assessment AND has >=1 post-baseline assessment"
              },
              {
                "id": "1d23470e-961d-4c95-86be-c708367203e0",
                "name": "Safety Population",
                "text": "The safety population consists of all randomized patients who received at least one full or partial dose of any study treatment, with patients grouped according to the actual treatment received.",
                "populationType": "Safety",
                "instanceType": "AnalysisPopulation",
                "label": "Safety",
                "populationDescription": "The safety population consists of all randomized patients who received at least one full or partial dose of any study treatment, with patients grouped according to the actual treatment received.",
                "criteria": "Randomized AND received >=1 full or partial dose"
              },
              {
                "id": "5e39d636-316a-46b7-93f9-06fc14413f2a",
                "name": "Anti-Drug-Antibody-Evaluable Population",
                "text": "The anti-drug-antibody (ADA)-evaluable population is defined as all patients who received any dose of atezolizumab and who have at least one post-baseline ADA assessment.",
                "populationType": "Safety",
                "instanceType": "AnalysisPopulation",
                "label": "ADA-evaluable",
                "populationDescription": "The anti-drug-antibody (ADA)-evaluable population is defined as all patients who received any dose of atezolizumab and who have at least one post-baseline ADA assessment.",
                "criteria": "Received any dose of atezolizumab AND has >=1 post-baseline ADA assessment"
              }
            ],
            "characteristics": [
              {
                "id": "6194dda9-56ed-4081-a801-3b9fb84dc692",
                "code": "GEOGRAPHIC_REGION",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Geographic region",
                "instanceType": "Code"
              },
              {
                "id": "52a1f726-3a04-41f0-8918-deafad3a370e",
                "code": "MACROVASCULAR_INVASI",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Macrovascular invasion and/or extrahepatic spread",
                "instanceType": "Code"
              },
              {
                "id": "1bf6e8aa-b2a6-4185-a8c0-86eb3698c438",
                "code": "BASELINE_AFP",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Baseline AFP",
                "instanceType": "Code"
              },
              {
                "id": "1e5684d9-26d2-48de-ba25-fb771237ee55",
                "code": "ECOG_PERFORMANCE_STA",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "ECOG Performance Status",
                "instanceType": "Code"
              }
            ],
            "extensionAttributes": [
              {
                "id": "2df099b2-4435-4b5c-91c2-d013b7d353e8",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-entityMaps",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"epochAliases\": {\"SCREENING\": \"epoch_1\", \"TREATMENT PHASE (Q3W)\": \"epoch_2\", \"TREATMENT_PHASE_(Q3W)\": \"epoch_2\", \"TREATMENT\": \"epoch_3\", \"TREATMENT DISCONTINUATION\": \"epoch_3\", \"TREATMENT_DISCONTINUATION\": \"epoch_3\", \"SURVIVAL FOLLOW-UP\": \"epoch_4\", \"SURVIVAL_FOLLOW-UP\": \"epoch_4\", \"FOLLOW_UP\": \"epoch_4\", \"SURVIVAL_FOLLOW_UP\": \"epoch_4\", \"END_OF_STUDY\": \"epoch_4\", \"SAFETY_FOLLOW_UP\": \"epoch_4\"}, \"visitAliases\": {\"SCREENING (-28 TO -1)\": \"enc_1\", \"SCREENING_(-28_TO_-1)\": \"enc_1\", \"SCREENING (-7 TO -1)\": \"enc_2\", \"SCREENING_(-7_TO_-1)\": \"enc_2\", \"DAY 1 OF EACH CYCLE\": \"enc_3\", \"DAY_1_OF_EACH_CYCLE\": \"enc_3\", \"TREATMENT DISCONTINUATION (\\u2264 30 DAYS AFTER LAST DOSE)\": \"enc_4\", \"TREATMENT_DISCONTINUATION_(\\u2264_30_DAYS_AFTER_LAST_DOSE)\": \"enc_4\", \"SURVIVAL FOLLOW-UP\": \"enc_5\", \"SURVIVAL_FOLLOW-UP\": \"enc_5\", \"screening\": \"enc_1\", \"randomization\": \"enc_3\", \"Follow-up\": \"enc_5\"}}"
              },
              {
                "id": "ext_conceptual_ca07ccd8-9bac-4ad1-ad1f-2a434eaa5b72",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-conceptualAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"f338bcdf-6c1d-4fe0-a4cb-38c9086eff96\", \"name\": \"ECOG Performance Status Assessment\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"1ce4289b-32a5-4e5e-8434-fd99b1d6a331\", \"name\": \"Child-Pugh Class Assessment\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"83ea85fc-b5fd-4eed-9ff3-c96f965643ac\", \"name\": \"Hematologic and End-organ Labs\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"c79cdadb-4e3c-49ba-a786-9529300ed5f2\", \"name\": \"Tumor Tissue Submission\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"43e0104a-8fcd-4684-a10c-911e56d11148\", \"name\": \"HBV DNA Testing\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"67e7125e-3be1-4ad3-8e90-2f939f23e349\", \"name\": \"Anti-HBV Treatment Initiation\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"3e69dbb9-a47a-4ff4-8052-e0007f3d6d69\", \"name\": \"Serum Pregnancy Test\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"7ef83de2-e7f0-44df-bafd-5f90cedb072d\", \"name\": \"EGD Window\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}, {\"id\": \"f6c8db26-12f0-4901-9b3f-b47d0b4dfd69\", \"name\": \"Live Vaccine Exclusion\", \"classification\": \"Conceptual\", \"note\": \"Pure timing reference - no visit or activity instance\"}]"
              },
              {
                "id": "90cd2d58-741c-4de3-9ac8-4555e4cd7328",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-promotionIssues",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'ECOG Performance Status Assessment' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Child-Pugh Class Assessment' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Hematologic and End-organ Labs' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Tumor Tissue Submission' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'HBV DNA Testing' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Anti-HBV Treatment Initiation' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Serum Pregnancy Test' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'EGD Window' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}, {\"severity\": \"info\", \"category\": \"conceptual_anchor_stored\", \"message\": \"CONCEPTUAL anchor 'Live Vaccine Exclusion' stored as timing reference (no visit)\", \"affectedPath\": \"$.extensionAttributes[?(@.url contains 'conceptualAnchors')]\"}]"
              },
              {
                "id": "0e4c8803-a483-4dde-a4f4-958d34d5bf74",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-timeAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"868576ee-f0c6-4b08-8018-cf6353a32551\", \"definition\": \"First administration of investigational product\", \"anchorType\": \"FirstDose\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 60, \"sourceText\": \"first dose of study treatment\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"035d9c49-de53-4f07-8b40-0f188a1cf6d4\", \"definition\": \"The date on which the patient is assigned to a treatment group through the randomization process\", \"anchorType\": \"Randomization\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 40, \"sourceText\": \"OS, defined as the time from randomization to death from any cause\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"2ceb909c-f460-48f6-95cd-66c55670891d\", \"definition\": \"Informed consent obtained\", \"anchorType\": \"InformedConsent\", \"classification\": \"Event\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 10, \"sourceText\": \"Informed Consent\", \"encounterId\": null, \"activityId\": null}, {\"id\": \"69b069d7-0b16-4ebc-8488-2fee5be3ee60\", \"definition\": \"procedure\", \"anchorType\": \"Custom\", \"classification\": \"Conceptual\", \"timelineId\": null, \"dayValue\": 1, \"intraDayOrder\": 100, \"sourceText\": \"procedure\", \"encounterId\": null, \"activityId\": null}]"
              },
              {
                "id": "e8447277-ca17-4a09-a64e-7573d5abda25",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-repetitions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"33424ee5-5cbc-41e2-945b-a225aefcc488\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"od\"}, {\"id\": \"886ab9ba-89dd-443a-8cd1-d5dd902c1825\", \"type\": \"Interval\", \"sourceText\": \"BID\"}, {\"id\": \"d298c64d-43ea-4d09-9ece-ade4d5c357e4\", \"type\": \"Cycle\", \"cycleLength\": \"P21D\", \"sourceText\": \"21-day cycle\"}, {\"id\": \"ca185cbd-a4ed-41f2-b014-5bcf2474d40b\", \"type\": \"Cycle\", \"cycleLength\": \"P3D\", \"sourceText\": \"3-week cycle\"}, {\"id\": \"ea722418-cbc0-4406-9d9b-511db29477d1\", \"type\": \"Cycle\", \"exitCondition\": \"Disease progression\", \"sourceText\": \"until disease progression\"}, {\"id\": \"c3eaf240-a49a-432b-ab73-32d13b05a511\", \"type\": \"Cycle\", \"exitCondition\": \"Disease progression\", \"sourceText\": \"until disease \\nprogression\"}, {\"id\": \"244f979a-daf5-4292-aff2-dfeccc9f17bb\", \"type\": \"Cycle\", \"exitCondition\": \"Unacceptable toxicity\", \"sourceText\": \"until unacceptable toxicity\"}, {\"id\": \"6518557b-0340-40a5-b6d0-36887a7abc5a\", \"type\": \"Cycle\", \"exitCondition\": \"Unacceptable toxicity\", \"sourceText\": \"until unacceptable \\ntoxicity\"}, {\"id\": \"70f59598-b30f-4659-815b-6338b7c3a359\", \"type\": \"Cycle\", \"exitCondition\": \"Disease progression\", \"sourceText\": \"until death\"}, {\"id\": \"cf76f6dd-7e24-41fb-8171-383a3ac8e595\", \"type\": \"Cycle\", \"startOffset\": \"P0D\", \"interval\": \"P21D\", \"minObservations\": 2, \"exitCondition\": \"death from any cause within 3 weeks\", \"sourceText\": \"Mean and mean changes from baseline score (by cycle) in all the subscales of the EORTC QLQ-C30 and QLQ-HCC18\"}, {\"id\": \"b9897946-5971-4a6a-90cb-5f07a1f88e1b\", \"type\": \"Continuous\", \"startOffset\": \"P0D\", \"interval\": \"P21D\", \"minObservations\": 2, \"exitCondition\": \"death from any cause within 3 weeks\", \"sourceText\": \"TTD maintained for 2 consecutive timepoints, or 1 timepoint followed by death from any cause within 3 weeks\"}, {\"id\": \"552ae4f2-c9a6-488b-b8a6-7aa3ea02d4c7\", \"type\": \"Interval\", \"startOffset\": \"P0D\", \"minObservations\": 2, \"sourceText\": \"Timing for Vital Sign Measurements for First and Subsequent Infusions\"}, {\"id\": \"983c236e-ab80-4a39-9411-2a0fb0607c5b\", \"type\": \"Interval\", \"startOffset\": \"P0D\", \"minObservations\": 2, \"sourceText\": \"Serum concentration of atezolizumab at specified timepoints\"}]"
              },
              {
                "id": "4343dfb3-c8fc-4928-804e-7f58b280c77e",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-traversalConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"7023cf45-0c59-49a3-83bb-d2df2b32627b\", \"requiredSequence\": [\"epoch_1\", \"epoch_3\", \"epoch_4\", \"epoch_4\", \"epoch_4\"], \"allowEarlyExit\": true, \"exitEpochIds\": [], \"mandatoryVisits\": [\"enc_5\", \"enc_1\", \"enc_3\", \"enc_3\", \"enc_4\"], \"sourceText\": \"[{'condition': 'Adverse Event requiring discontinuation', 'path': ['STUDY_TREATMENT_DISCONTINUATION', 'SAFETY_FOLLOW_UP', 'SURVIVAL_FOLLOW_UP']}, {'condition': 'Withdrawal of consent', 'path': ['PATIENT_DISCONTINUATION_FROM_STUDY']}]\"}]"
              },
              {
                "id": "aecbf3f3-da66-4aa0-9f79-6af5d0373fa5",
                "url": "https://protocol2usdm.io/extensions/x-footnoteConditions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"6321e873-b730-4dbc-a739-c5e6b1441cc6\", \"conditionType\": \"timing_after\", \"text\": \"a. The first dosing date (Cycle 1, Day 1) should occur within 3 business days from randomization, with the exception of the emergence of an adverse event for which dosing may be postponed. All visits and infusions thereafter may be administered with a window of \\u00b1 3 days.\", \"footnoteId\": \"60e2c9ca-06c9-403c-8648-96b3d13d5880\", \"structuredCondition\": \"timing.after(randomization, P3D) && timing.window(subsequent_visits, P3D)\", \"appliesToActivityIds\": [\"1cb596db-3995-4454-a9a6-2196bf8e2aff\", \"816e3ef5-8953-48e4-a4fd-aa8101ae6f2b\"], \"sourceText\": \"a. The first dosing date (Cycle 1, Day 1) should occur within 3 business days from randomization, wi\"}, {\"id\": \"f44b3d16-92d1-424c-87eb-43a87dea04f0\", \"conditionType\": \"timing_before\", \"text\": \"b. Written informed consent can be obtained up to 30 days prior to study entry and is required before performing any study-specific tests or procedures. Results of standard of care tests or examinations performed prior to obtaining informed consent and per protocol relevant window may be used for screening assessments rather than repeating such tests. Screening local laboratory assessments obtained \\u2264 96 hours prior to the initiation of study treatment do not have to be repeated for Cycle 1. Test results should be reviewed prior to administration of study treatment.\", \"footnoteId\": \"e1edce6e-a4b4-499b-a1b9-3530fb96f40a\", \"structuredCondition\": \"timing.before(the initiation of study treatment do not have to be repeated for cycle 1. test results should be reviewed prior to administration of study treatment., PT96M)\", \"appliesToActivityIds\": [\"f29cee6a-2192-43a1-8cce-67e50e3608e6\", \"95424f85-cacb-418c-a51f-405dd241e8be\"], \"timingConstraint\": \"PT96H\", \"sourceText\": \"b. Written informed consent can be obtained up to 30 days prior to study entry and is required befor\"}, {\"id\": \"ffd8ce82-f159-4ab6-8874-41a0b3662f82\", \"conditionType\": \"timing_before\", \"text\": \"c. Patients will be asked to return to the clinic 30 days after the last dose of study treatment for an end-of-treatment visit. After this visit, serious adverse events and protocol defined adverse events of special interest, regardless of attribution, will be recorded until 90 days after the last dose of study treatment or until initiation of another systemic anti-cancer therapy, whichever occurs first. Ongoing adverse events thought to be related to study treatment will be followed until the event has resolved to baseline grade or better, the event is assessed by the investigator as stable, new anti-cancer treatment is initiated, the patient is lost to follow-up, the patient withdraws consent, or it is determined that the study treatment or participation is not the cause of the adverse event. Scans performed within 6 weeks prior to the treatment discontinuation visit do not need to be repeated.\", \"footnoteId\": \"e7520fa6-82db-4e84-99fd-a3a65091c87b\", \"structuredCondition\": \"timing.after(last_dose, P30D) && timing.after(last_dose, P90D)\", \"appliesToActivityIds\": [\"95424f85-cacb-418c-a51f-405dd241e8be\", \"816e3ef5-8953-48e4-a4fd-aa8101ae6f2b\", \"828c269f-2bb0-4f00-a838-e6316bf9fe33\", \"08dbf4d9-7773-4dce-8dde-78683a3c8f87\", \"1cb596db-3995-4454-a9a6-2196bf8e2aff\", \"698106bf-4042-47b2-af87-2619eb2e0c62\"], \"sourceText\": \"c. Patients will be asked to return to the clinic 30 days after the last dose of study treatment for\"}, {\"id\": \"018708db-4692-46be-bafd-a33069c94daf\", \"conditionType\": \"general\", \"text\": \"d. Cancer history includes stage, date of diagnosis, and prior anti-tumor treatment. Demographic information includes age and self-reported race/ethnicity. Reproductive status and smoking history should also be captured.\", \"footnoteId\": \"b2346783-832e-41dd-87ea-c060c2ff1ab7\", \"sourceText\": \"d. Cancer history includes stage, date of diagnosis, and prior anti-tumor treatment. Demographic inf\", \"appliesToActivityIds\": [\"08dbf4d9-7773-4dce-8dde-78683a3c8f87\", \"c6c141c9-bba2-47e6-9414-bea3c0135857\", \"698106bf-4042-47b2-af87-2619eb2e0c62\", \"763973ad-b0bc-4bbe-bf6f-b683cea2db94\"]}, {\"id\": \"770ad4d2-be86-45c1-b12d-f9dc6cf99c2a\", \"conditionType\": \"general\", \"text\": \"e. A complete physical examination at screening should include the evaluation of head, eye, ear, nose, and throat and cardiovascular, dermatologic, musculoskeletal, respiratory, gastrointestinal, genitourinary, and neurologic systems. Changes in abnormalities noted at baseline should be recorded at the end of the visit. New or worsened abnormalities should be recorded as adverse events if appropriate.\", \"footnoteId\": \"fb0973f0-da74-4d6b-a943-7135937a150e\", \"sourceText\": \"e. A complete physical examination at screening should include the evaluation of head, eye, ear, nos\", \"appliesToActivityIds\": [\"1cb596db-3995-4454-a9a6-2196bf8e2aff\", \"25d75c60-587d-452d-aabf-0890d5992450\", \"b2c3814e-81f4-4171-bced-4f4499cf84fa\"]}, {\"id\": \"18e9edea-ae6f-4de3-b6b4-bee914c76af2\", \"conditionType\": \"general\", \"text\": \"f. A limited physical examination will be performed at other visits to assess changes from baseline abnormalities and any new abnormalities and to evaluate patient-reported symptoms. New or worsened abnormalities should be recorded as adverse events if appropriate.\", \"footnoteId\": \"cdba2b41-cdea-4129-a203-dd97a6656300\", \"sourceText\": \"f. A limited physical examination will be performed at other visits to assess changes from baseline \", \"appliesToActivityIds\": [\"ce5762b2-32e2-460e-b3bf-fc1e51b8ff07\", \"1cb596db-3995-4454-a9a6-2196bf8e2aff\", \"25d75c60-587d-452d-aabf-0890d5992450\", \"95f20827-374c-44ed-bf19-1a1bf8abac09\"]}, {\"id\": \"5aa968ec-ef6f-4bd8-bd1d-4e984f8bdb5e\", \"conditionType\": \"timing_before\", \"text\": \"g. ECOG Performance Status, limited physical examination, local laboratory assessments, and PROs may be obtained \\u2264 96 hours before Day 1 of each cycle.\", \"footnoteId\": \"e915bd87-c91a-4e90-8e31-88681ec17e9f\", \"structuredCondition\": \"timing.before(day 1 of each cycle., PT96M)\", \"appliesToActivityIds\": [\"25d75c60-587d-452d-aabf-0890d5992450\", \"c6c141c9-bba2-47e6-9414-bea3c0135857\", \"f29cee6a-2192-43a1-8cce-67e50e3608e6\"], \"timingConstraint\": \"PT96H\", \"sourceText\": \"g. ECOG Performance Status, limited physical examination, local laboratory assessments, and PROs may\"}, {\"id\": \"7d11ef21-33fa-4e00-9790-b01844ab5fcc\", \"conditionType\": \"timing_before\", \"text\": \"h. The EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D-5L questionnaires will be completed by all patients on paper starting on Day 1 of Cycle 1 and Day 1 of every cycle thereafter. All PRO questionnaires scheduled for administration during a clinic visit are required to be completed by the patient at the investigational site at the start of the clinic visit before discussion of the patient's health state, lab results or health record, before administration of study treatment, and/or prior to any other study assessment(s). This is to avoid any potential bias to patients' responses to ensure that the validity of the instrument is not compromised and that data quality meets regulatory requirements. Interview assessment by a member of the clinic staff will be allowed if the patient is not able to complete the measure on their own. Study personnel should review all questionnaires for completeness before the patient leaves the investigational site. During survival follow-up, all PRO questionnaires will be completed every 3 months (for 1 year), unless the patient withdraws consent or the Sponsor terminates the study. PRO questionnaires during the survival follow-up period may be completed at the investigational site should the patient come in for a clinic visit or be administered via interview in telephone calls.\", \"footnoteId\": \"10424952-88c4-483d-9a26-e8d9522eb8b2\", \"structuredCondition\": \"sequence.before(treatment_administration) && sequence.before(health_discussion)\", \"appliesToActivityIds\": [\"25d75c60-587d-452d-aabf-0890d5992450\", \"95424f85-cacb-418c-a51f-405dd241e8be\", \"816e3ef5-8953-48e4-a4fd-aa8101ae6f2b\", \"828c269f-2bb0-4f00-a838-e6316bf9fe33\", \"763973ad-b0bc-4bbe-bf6f-b683cea2db94\", \"698106bf-4042-47b2-af87-2619eb2e0c62\", \"1f86581c-8fca-4949-a962-2eee8dbd454b\"], \"sourceText\": \"h. The EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D-5L questionnaires will be completed by all patients\"}, {\"id\": \"0615e6dd-1fc3-426f-9b31-7cf57a1e726c\", \"conditionType\": \"timing_before\", \"text\": \"i. All measurable and evaluable lesions should be assessed and documented at the screening visit. Radiologic imaging performed during the screening period should consist of 1) CT and/or MRI of the chest/abdomen/pelvis and brain, 2) bone scan or PET scan as clinically indicated, and 3) any other imaging studies (CT scan of the neck, plain films, etc.) as clinically indicated by the treating physician. The same radiographic procedures and technique must be used throughout the study for each patient (e.g., if the patient had CT chest/abdomen/pelvis performed during screening, then she should subsequently undergo CT performed with use of the same radiologic protocol throughout the remainder of the study). Results must be reviewed by the investigator before dosing at the next cycle. Tumor assessments will be performed at baseline, every 6 weeks (\\u00b1 1 week) for the first 54 weeks following the initiation of study treatment, and every 9 weeks (\\u00b1 1 week) thereafter, with additional scans as clinically indicated. All known sites of disease documented at screening should be re-assessed at each subsequent tumor evaluation. Tumor response will be evaluated by the investigator with use of RECIST version 1.1 and imRECIST. In the absence of disease progression, tumor assessments should continue regardless of whether patients discontinue study treatment or start new anti-cancer treatment, unless the patient dies, withdraws consent, or the study is terminated by the Sponsor, whichever occurs first.\", \"footnoteId\": \"741ab5f1-69e5-47a0-8e41-8853545faa5c\", \"structuredCondition\": \"frequency.interval(P6W, P1W) && frequency.interval(P9W, P1W)\", \"appliesToActivityIds\": [\"763973ad-b0bc-4bbe-bf6f-b683cea2db94\"], \"sourceText\": \"i. All measurable and evaluable lesions should be assessed and documented at the screening visit. Ra\"}, {\"id\": \"ad937845-4110-4ffe-840e-d8a10a4e3da9\", \"conditionType\": \"timing_before\", \"text\": \"j. Vital signs include heart rate, respiratory rate, blood pressure, and temperature. For patients randomized to Arm A, on days of study treatment administration (atezolizumab and bevacizumab), the patient's vital signs should be determined up to 60 minutes before all infusions. Vital signs will be measured at the end of bevacizumab infusion and 2 (\\u00b1 1) hours after end of the infusion and will also be collected during and after every infusion of atezolizumab if clinically indicated.\", \"footnoteId\": \"086bfcf8-f748-43b0-ad3f-d6099afc8049\", \"structuredCondition\": \"timing.before(all infusions. vital signs will be measured at the end of bevacizumab infusion and 2 (\\u00b1 1) hours after end of the infusion and will also be collected during and after every infusion of atezolizumab if clinically indicated., PT60M)\", \"appliesToActivityIds\": [\"60004221-4821-455e-a413-9f55e93f5239\"], \"timingConstraint\": \"PT60H\", \"sourceText\": \"j. Vital signs include heart rate, respiratory rate, blood pressure, and temperature. For patients r\"}, {\"id\": \"4f0ff4f4-72a9-4dbc-9800-3614ec281a13\", \"conditionType\": \"timing_before\", \"text\": \"k. The dose of bevacizumab will be based on the patient's weight (in kilograms) measured \\u2264 14 days prior to baseline (the initiation of study treatment) and will remain the same throughout the study unless there is a weight change of > 10% from baseline. If re-baseline is needed the latest baseline weight should always be used to calculate percent change in weight for all subsequent doses.\", \"footnoteId\": \"be0b1874-9f58-4794-8da6-c8f5eeb871e4\", \"structuredCondition\": \"if(weight_change > 0.10) { recalculate_dose() }\", \"appliesToActivityIds\": [\"5eef4a97-c02b-4fb9-910a-9add09c89013\"], \"sourceText\": \"k. The dose of bevacizumab will be based on the patient's weight (in kilograms) measured \\u2264 14 days p\"}, {\"id\": \"601199f7-f052-4f15-a8b0-03cecb97cc2e\", \"conditionType\": \"timing_before\", \"text\": \"l. Patients should be resting and in a supine position for at least 10 minutes prior to each ECG collection.\", \"footnoteId\": \"8890fb97-e9de-411e-8b14-fbb66114284a\", \"structuredCondition\": \"timing.before(each ecg collection., PT10M)\", \"appliesToActivityIds\": [\"595631ed-5b13-4ba5-8b6a-b67dabe11674\"], \"timingConstraint\": \"PT10M\", \"sourceText\": \"l. Patients should be resting and in a supine position for at least 10 minutes prior to each ECG col\"}, {\"id\": \"a5f87586-e17f-4cbf-9e63-47d5ccfa109d\", \"conditionType\": \"timing_before\", \"text\": \"m. All patients must undergo an EGD and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment.\", \"footnoteId\": \"0ab90201-3ffe-4023-a7a9-96c9ab7f4191\", \"sourceText\": \"m. All patients must undergo an EGD and all size of varices (small to large) must be assessed and tr\", \"appliesToActivityIds\": [\"356adf92-7500-447d-b122-76bc02816824\"]}, {\"id\": \"12aa0aaa-8653-4a75-8619-202aa1266fd8\", \"conditionType\": \"procedure_conditional\", \"text\": \"n. Hematology consists of CBC, including RBC count, hemoglobin, hematocrit, WBC count with differential (neutrophils, eosinophils, lymphocytes, monocytes, basophils, and other cells), and platelet count. A manual differential can be done if clinically indicated.\", \"footnoteId\": \"a9c1ee70-58da-4275-af25-1c298ad0e811\", \"sourceText\": \"n. Hematology consists of CBC, including RBC count, hemoglobin, hematocrit, WBC count with different\", \"appliesToActivityIds\": [\"08dbf4d9-7773-4dce-8dde-78683a3c8f87\", \"7b4dc48e-8841-41d3-8b7a-d1b82b9ba3bd\"]}, {\"id\": \"705949df-7634-4b9e-af59-d62a98ca1cf3\", \"conditionType\": \"general\", \"text\": \"o. Serum chemistry includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, potassium, magnesium, chloride, glucose, BUN or urea, creatinine, total protein, albumin, phosphorus, calcium, total bilirubin, alkaline phosphatase, ALT, AST, and LDH.\", \"footnoteId\": \"da7ddd21-f952-4af1-81f2-ead32319f8b3\", \"sourceText\": \"o. Serum chemistry includes bicarbonate or total carbon dioxide (if considered standard of care for \", \"appliesToActivityIds\": [\"342637c8-3ba7-4142-8a2a-2c715b33bfd8\"]}, {\"id\": \"c236d0d4-acae-489d-93f5-b6b9d7911c25\", \"conditionType\": \"timing_before\", \"text\": \"p. All patients will be tested for HIV locally prior to the inclusion into the study and if not in contradiction with local legislation; HIV-positive patients will be excluded from the clinical study. HBsAg, HBcAb, and HBsAb should be collected during screening and tested locally. HBV DNA must be collected prior to Cycle 1, Day 1 in patients who have negative serology for HBsAg and positive serology for anti-HBcAb.\", \"footnoteId\": \"c4cdddcb-2f2d-4616-b798-031b265d722a\", \"sourceText\": \"p. All patients will be tested for HIV locally prior to the inclusion into the study and if not in c\", \"appliesToActivityIds\": [\"bb9bf26a-337e-448e-b9a3-dc0de7878578\", \"ecf70b4c-6605-4f42-9249-36d7e43a1f65\", \"816e3ef5-8953-48e4-a4fd-aa8101ae6f2b\", \"b2c3814e-81f4-4171-bced-4f4499cf84fa\"]}, {\"id\": \"6151ea5f-69ce-4a8f-9dec-73be6f6e103a\", \"conditionType\": \"general\", \"text\": \"q. Only if patient tests positive for HBsAg, HBcAb, quantitative HBsAg and HBV DNA will be tested during screening; Cycle 5, Day 1; Cycle 9, Day 1; and at treatment discontinuation. Quantitative HBsAg will be tested by central laboratory. If a patient tests positive for HCV antibody at screening, quantitative HCV RNA must be tested locally at screening, Cycle 5 Day 1, Cycle 9 Day 1, and at treatment discontinuation.\", \"footnoteId\": \"4f687133-58d7-4980-819f-932cdfec8e81\", \"sourceText\": \"q. Only if patient tests positive for HBsAg, HBcAb, quantitative HBsAg and HBV DNA will be tested du\", \"appliesToActivityIds\": [\"ecf70b4c-6605-4f42-9249-36d7e43a1f65\", \"f29cee6a-2192-43a1-8cce-67e50e3608e6\", \"b2c3814e-81f4-4171-bced-4f4499cf84fa\", \"698106bf-4042-47b2-af87-2619eb2e0c62\"]}, {\"id\": \"7572673d-0b43-438a-b87e-8c805f9ad9a5\", \"conditionType\": \"timing_before\", \"text\": \"r. Urine dipstick includes specific gravity, pH, glucose, protein, ketones, and blood and should be repeated before every cycle during treatment. Urine dipstick for proteinuria must be < 2+ within 7 days prior to initiation of study treatment. Patients discovered to have \\u2265 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours.\", \"footnoteId\": \"0a9871f7-a4e5-47dd-9d3e-60d53778d271\", \"structuredCondition\": \"timing.before(treatment_initiation, P7D)\", \"appliesToActivityIds\": [\"816e3ef5-8953-48e4-a4fd-aa8101ae6f2b\", \"698106bf-4042-47b2-af87-2619eb2e0c62\", \"f8a2de8e-cccf-4f46-8106-bb52e9f19316\"], \"timingConstraint\": \"PT24H\", \"sourceText\": \"r. Urine dipstick includes specific gravity, pH, glucose, protein, ketones, and blood and should be \"}, {\"id\": \"e85d386b-8487-4582-a46e-8d8504b502f3\", \"conditionType\": \"timing_before\", \"text\": \"s. Serum pregnancy test within 14 days before Cycle 1, Day 1.\", \"footnoteId\": \"3844f4f5-7622-4078-a705-8738af6d7241\", \"structuredCondition\": \"timing.before(Cycle_1_Day_1, P14D)\", \"appliesToActivityIds\": [\"b2c3814e-81f4-4171-bced-4f4499cf84fa\"], \"sourceText\": \"s. Serum pregnancy test within 14 days before Cycle 1, Day 1.\"}, {\"id\": \"77b780b9-e431-4f40-bfb7-38ad2e187d48\", \"conditionType\": \"general\", \"text\": \"t. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.\", \"footnoteId\": \"5721b16a-791a-4658-9164-58aedfd92847\", \"sourceText\": \"t. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum preg\", \"appliesToActivityIds\": [\"342637c8-3ba7-4142-8a2a-2c715b33bfd8\", \"b2c3814e-81f4-4171-bced-4f4499cf84fa\"]}, {\"id\": \"02d46266-0a67-4d07-abd7-8d88542f70af\", \"conditionType\": \"timing_before\", \"text\": \"u. Concomitant medications include any prescription medications or over-the-counter medications. At screening, any medications the patient has used within the 7 days prior to initiation of study treatment should be documented. At subsequent visits, changes to current medications or medications used since the last documentation of medications will be recorded.\", \"footnoteId\": \"97cd9e8b-1cd2-4daa-bccc-883c46bcccef\", \"sourceText\": \"u. Concomitant medications include any prescription medications or over-the-counter medications. At \", \"appliesToActivityIds\": [\"816e3ef5-8953-48e4-a4fd-aa8101ae6f2b\", \"ba6a9168-9994-4f90-a10f-60e6ad357f3a\", \"698106bf-4042-47b2-af87-2619eb2e0c62\"]}, {\"id\": \"19b50b1a-8e02-4052-97d6-e92cca0c8f55\", \"conditionType\": \"timing_before\", \"text\": \"v. After informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protocol-mandated intervention should be reported. After initiation of study drug, all adverse events will be reported until 30 days after the last dose of study treatment or until initiation of another anti-cancer therapy, whichever occurs first. Serious adverse events and adverse events of special interest will continue to be reported until 90 days after the last dose of study treatment or until initiation of new anti-cancer therapy, whichever occurs first. After this period, investigators should report any serious adverse events and adverse events of special interest that are believed to be related to prior treatment with study drug. The investigator should follow each adverse event until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, new systemic anti-cancer treatment is initiated, the patient is lost to follow-up, the patient withdraws consent, or it is determined that the study treatment or participation is not the cause of the adverse event. Every effort should be made to follow all serious adverse events considered to be related to study drug or study-related procedures until a final outcome can be reported.\", \"footnoteId\": \"9217f924-4710-4ec8-819b-de1052532983\", \"sourceText\": \"v. After informed consent has been obtained but prior to initiation of study drug, only serious adve\", \"appliesToActivityIds\": [\"95424f85-cacb-418c-a51f-405dd241e8be\", \"816e3ef5-8953-48e4-a4fd-aa8101ae6f2b\", \"828c269f-2bb0-4f00-a838-e6316bf9fe33\", \"08dbf4d9-7773-4dce-8dde-78683a3c8f87\", \"1cb596db-3995-4454-a9a6-2196bf8e2aff\", \"698106bf-4042-47b2-af87-2619eb2e0c62\"]}, {\"id\": \"8d99c5ad-45d7-4c99-87ac-b33eff9acd1d\", \"conditionType\": \"sequence\", \"text\": \"w. The initial dose of atezolizumab will be delivered over 60 (\\u00b1 15) minutes. If the first infusion is tolerated without infusion-associated adverse events, the second infusion may be delivered over 30 (\\u00b1 10) minutes. If the 30-minute infusion is well-tolerated, all subsequent infusions may be delivered over 30 (\\u00b1 10) minutes. The initial dose of bevacizumab will be delivered over 90 (\\u00b1 15) minutes. If the first infusion is tolerated without infusion-associated adverse events, the second infusion may be delivered over 60 (\\u00b1 10) minutes. If the 60-minute infusion is well-tolerated, all subsequent infusions may be delivered over 30 (\\u00b1 10) minutes. For patients randomized to Arm A, atezolizumab will be administered first followed by bevacizumab, with a minimum of 5 minutes between dosing. In the absence of unacceptable toxicity, patients may continue study treatment until there is evidence of disease progression or lack of clinical benefit.\", \"footnoteId\": \"9a736cb4-2a79-4c94-98d1-635303da8db4\", \"structuredCondition\": \"timing.duration(atezolizumab, PT60M) && timing.duration(bevacizumab, PT90M) && timing.gap(PT5M)\", \"appliesToActivityIds\": [\"1cb596db-3995-4454-a9a6-2196bf8e2aff\", \"816e3ef5-8953-48e4-a4fd-aa8101ae6f2b\", \"698106bf-4042-47b2-af87-2619eb2e0c62\"], \"timingConstraint\": \"PT5M\", \"sourceText\": \"w. The initial dose of atezolizumab will be delivered over 60 (\\u00b1 15) minutes. If the first infusion \"}, {\"id\": \"aef39445-09bc-42c3-a42c-37d18c0d49e1\", \"conditionType\": \"general\", \"text\": \"x. Sorafenib is taken by mouth twice a day continuously.\", \"footnoteId\": \"34f30e8b-1360-43cb-a800-a7b3beb52a01\", \"sourceText\": \"x. Sorafenib is taken by mouth twice a day continuously.\", \"appliesToActivityIds\": [\"55090bbc-c623-4797-86a4-5f8e56cccf2e\"]}, {\"id\": \"240cdc8c-c6da-457d-b3b0-ad45aac91d5b\", \"conditionType\": \"general\", \"text\": \"y. Survival follow-up information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 3 months (\\u00b1 21 days) until death, loss to follow-up, or until study termination by the Sponsor. All patients will be followed for survival and new anti-cancer therapy (including targeted therapy and immunotherapy) information unless the patient requests to be withdrawn from follow-up; this request must be documented in the source documents and signed by the investigator. If the patient withdraws from study, the study staff may use a public information source (e.g., county records) to obtain information about survival status only.\", \"footnoteId\": \"820a3520-ba9f-475d-8c56-a5259d40eb5a\", \"sourceText\": \"y. Survival follow-up information will be collected via telephone calls, patient medical records, an\", \"appliesToActivityIds\": [\"95424f85-cacb-418c-a51f-405dd241e8be\", \"c6c141c9-bba2-47e6-9414-bea3c0135857\", \"816e3ef5-8953-48e4-a4fd-aa8101ae6f2b\", \"828c269f-2bb0-4f00-a838-e6316bf9fe33\", \"08dbf4d9-7773-4dce-8dde-78683a3c8f87\"]}, {\"id\": \"39baf356-ed5c-4b20-8ea7-d3e0f5f607e0\", \"conditionType\": \"timing_before\", \"text\": \"z. Local laboratory assessments from each cycle must be reviewed prior to study treatment administration for each cycle.\", \"footnoteId\": \"34116c74-cc3c-4719-909d-720630e61f1a\", \"sourceText\": \"z. Local laboratory assessments from each cycle must be reviewed prior to study treatment administra\", \"appliesToActivityIds\": [\"f29cee6a-2192-43a1-8cce-67e50e3608e6\", \"816e3ef5-8953-48e4-a4fd-aa8101ae6f2b\", \"43f4be9d-e5a6-42a8-99e1-8d570b7a88c2\", \"763973ad-b0bc-4bbe-bf6f-b683cea2db94\", \"698106bf-4042-47b2-af87-2619eb2e0c62\", \"1f86581c-8fca-4949-a962-2eee8dbd454b\"]}]"
              },
              {
                "id": "0bd73cb4-8dd7-4b25-adb1-b932c61d1502",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-endpointAlgorithms",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"1b47e68f-7105-4a35-becc-607aa619d2fc\", \"name\": \"Co-Primary: Overall Survival (OS)\", \"endpointType\": \"Primary\", \"inputs\": [\"date of randomization\", \"date of death\", \"last date known alive\", \"data cutoff date\"], \"timeWindow\": {\"reference\": \"randomization\", \"duration\": \"until death or data cutoff\"}, \"algorithm\": \"date_of_death - date_of_randomization\", \"successCriteria\": \"Statistically significant improvement (2-sided alpha = 0.048) via stratified log-rank test\", \"sourceText\": \"Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients who are alive at the time of the analysis data cutoff will be censored at the last \"}, {\"id\": \"b2f53daf-1070-4890-9231-4f496c304a6f\", \"name\": \"Co-Primary: Progression-Free Survival (PFS)\", \"endpointType\": \"Primary\", \"inputs\": [\"date of randomization\", \"date of first IRF-assessed disease progression\", \"date of death\", \"RECIST v1.1 criteria\"], \"timeWindow\": {\"reference\": \"randomization\", \"duration\": \"until progression or death\"}, \"algorithm\": \"min(date_of_progression, date_of_death) - date_of_randomization\", \"successCriteria\": \"Statistically significant improvement (2-sided alpha = 0.002) via stratified log-rank test\", \"sourceText\": \"The primary efficacy objective for this study is to evaluate the efficacy of atezolizumab in combination with bevacizumab compared with sorafenib on the basis of the co-primary efficacy endpoints of O\"}]"
              },
              {
                "id": "3c920027-d3a6-4b2c-9ea3-d71c3d8626f8",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-derivedVariables",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"a6856d96-b9e1-464f-b532-106855798f6e\", \"name\": \"Mean change from baseline in EORTC QLQ-C30 subscales\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"EORTC QLQ-C30 subscale scores\"], \"derivationRule\": \"Post-baseline score - Baseline score\", \"baselineDefinition\": \"Score at baseline (pre-treatment)\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"By cycle\", \"imputationRule\": \"Not specified\", \"unit\": \"Score\"}, {\"id\": \"3fe6859f-ed16-4ded-ae21-2b660a46d49e\", \"name\": \"Mean change from baseline in EORTC QLQ-HCC18 subscales\", \"variableType\": \"ChangeFromBaseline\", \"sourceVariables\": [\"EORTC QLQ-HCC18 subscale scores\"], \"derivationRule\": \"Post-baseline score - Baseline score\", \"baselineDefinition\": \"Score at baseline (pre-treatment)\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"By cycle\", \"imputationRule\": \"Not specified\", \"unit\": \"Score\"}, {\"id\": \"6a87efb8-ac28-4fa0-90b6-6e6833897d73\", \"name\": \"Clinically meaningful change in select QLQ-C30 and QLQ-HCC18 scales\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"GHS/QoL\", \"Physical function\", \"Role function\", \"Appetite loss\", \"Diarrhea\", \"Fatigue\", \"Pain\", \"Jaundice\"], \"derivationRule\": \"Proportion of patients meeting a predefined threshold for clinically meaningful change\", \"baselineDefinition\": \"Baseline score for the specific scale\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Study duration\", \"imputationRule\": \"Not specified\", \"unit\": \"Proportion\"}, {\"id\": \"ebc4762f-8581-48db-87f7-5cd053b23de7\", \"name\": \"Time to Deterioration (TTD) in select QLQ-C30 and QLQ-HCC18 scales\", \"variableType\": \"TimeToEvent\", \"sourceVariables\": [\"Appetite loss\", \"Diarrhea\", \"Fatigue\", \"Pain\", \"Jaundice\"], \"derivationRule\": \"Time from randomization to deterioration maintained for 2 consecutive timepoints, or 1 timepoint followed by death from any cause within 3 weeks\", \"baselineDefinition\": \"Baseline score for the specific scale\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Study duration\", \"imputationRule\": \"Not specified\", \"unit\": \"Days/Months\"}, {\"id\": \"3872b304-a545-4f7f-b7f6-45d6c68000d8\", \"name\": \"Time to Deterioration (TTD) in HRQoL/GHS, physical function, and role function\", \"variableType\": \"TimeToEvent\", \"sourceVariables\": [\"HRQoL/GHS\", \"Physical function\", \"Role function\"], \"derivationRule\": \"Time from randomization to deterioration maintained for 2 consecutive timepoints, or 1 timepoint followed by death from any cause within 3 weeks\", \"baselineDefinition\": \"Baseline score for the specific scale\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Study duration\", \"imputationRule\": \"Not specified\", \"unit\": \"Days/Months\"}, {\"id\": \"56aa40a0-332d-44f3-a20d-80b0ea13a6a4\", \"name\": \"Presence of ADAs to atezolizumab relative to baseline\", \"variableType\": \"Categorical\", \"sourceVariables\": [\"Anti-drug antibody (ADA) status\"], \"derivationRule\": \"Comparison of post-baseline ADA presence vs. baseline ADA presence\", \"baselineDefinition\": \"ADA status at baseline\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"During the study\", \"imputationRule\": \"Not specified\", \"unit\": \"Presence/Absence\"}, {\"id\": \"61377ac6-2caa-48cb-97a1-51982a0de945\", \"name\": \"Health utility and VAS scores (EQ-5D-5L)\", \"variableType\": \"Custom\", \"sourceVariables\": [\"EQ-5D-5L questionnaire items\"], \"derivationRule\": \"Utility scores generated from EQ-5D-5L responses and Visual Analog Scale (VAS) scores\", \"baselineDefinition\": \"Baseline EQ-5D-5L assessment\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Study duration\", \"imputationRule\": \"Not specified\", \"unit\": \"Utility index / 0-100 scale\"}]"
              },
              {
                "id": "e681af31-c797-476d-ae0e-bd79b648bf79",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-stateMachine",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"4f0d1d90-a0ed-469b-9e31-8c04a410f5c9\", \"initialState\": \"Screening\", \"terminalStates\": [\"Early Termination\", \"Completed\"], \"states\": [\"Screening\", \"Treatment\", \"Safety Follow Up\", \"Survival Follow Up\", \"End Of Study\", \"Early Termination\"], \"transitions\": [{\"fromState\": \"Screening\", \"toState\": \"Treatment\", \"trigger\": \"Progress to Treatment\"}, {\"fromState\": \"Treatment\", \"toState\": \"Safety Follow Up\", \"trigger\": \"Progress to Safety Follow Up\"}, {\"fromState\": \"Safety Follow Up\", \"toState\": \"Survival Follow Up\", \"trigger\": \"Progress to Survival Follow Up\"}, {\"fromState\": \"Survival Follow Up\", \"toState\": \"End Of Study\", \"trigger\": \"Progress to End Of Study\"}, {\"fromState\": \"Treatment\", \"toState\": \"Early Termination\", \"trigger\": \"Subject exits to Early Termination\"}], \"epochIds\": {\"Screening\": \"SCREENING\", \"Treatment\": \"TREATMENT\", \"Safety Follow Up\": \"SAFETY_FOLLOW_UP\", \"Survival Follow Up\": \"SURVIVAL_FOLLOW_UP\", \"End Of Study\": \"END_OF_STUDY\", \"Early Termination\": \"EARLY_TERMINATION\"}}"
              },
              {
                "id": "0021a30b-056f-419a-b6a5-11360e283e1a",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-dosingRegimens",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"06515a38-d532-4f15-b6fe-2a013768d8d6\", \"treatmentName\": \"Atezolizumab\", \"frequency\": \"BID\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1200.0, \"unit\": \"mg\"}, {\"amount\": 400.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"durationDescription\": \"3 weeks\", \"doseModifications\": [\"Dose management for Grade 3 dermatologic events\", \"Management for Stevens-Johnson syndrome or toxic epidermal necrolysis\", \"Management for Hepatic Events\"], \"sourceText\": \"or metastatic HCC who have received no prior systemic treatment. This study will enroll approximately 480 patients randomized in a 2:1 ratio to one of two treatment arms: \\uf0b7 Arm A (experimental arm): A\"}, {\"id\": \"5f45a229-d11a-4a47-965e-fdd16dffe041\", \"treatmentName\": \"Sorafenib\", \"frequency\": \"BID\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 400.0, \"unit\": \"mg\"}, {\"amount\": 1200.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"durationDescription\": \"3 weeks\", \"doseModifications\": [\"Dose reduction for treatment-emergent toxicities\"], \"sourceText\": \"reatment arms: \\uf0b7 Arm A (experimental arm): Atezolizumab 1200 mg IV infusion every 3 weeks (Q3W; dosed in 3-week cycles) and bevacizumab 15 mg/kg Q3W (dosed in 3-week cycles) \\uf0b7 Arm B (control arm): Sor\"}, {\"id\": \"10f9bca1-0937-472b-9cbe-111be0c7db21\", \"treatmentName\": \"Patients received\", \"frequency\": \"Q3W\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 1200.0, \"unit\": \"mg\"}, {\"amount\": 15.0, \"unit\": \"mg\"}], \"sourceText\": \"with metastatic cancer. Arm A is designed to test the combination of atezolizumab and bevacizumab in patients with locally advanced or metastatic HCC who have not received prior systemic therapy. Pati\"}, {\"id\": \"6e11ed15-4fe0-4569-b3c2-ce4096cc6ec5\", \"treatmentName\": \"Bevacizumab\", \"frequency\": \"Q3W\", \"route\": \"IV\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 15.0, \"unit\": \"mg/kg\", \"description\": \"Weight-based dose\"}], \"durationDescription\": \"Until loss of clinical benefit or unacceptable toxicity\", \"doseModifications\": [\"Dose modifications for toxicity as per protocol guidelines\"]}]"
              },
              {
                "id": "abc234fa-d6d8-4651-986e-9a3a77348d15",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-visitWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"3837a6b2-51eb-4199-8d9a-743ac4ecff2d\", \"visitName\": \"screening\", \"targetDay\": -14, \"windowBefore\": 7, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 1, \"epoch\": \"Screening\", \"sourceText\": \"Negative HIV test at screening \\uf0b7 Documented virology status of hepatitis, as confirmed by screening hepatitis B virus (HBV)\"}, {\"id\": \"5dbf4b9e-1774-48a2-98b2-7b2e46bfd255\", \"visitName\": \"baseline\", \"targetDay\": 0, \"windowBefore\": 1, \"windowAfter\": 1, \"isRequired\": true, \"visitNumber\": 2, \"epoch\": \"Screening\", \"sourceText\": \"Patients discovered to have \\uf0b32\\uf02bproteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \\uf03c1 g of protein in 24 hours.\"}, {\"id\": \"74716e68-9048-45ad-a075-960391e79cb0\", \"visitName\": \"Early Termination\", \"targetDay\": null, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 3, \"sourceText\": \"heterosexual intercourse) or use contraceptive methods with a failure rate of \\uf03c1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, 6 months after the\"}, {\"id\": \"a86df8c8-dc45-4221-a0ab-47a7e02bdc71\", \"visitName\": \"Visit 1\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 4, \"sourceText\": \"Measurable disease, per RECIST v1.1, must be present outside the CNS. \\u2013 The patient has no history of intracranial hemorrhage or spinal cord hemorrhage.\"}, {\"id\": \"67a27bb0-246a-46f3-90d4-fca33bc237a0\", \"visitName\": \"eot\", \"targetDay\": null, \"windowBefore\": 28, \"windowAfter\": 28, \"isRequired\": true, \"visitNumber\": 5, \"sourceText\": \"The patient has not undergone stereotactic, whole-brain radiotherapy, and/or neurosurgical resection within 28 days prior to initiation of study treatment. \\u2013\"}, {\"id\": \"62ae1e95-5064-4a4d-94c4-4e4095d46cae\", \"visitName\": \"End of Study\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 6, \"sourceText\": \"End of Study The end of this study is defined as the date when the last patient, last visit (LPLV) occurs (i.e., last patient in the global and extended China enrollment phases combined) or safety\"}, {\"id\": \"080a8cba-953c-4377-88a4-4271422c09ff\", \"visitName\": \"randomization\", \"targetDay\": 1, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 7, \"sourceText\": \"Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients who are alive at the time of the analysis data cutoff will be censored at the last \"}, {\"id\": \"088c8ee5-fbdd-4065-9363-df06ede3287e\", \"visitName\": \"Follow-up\", \"targetDay\": 365, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 8, \"sourceText\": \"follow-up is received from the last patient (global and extended China enrollment phases combined), whichever occurs later. In addition, the Sponsor may decide to terminate the study at any time.\"}]"
              },
              {
                "id": "eda2e1fd-8a0d-4555-b02e-386d25b10345",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-randomizationScheme",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"f5697e56-0a80-4278-b777-4019bca7100c\", \"ratio\": \"2:1\", \"method\": \"Stratified randomization\", \"centralRandomization\": true, \"stratificationFactors\": [{\"id\": \"9203b45c-f571-4339-83dd-a4cd3cc90482\", \"name\": \"Region\", \"categories\": [\"North America\", \"Europe\", \"Asia\", \"Rest of World\"], \"isBlocking\": false, \"sourceText\": \"geographic region (asia excluding japan vs\"}, {\"id\": \"2f634c32-f18e-4fbd-bb2a-931137e21e8c\", \"name\": \"Geographic region\", \"categories\": [\"Asia excluding Japan\", \"rest of world\"], \"isBlocking\": false}, {\"id\": \"8f19ec8c-636b-4b30-9b91-22d47ff8caec\", \"name\": \"Macrovascular invasion and/or extrahepatic spread\", \"categories\": [\"presence\", \"absence\"], \"isBlocking\": false}, {\"id\": \"61facb04-e6f7-4338-8797-a5d0a6330028\", \"name\": \"Baseline \\u03b1-fetoprotein\", \"categories\": [\"<400 ng/mL\", \"\\u2265400 ng/mL\"], \"isBlocking\": false}, {\"id\": \"2feafa0c-c180-4690-a40a-3ac6fde22e20\", \"name\": \"Eastern Cooperative Oncology Group Performance Status\", \"categories\": [\"0\", \"1\"], \"isBlocking\": false}], \"sourceText\": \"Atezolizumab\\u2014F. Hoffmann-La Roche Ltd\\n4/Protocol YO40245, Version 6\\n3.3.7\\nRationale for Stratification...................................................... 47\\n3.3.7.1\\nGeographic Region...............\"}"
              },
              {
                "id": "ext_execution_model_5cd95494-c407-4d16-b48b-b8c59517de03",
                "url": "https://protocol2usdm.io/extensions/x-executionModel",
                "instanceType": "ExtensionAttribute",
                "valueObject": {
                  "schemaVersion": "1.0.0",
                  "extractionTimestamp": "2026-01-23T03:53:40.539256",
                  "executionModel": {
                    "timeAnchors": [
                      {
                        "id": "868576ee-f0c6-4b08-8018-cf6353a32551",
                        "definition": "First administration of investigational product",
                        "anchorType": "FirstDose",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 60,
                        "sourceText": "first dose of study treatment",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "035d9c49-de53-4f07-8b40-0f188a1cf6d4",
                        "definition": "The date on which the patient is assigned to a treatment group through the randomization process",
                        "anchorType": "Randomization",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 40,
                        "sourceText": "OS, defined as the time from randomization to death from any cause",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "2ceb909c-f460-48f6-95cd-66c55670891d",
                        "definition": "Informed consent obtained",
                        "anchorType": "InformedConsent",
                        "classification": "Event",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 10,
                        "sourceText": "Informed Consent",
                        "encounterId": null,
                        "activityId": null
                      },
                      {
                        "id": "69b069d7-0b16-4ebc-8488-2fee5be3ee60",
                        "definition": "procedure",
                        "anchorType": "Custom",
                        "classification": "Conceptual",
                        "timelineId": null,
                        "dayValue": 1,
                        "intraDayOrder": 100,
                        "sourceText": "procedure",
                        "encounterId": null,
                        "activityId": null
                      }
                    ],
                    "repetitions": [
                      {
                        "id": "33424ee5-5cbc-41e2-945b-a225aefcc488",
                        "type": "Daily",
                        "interval": "P1D",
                        "sourceText": "od"
                      },
                      {
                        "id": "886ab9ba-89dd-443a-8cd1-d5dd902c1825",
                        "type": "Interval",
                        "sourceText": "BID"
                      },
                      {
                        "id": "d298c64d-43ea-4d09-9ece-ade4d5c357e4",
                        "type": "Cycle",
                        "cycleLength": "P21D",
                        "sourceText": "21-day cycle"
                      },
                      {
                        "id": "ca185cbd-a4ed-41f2-b014-5bcf2474d40b",
                        "type": "Cycle",
                        "cycleLength": "P3D",
                        "sourceText": "3-week cycle"
                      },
                      {
                        "id": "ea722418-cbc0-4406-9d9b-511db29477d1",
                        "type": "Cycle",
                        "exitCondition": "Disease progression",
                        "sourceText": "until disease progression"
                      },
                      {
                        "id": "c3eaf240-a49a-432b-ab73-32d13b05a511",
                        "type": "Cycle",
                        "exitCondition": "Disease progression",
                        "sourceText": "until disease \nprogression"
                      },
                      {
                        "id": "244f979a-daf5-4292-aff2-dfeccc9f17bb",
                        "type": "Cycle",
                        "exitCondition": "Unacceptable toxicity",
                        "sourceText": "until unacceptable toxicity"
                      },
                      {
                        "id": "6518557b-0340-40a5-b6d0-36887a7abc5a",
                        "type": "Cycle",
                        "exitCondition": "Unacceptable toxicity",
                        "sourceText": "until unacceptable \ntoxicity"
                      },
                      {
                        "id": "70f59598-b30f-4659-815b-6338b7c3a359",
                        "type": "Cycle",
                        "exitCondition": "Disease progression",
                        "sourceText": "until death"
                      },
                      {
                        "id": "cf76f6dd-7e24-41fb-8171-383a3ac8e595",
                        "type": "Cycle",
                        "startOffset": "P0D",
                        "interval": "P21D",
                        "minObservations": 2,
                        "exitCondition": "death from any cause within 3 weeks",
                        "sourceText": "Mean and mean changes from baseline score (by cycle) in all the subscales of the EORTC QLQ-C30 and QLQ-HCC18"
                      },
                      {
                        "id": "b9897946-5971-4a6a-90cb-5f07a1f88e1b",
                        "type": "Continuous",
                        "startOffset": "P0D",
                        "interval": "P21D",
                        "minObservations": 2,
                        "exitCondition": "death from any cause within 3 weeks",
                        "sourceText": "TTD maintained for 2 consecutive timepoints, or 1 timepoint followed by death from any cause within 3 weeks"
                      },
                      {
                        "id": "552ae4f2-c9a6-488b-b8a6-7aa3ea02d4c7",
                        "type": "Interval",
                        "startOffset": "P0D",
                        "minObservations": 2,
                        "sourceText": "Timing for Vital Sign Measurements for First and Subsequent Infusions"
                      },
                      {
                        "id": "983c236e-ab80-4a39-9411-2a0fb0607c5b",
                        "type": "Interval",
                        "startOffset": "P0D",
                        "minObservations": 2,
                        "sourceText": "Serum concentration of atezolizumab at specified timepoints"
                      }
                    ],
                    "samplingConstraints": [],
                    "traversalConstraints": [
                      {
                        "id": "7023cf45-0c59-49a3-83bb-d2df2b32627b",
                        "requiredSequence": [
                          "epoch_1",
                          "epoch_3",
                          "epoch_4",
                          "epoch_4",
                          "epoch_4"
                        ],
                        "allowEarlyExit": true,
                        "exitEpochIds": [
                          "621d4a10-769e-4da0-afe7-537c31be78d4"
                        ],
                        "mandatoryVisits": [
                          "Safety Follow-up Visit",
                          "Screening",
                          "Cycle 1 Day 1",
                          "Day 1",
                          "End of Study",
                          "Treatment Discontinuation Visit"
                        ],
                        "sourceText": "[{'condition': 'Adverse Event requiring discontinuation', 'path': ['STUDY_TREATMENT_DISCONTINUATION', 'SAFETY_FOLLOW_UP', 'SURVIVAL_FOLLOW_UP']}, {'condition': 'Withdrawal of consent', 'path': ['PATIENT_DISCONTINUATION_FROM_STUDY']}]"
                      }
                    ],
                    "executionTypes": [
                      {
                        "activityId": "Serum Sample",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 1"
                      },
                      {
                        "activityId": "Vital Signs",
                        "executionType": "Window",
                        "rationale": "WINDOW signals: 2; SINGLE signals: 1"
                      },
                      {
                        "activityId": "Electrocardiogram",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Pe",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 3"
                      },
                      {
                        "activityId": "Adverse Events",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Concomitant Medication",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 1"
                      },
                      {
                        "activityId": "Laboratory Test",
                        "executionType": "Single",
                        "rationale": "WINDOW signals: 2; SINGLE signals: 3"
                      },
                      {
                        "activityId": "Pharmacokinetic",
                        "executionType": "Window",
                        "rationale": "WINDOW signals: 1"
                      },
                      {
                        "activityId": "Pharmacodynamic",
                        "executionType": "Recurring",
                        "rationale": "RECURRING signals: 2"
                      },
                      {
                        "activityId": "Drug Administration",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Imaging",
                        "executionType": "Episode",
                        "rationale": "EPISODE signals: 1; SINGLE signals: 1; RECURRING signals: 1"
                      },
                      {
                        "activityId": "Tissue Sample",
                        "executionType": "Single",
                        "rationale": "SINGLE signals: 1"
                      },
                      {
                        "activityId": "Questionnaire",
                        "executionType": "Single",
                        "rationale": "No strong signals detected"
                      },
                      {
                        "activityId": "Overall Survival (OS) Analysis",
                        "executionType": "Window",
                        "rationale": "Described as pre-planned interim analyses and subsequent analyses once statistical significance is reached, indicating a continuous monitoring period."
                      },
                      {
                        "activityId": "Management of Dermatologic Events",
                        "executionType": "Episode",
                        "rationale": "Guidelines for Grade 3 events and Stevens-Johnson syndrome involve conditional workflows and decision points based on the severity of the reaction."
                      },
                      {
                        "activityId": "cf5c5cc4-079c-48de-950f-d5739bdb5bfc",
                        "executionType": "Episode",
                        "rationale": "Requires specific management actions and decision-making protocols triggered by the occurrence of a reaction."
                      },
                      {
                        "activityId": "Screening for Severe Infection",
                        "executionType": "Single",
                        "rationale": "Assessment of infection within 4 weeks prior to initiation of study treatment to determine eligibility."
                      },
                      {
                        "activityId": "Safety Monitoring (Safety Plan)",
                        "executionType": "Recurring",
                        "rationale": "Ongoing assessment of patient safety and risks (including COVID-19) throughout the study participation."
                      }
                    ],
                    "footnoteConditions": [
                      {
                        "id": "6321e873-b730-4dbc-a739-c5e6b1441cc6",
                        "conditionType": "timing_after",
                        "text": "a. The first dosing date (Cycle 1, Day 1) should occur within 3 business days from randomization, with the exception of the emergence of an adverse event for which dosing may be postponed. All visits and infusions thereafter may be administered with a window of  3 days.",
                        "footnoteId": "60e2c9ca-06c9-403c-8648-96b3d13d5880",
                        "structuredCondition": "timing.after(randomization, P3D) && timing.window(subsequent_visits, P3D)",
                        "appliesToActivityIds": [
                          "Dosing",
                          "All visits",
                          "Infusions"
                        ],
                        "sourceText": "a. The first dosing date (Cycle 1, Day 1) should occur within 3 business days from randomization, wi"
                      },
                      {
                        "id": "f44b3d16-92d1-424c-87eb-43a87dea04f0",
                        "conditionType": "timing_before",
                        "text": "b. Written informed consent can be obtained up to 30 days prior to study entry and is required before performing any study-specific tests or procedures. Results of standard of care tests or examinations performed prior to obtaining informed consent and per protocol relevant window may be used for screening assessments rather than repeating such tests. Screening local laboratory assessments obtained  96 hours prior to the initiation of study treatment do not have to be repeated for Cycle 1. Test results should be reviewed prior to administration of study treatment.",
                        "footnoteId": "e1edce6e-a4b4-499b-a1b9-3530fb96f40a",
                        "structuredCondition": "timing.before(the initiation of study treatment do not have to be repeated for cycle 1. test results should be reviewed prior to administration of study treatment., PT96M)",
                        "appliesToActivityIds": [
                          "Informed Consent",
                          "Local laboratory assessments"
                        ],
                        "timingConstraint": "PT96H",
                        "sourceText": "b. Written informed consent can be obtained up to 30 days prior to study entry and is required befor"
                      },
                      {
                        "id": "ffd8ce82-f159-4ab6-8874-41a0b3662f82",
                        "conditionType": "timing_before",
                        "text": "c. Patients will be asked to return to the clinic 30 days after the last dose of study treatment for an end-of-treatment visit. After this visit, serious adverse events and protocol defined adverse events of special interest, regardless of attribution, will be recorded until 90 days after the last dose of study treatment or until initiation of another systemic anti-cancer therapy, whichever occurs first. Ongoing adverse events thought to be related to study treatment will be followed until the event has resolved to baseline grade or better, the event is assessed by the investigator as stable, new anti-cancer treatment is initiated, the patient is lost to follow-up, the patient withdraws consent, or it is determined that the study treatment or participation is not the cause of the adverse event. Scans performed within 6 weeks prior to the treatment discontinuation visit do not need to be repeated.",
                        "footnoteId": "e7520fa6-82db-4e84-99fd-a3a65091c87b",
                        "structuredCondition": "timing.after(last_dose, P30D) && timing.after(last_dose, P90D)",
                        "appliesToActivityIds": [
                          "9326f4ee-ca01-408b-a36b-e2e4ecbdf424",
                          "AE reporting",
                          "Scans"
                        ],
                        "sourceText": "c. Patients will be asked to return to the clinic 30 days after the last dose of study treatment for"
                      },
                      {
                        "id": "018708db-4692-46be-bafd-a33069c94daf",
                        "conditionType": "general",
                        "text": "d. Cancer history includes stage, date of diagnosis, and prior anti-tumor treatment. Demographic information includes age and self-reported race/ethnicity. Reproductive status and smoking history should also be captured.",
                        "footnoteId": "b2346783-832e-41dd-87ea-c060c2ff1ab7",
                        "sourceText": "d. Cancer history includes stage, date of diagnosis, and prior anti-tumor treatment. Demographic inf"
                      },
                      {
                        "id": "770ad4d2-be86-45c1-b12d-f9dc6cf99c2a",
                        "conditionType": "general",
                        "text": "e. A complete physical examination at screening should include the evaluation of head, eye, ear, nose, and throat and cardiovascular, dermatologic, musculoskeletal, respiratory, gastrointestinal, genitourinary, and neurologic systems. Changes in abnormalities noted at baseline should be recorded at the end of the visit. New or worsened abnormalities should be recorded as adverse events if appropriate.",
                        "footnoteId": "fb0973f0-da74-4d6b-a943-7135937a150e",
                        "sourceText": "e. A complete physical examination at screening should include the evaluation of head, eye, ear, nos"
                      },
                      {
                        "id": "18e9edea-ae6f-4de3-b6b4-bee914c76af2",
                        "conditionType": "general",
                        "text": "f. A limited physical examination will be performed at other visits to assess changes from baseline abnormalities and any new abnormalities and to evaluate patient-reported symptoms. New or worsened abnormalities should be recorded as adverse events if appropriate.",
                        "footnoteId": "cdba2b41-cdea-4129-a203-dd97a6656300",
                        "sourceText": "f. A limited physical examination will be performed at other visits to assess changes from baseline "
                      },
                      {
                        "id": "5aa968ec-ef6f-4bd8-bd1d-4e984f8bdb5e",
                        "conditionType": "timing_before",
                        "text": "g. ECOG Performance Status, limited physical examination, local laboratory assessments, and PROs may be obtained  96 hours before Day 1 of each cycle.",
                        "footnoteId": "e915bd87-c91a-4e90-8e31-88681ec17e9f",
                        "structuredCondition": "timing.before(day 1 of each cycle., PT96M)",
                        "appliesToActivityIds": [
                          "ECOG Performance Status",
                          "Physical examination",
                          "Local laboratory assessments",
                          "PROs"
                        ],
                        "timingConstraint": "PT96H",
                        "sourceText": "g. ECOG Performance Status, limited physical examination, local laboratory assessments, and PROs may"
                      },
                      {
                        "id": "7d11ef21-33fa-4e00-9790-b01844ab5fcc",
                        "conditionType": "timing_before",
                        "text": "h. The EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D-5L questionnaires will be completed by all patients on paper starting on Day 1 of Cycle 1 and Day 1 of every cycle thereafter. All PRO questionnaires scheduled for administration during a clinic visit are required to be completed by the patient at the investigational site at the start of the clinic visit before discussion of the patient's health state, lab results or health record, before administration of study treatment, and/or prior to any other study assessment(s). This is to avoid any potential bias to patients' responses to ensure that the validity of the instrument is not compromised and that data quality meets regulatory requirements. Interview assessment by a member of the clinic staff will be allowed if the patient is not able to complete the measure on their own. Study personnel should review all questionnaires for completeness before the patient leaves the investigational site. During survival follow-up, all PRO questionnaires will be completed every 3 months (for 1 year), unless the patient withdraws consent or the Sponsor terminates the study. PRO questionnaires during the survival follow-up period may be completed at the investigational site should the patient come in for a clinic visit or be administered via interview in telephone calls.",
                        "footnoteId": "10424952-88c4-483d-9a26-e8d9522eb8b2",
                        "structuredCondition": "sequence.before(treatment_administration) && sequence.before(health_discussion)",
                        "appliesToActivityIds": [
                          "PRO questionnaires",
                          "a8c0d9a1-e6ae-42e8-8d0c-f7dc5673337a",
                          "7fb61392-4147-4d7c-b74e-d94cbc9808cc",
                          "1c724bbc-657b-440f-a416-25544fbffd28"
                        ],
                        "sourceText": "h. The EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D-5L questionnaires will be completed by all patients"
                      },
                      {
                        "id": "0615e6dd-1fc3-426f-9b31-7cf57a1e726c",
                        "conditionType": "timing_before",
                        "text": "i. All measurable and evaluable lesions should be assessed and documented at the screening visit. Radiologic imaging performed during the screening period should consist of 1) CT and/or MRI of the chest/abdomen/pelvis and brain, 2) bone scan or PET scan as clinically indicated, and 3) any other imaging studies (CT scan of the neck, plain films, etc.) as clinically indicated by the treating physician. The same radiographic procedures and technique must be used throughout the study for each patient (e.g., if the patient had CT chest/abdomen/pelvis performed during screening, then she should subsequently undergo CT performed with use of the same radiologic protocol throughout the remainder of the study). Results must be reviewed by the investigator before dosing at the next cycle. Tumor assessments will be performed at baseline, every 6 weeks ( 1 week) for the first 54 weeks following the initiation of study treatment, and every 9 weeks ( 1 week) thereafter, with additional scans as clinically indicated. All known sites of disease documented at screening should be re-assessed at each subsequent tumor evaluation. Tumor response will be evaluated by the investigator with use of RECIST version 1.1 and imRECIST. In the absence of disease progression, tumor assessments should continue regardless of whether patients discontinue study treatment or start new anti-cancer treatment, unless the patient dies, withdraws consent, or the study is terminated by the Sponsor, whichever occurs first.",
                        "footnoteId": "741ab5f1-69e5-47a0-8e41-8853545faa5c",
                        "structuredCondition": "frequency.interval(P6W, P1W) && frequency.interval(P9W, P1W)",
                        "appliesToActivityIds": [
                          "Tumor assessments",
                          "Radiologic imaging"
                        ],
                        "sourceText": "i. All measurable and evaluable lesions should be assessed and documented at the screening visit. Ra"
                      },
                      {
                        "id": "ad937845-4110-4ffe-840e-d8a10a4e3da9",
                        "conditionType": "timing_before",
                        "text": "j. Vital signs include heart rate, respiratory rate, blood pressure, and temperature. For patients randomized to Arm A, on days of study treatment administration (atezolizumab and bevacizumab), the patient's vital signs should be determined up to 60 minutes before all infusions. Vital signs will be measured at the end of bevacizumab infusion and 2 ( 1) hours after end of the infusion and will also be collected during and after every infusion of atezolizumab if clinically indicated.",
                        "footnoteId": "086bfcf8-f748-43b0-ad3f-d6099afc8049",
                        "structuredCondition": "timing.before(all infusions. vital signs will be measured at the end of bevacizumab infusion and 2 ( 1) hours after end of the infusion and will also be collected during and after every infusion of atezolizumab if clinically indicated., PT60M)",
                        "appliesToActivityIds": [
                          "Vital signs"
                        ],
                        "timingConstraint": "PT60H",
                        "sourceText": "j. Vital signs include heart rate, respiratory rate, blood pressure, and temperature. For patients r"
                      },
                      {
                        "id": "4f0ff4f4-72a9-4dbc-9800-3614ec281a13",
                        "conditionType": "timing_before",
                        "text": "k. The dose of bevacizumab will be based on the patient's weight (in kilograms) measured  14 days prior to baseline (the initiation of study treatment) and will remain the same throughout the study unless there is a weight change of > 10% from baseline. If re-baseline is needed the latest baseline weight should always be used to calculate percent change in weight for all subsequent doses.",
                        "footnoteId": "be0b1874-9f58-4794-8da6-c8f5eeb871e4",
                        "structuredCondition": "if(weight_change > 0.10) { recalculate_dose() }",
                        "appliesToActivityIds": [
                          "Bevacizumab dosing",
                          "Weight measurement"
                        ],
                        "sourceText": "k. The dose of bevacizumab will be based on the patient's weight (in kilograms) measured  14 days p"
                      },
                      {
                        "id": "601199f7-f052-4f15-a8b0-03cecb97cc2e",
                        "conditionType": "timing_before",
                        "text": "l. Patients should be resting and in a supine position for at least 10 minutes prior to each ECG collection.",
                        "footnoteId": "8890fb97-e9de-411e-8b14-fbb66114284a",
                        "structuredCondition": "timing.before(each ecg collection., PT10M)",
                        "appliesToActivityIds": [
                          "ECG"
                        ],
                        "timingConstraint": "PT10M",
                        "sourceText": "l. Patients should be resting and in a supine position for at least 10 minutes prior to each ECG col"
                      },
                      {
                        "id": "a5f87586-e17f-4cbf-9e63-47d5ccfa109d",
                        "conditionType": "timing_before",
                        "text": "m. All patients must undergo an EGD and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment.",
                        "footnoteId": "0ab90201-3ffe-4023-a7a9-96c9ab7f4191",
                        "sourceText": "m. All patients must undergo an EGD and all size of varices (small to large) must be assessed and tr"
                      },
                      {
                        "id": "12aa0aaa-8653-4a75-8619-202aa1266fd8",
                        "conditionType": "procedure_conditional",
                        "text": "n. Hematology consists of CBC, including RBC count, hemoglobin, hematocrit, WBC count with differential (neutrophils, eosinophils, lymphocytes, monocytes, basophils, and other cells), and platelet count. A manual differential can be done if clinically indicated.",
                        "footnoteId": "a9c1ee70-58da-4275-af25-1c298ad0e811",
                        "sourceText": "n. Hematology consists of CBC, including RBC count, hemoglobin, hematocrit, WBC count with different"
                      },
                      {
                        "id": "705949df-7634-4b9e-af59-d62a98ca1cf3",
                        "conditionType": "general",
                        "text": "o. Serum chemistry includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, potassium, magnesium, chloride, glucose, BUN or urea, creatinine, total protein, albumin, phosphorus, calcium, total bilirubin, alkaline phosphatase, ALT, AST, and LDH.",
                        "footnoteId": "da7ddd21-f952-4af1-81f2-ead32319f8b3",
                        "sourceText": "o. Serum chemistry includes bicarbonate or total carbon dioxide (if considered standard of care for "
                      },
                      {
                        "id": "c236d0d4-acae-489d-93f5-b6b9d7911c25",
                        "conditionType": "timing_before",
                        "text": "p. All patients will be tested for HIV locally prior to the inclusion into the study and if not in contradiction with local legislation; HIV-positive patients will be excluded from the clinical study. HBsAg, HBcAb, and HBsAb should be collected during screening and tested locally. HBV DNA must be collected prior to Cycle 1, Day 1 in patients who have negative serology for HBsAg and positive serology for anti-HBcAb.",
                        "footnoteId": "c4cdddcb-2f2d-4616-b798-031b265d722a",
                        "sourceText": "p. All patients will be tested for HIV locally prior to the inclusion into the study and if not in c"
                      },
                      {
                        "id": "6151ea5f-69ce-4a8f-9dec-73be6f6e103a",
                        "conditionType": "general",
                        "text": "q. Only if patient tests positive for HBsAg, HBcAb, quantitative HBsAg and HBV DNA will be tested during screening; Cycle 5, Day 1; Cycle 9, Day 1; and at treatment discontinuation. Quantitative HBsAg will be tested by central laboratory. If a patient tests positive for HCV antibody at screening, quantitative HCV RNA must be tested locally at screening, Cycle 5 Day 1, Cycle 9 Day 1, and at treatment discontinuation.",
                        "footnoteId": "4f687133-58d7-4980-819f-932cdfec8e81",
                        "sourceText": "q. Only if patient tests positive for HBsAg, HBcAb, quantitative HBsAg and HBV DNA will be tested du"
                      },
                      {
                        "id": "7572673d-0b43-438a-b87e-8c805f9ad9a5",
                        "conditionType": "timing_before",
                        "text": "r. Urine dipstick includes specific gravity, pH, glucose, protein, ketones, and blood and should be repeated before every cycle during treatment. Urine dipstick for proteinuria must be < 2+ within 7 days prior to initiation of study treatment. Patients discovered to have  2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours.",
                        "footnoteId": "0a9871f7-a4e5-47dd-9d3e-60d53778d271",
                        "structuredCondition": "timing.before(treatment_initiation, P7D)",
                        "appliesToActivityIds": [
                          "Urine dipstick"
                        ],
                        "timingConstraint": "PT24H",
                        "sourceText": "r. Urine dipstick includes specific gravity, pH, glucose, protein, ketones, and blood and should be "
                      },
                      {
                        "id": "e85d386b-8487-4582-a46e-8d8504b502f3",
                        "conditionType": "timing_before",
                        "text": "s. Serum pregnancy test within 14 days before Cycle 1, Day 1.",
                        "footnoteId": "3844f4f5-7622-4078-a705-8738af6d7241",
                        "structuredCondition": "timing.before(Cycle_1_Day_1, P14D)",
                        "appliesToActivityIds": [
                          "Serum pregnancy test"
                        ],
                        "sourceText": "s. Serum pregnancy test within 14 days before Cycle 1, Day 1."
                      },
                      {
                        "id": "77b780b9-e431-4f40-bfb7-38ad2e187d48",
                        "conditionType": "general",
                        "text": "t. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.",
                        "footnoteId": "5721b16a-791a-4658-9164-58aedfd92847",
                        "sourceText": "t. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum preg"
                      },
                      {
                        "id": "02d46266-0a67-4d07-abd7-8d88542f70af",
                        "conditionType": "timing_before",
                        "text": "u. Concomitant medications include any prescription medications or over-the-counter medications. At screening, any medications the patient has used within the 7 days prior to initiation of study treatment should be documented. At subsequent visits, changes to current medications or medications used since the last documentation of medications will be recorded.",
                        "footnoteId": "97cd9e8b-1cd2-4daa-bccc-883c46bcccef",
                        "sourceText": "u. Concomitant medications include any prescription medications or over-the-counter medications. At "
                      },
                      {
                        "id": "19b50b1a-8e02-4052-97d6-e92cca0c8f55",
                        "conditionType": "timing_before",
                        "text": "v. After informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protocol-mandated intervention should be reported. After initiation of study drug, all adverse events will be reported until 30 days after the last dose of study treatment or until initiation of another anti-cancer therapy, whichever occurs first. Serious adverse events and adverse events of special interest will continue to be reported until 90 days after the last dose of study treatment or until initiation of new anti-cancer therapy, whichever occurs first. After this period, investigators should report any serious adverse events and adverse events of special interest that are believed to be related to prior treatment with study drug. The investigator should follow each adverse event until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, new systemic anti-cancer treatment is initiated, the patient is lost to follow-up, the patient withdraws consent, or it is determined that the study treatment or participation is not the cause of the adverse event. Every effort should be made to follow all serious adverse events considered to be related to study drug or study-related procedures until a final outcome can be reported.",
                        "footnoteId": "9217f924-4710-4ec8-819b-de1052532983",
                        "sourceText": "v. After informed consent has been obtained but prior to initiation of study drug, only serious adve"
                      },
                      {
                        "id": "8d99c5ad-45d7-4c99-87ac-b33eff9acd1d",
                        "conditionType": "sequence",
                        "text": "w. The initial dose of atezolizumab will be delivered over 60 ( 15) minutes. If the first infusion is tolerated without infusion-associated adverse events, the second infusion may be delivered over 30 ( 10) minutes. If the 30-minute infusion is well-tolerated, all subsequent infusions may be delivered over 30 ( 10) minutes. The initial dose of bevacizumab will be delivered over 90 ( 15) minutes. If the first infusion is tolerated without infusion-associated adverse events, the second infusion may be delivered over 60 ( 10) minutes. If the 60-minute infusion is well-tolerated, all subsequent infusions may be delivered over 30 ( 10) minutes. For patients randomized to Arm A, atezolizumab will be administered first followed by bevacizumab, with a minimum of 5 minutes between dosing. In the absence of unacceptable toxicity, patients may continue study treatment until there is evidence of disease progression or lack of clinical benefit.",
                        "footnoteId": "9a736cb4-2a79-4c94-98d1-635303da8db4",
                        "structuredCondition": "timing.duration(atezolizumab, PT60M) && timing.duration(bevacizumab, PT90M) && timing.gap(PT5M)",
                        "appliesToActivityIds": [
                          "Atezolizumab infusion",
                          "Bevacizumab infusion"
                        ],
                        "timingConstraint": "PT5M",
                        "sourceText": "w. The initial dose of atezolizumab will be delivered over 60 ( 15) minutes. If the first infusion "
                      },
                      {
                        "id": "aef39445-09bc-42c3-a42c-37d18c0d49e1",
                        "conditionType": "general",
                        "text": "x. Sorafenib is taken by mouth twice a day continuously.",
                        "footnoteId": "34f30e8b-1360-43cb-a800-a7b3beb52a01",
                        "sourceText": "x. Sorafenib is taken by mouth twice a day continuously."
                      },
                      {
                        "id": "240cdc8c-c6da-457d-b3b0-ad45aac91d5b",
                        "conditionType": "general",
                        "text": "y. Survival follow-up information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 3 months ( 21 days) until death, loss to follow-up, or until study termination by the Sponsor. All patients will be followed for survival and new anti-cancer therapy (including targeted therapy and immunotherapy) information unless the patient requests to be withdrawn from follow-up; this request must be documented in the source documents and signed by the investigator. If the patient withdraws from study, the study staff may use a public information source (e.g., county records) to obtain information about survival status only.",
                        "footnoteId": "820a3520-ba9f-475d-8c56-a5259d40eb5a",
                        "sourceText": "y. Survival follow-up information will be collected via telephone calls, patient medical records, an"
                      },
                      {
                        "id": "39baf356-ed5c-4b20-8ea7-d3e0f5f607e0",
                        "conditionType": "timing_before",
                        "text": "z. Local laboratory assessments from each cycle must be reviewed prior to study treatment administration for each cycle.",
                        "footnoteId": "34116c74-cc3c-4719-909d-720630e61f1a",
                        "sourceText": "z. Local laboratory assessments from each cycle must be reviewed prior to study treatment administra"
                      }
                    ],
                    "endpointAlgorithms": [
                      {
                        "id": "1b47e68f-7105-4a35-becc-607aa619d2fc",
                        "name": "Co-Primary: Overall Survival (OS)",
                        "endpointType": "Primary",
                        "inputs": [
                          "date of randomization",
                          "date of death",
                          "last date known alive",
                          "data cutoff date"
                        ],
                        "timeWindow": {
                          "reference": "randomization",
                          "duration": "until death or data cutoff"
                        },
                        "algorithm": "date_of_death - date_of_randomization",
                        "successCriteria": "Statistically significant improvement (2-sided alpha = 0.048) via stratified log-rank test",
                        "sourceText": "Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients who are alive at the time of the analysis data cutoff will be censored at the last "
                      },
                      {
                        "id": "b2f53daf-1070-4890-9231-4f496c304a6f",
                        "name": "Co-Primary: Progression-Free Survival (PFS)",
                        "endpointType": "Primary",
                        "inputs": [
                          "date of randomization",
                          "date of first IRF-assessed disease progression",
                          "date of death",
                          "RECIST v1.1 criteria"
                        ],
                        "timeWindow": {
                          "reference": "randomization",
                          "duration": "until progression or death"
                        },
                        "algorithm": "min(date_of_progression, date_of_death) - date_of_randomization",
                        "successCriteria": "Statistically significant improvement (2-sided alpha = 0.002) via stratified log-rank test",
                        "sourceText": "The primary efficacy objective for this study is to evaluate the efficacy of atezolizumab in combination with bevacizumab compared with sorafenib on the basis of the co-primary efficacy endpoints of O"
                      }
                    ],
                    "derivedVariables": [
                      {
                        "id": "a6856d96-b9e1-464f-b532-106855798f6e",
                        "name": "Mean change from baseline in EORTC QLQ-C30 subscales",
                        "variableType": "ChangeFromBaseline",
                        "sourceVariables": [
                          "EORTC QLQ-C30 subscale scores"
                        ],
                        "derivationRule": "Post-baseline score - Baseline score",
                        "baselineDefinition": "Score at baseline (pre-treatment)",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "By cycle",
                        "imputationRule": "Not specified",
                        "unit": "Score"
                      },
                      {
                        "id": "3fe6859f-ed16-4ded-ae21-2b660a46d49e",
                        "name": "Mean change from baseline in EORTC QLQ-HCC18 subscales",
                        "variableType": "ChangeFromBaseline",
                        "sourceVariables": [
                          "EORTC QLQ-HCC18 subscale scores"
                        ],
                        "derivationRule": "Post-baseline score - Baseline score",
                        "baselineDefinition": "Score at baseline (pre-treatment)",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "By cycle",
                        "imputationRule": "Not specified",
                        "unit": "Score"
                      },
                      {
                        "id": "6a87efb8-ac28-4fa0-90b6-6e6833897d73",
                        "name": "Clinically meaningful change in select QLQ-C30 and QLQ-HCC18 scales",
                        "variableType": "Categorical",
                        "sourceVariables": [
                          "GHS/QoL",
                          "Physical function",
                          "Role function",
                          "Appetite loss",
                          "Diarrhea",
                          "Fatigue",
                          "Pain",
                          "Jaundice"
                        ],
                        "derivationRule": "Proportion of patients meeting a predefined threshold for clinically meaningful change",
                        "baselineDefinition": "Baseline score for the specific scale",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "Study duration",
                        "imputationRule": "Not specified",
                        "unit": "Proportion"
                      },
                      {
                        "id": "ebc4762f-8581-48db-87f7-5cd053b23de7",
                        "name": "Time to Deterioration (TTD) in select QLQ-C30 and QLQ-HCC18 scales",
                        "variableType": "TimeToEvent",
                        "sourceVariables": [
                          "Appetite loss",
                          "Diarrhea",
                          "Fatigue",
                          "Pain",
                          "Jaundice"
                        ],
                        "derivationRule": "Time from randomization to deterioration maintained for 2 consecutive timepoints, or 1 timepoint followed by death from any cause within 3 weeks",
                        "baselineDefinition": "Baseline score for the specific scale",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "Study duration",
                        "imputationRule": "Not specified",
                        "unit": "Days/Months"
                      },
                      {
                        "id": "3872b304-a545-4f7f-b7f6-45d6c68000d8",
                        "name": "Time to Deterioration (TTD) in HRQoL/GHS, physical function, and role function",
                        "variableType": "TimeToEvent",
                        "sourceVariables": [
                          "HRQoL/GHS",
                          "Physical function",
                          "Role function"
                        ],
                        "derivationRule": "Time from randomization to deterioration maintained for 2 consecutive timepoints, or 1 timepoint followed by death from any cause within 3 weeks",
                        "baselineDefinition": "Baseline score for the specific scale",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "Study duration",
                        "imputationRule": "Not specified",
                        "unit": "Days/Months"
                      },
                      {
                        "id": "56aa40a0-332d-44f3-a20d-80b0ea13a6a4",
                        "name": "Presence of ADAs to atezolizumab relative to baseline",
                        "variableType": "Categorical",
                        "sourceVariables": [
                          "Anti-drug antibody (ADA) status"
                        ],
                        "derivationRule": "Comparison of post-baseline ADA presence vs. baseline ADA presence",
                        "baselineDefinition": "ADA status at baseline",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "During the study",
                        "imputationRule": "Not specified",
                        "unit": "Presence/Absence"
                      },
                      {
                        "id": "61377ac6-2caa-48cb-97a1-51982a0de945",
                        "name": "Health utility and VAS scores (EQ-5D-5L)",
                        "variableType": "Custom",
                        "sourceVariables": [
                          "EQ-5D-5L questionnaire items"
                        ],
                        "derivationRule": "Utility scores generated from EQ-5D-5L responses and Visual Analog Scale (VAS) scores",
                        "baselineDefinition": "Baseline EQ-5D-5L assessment",
                        "baselineVisit": "Baseline",
                        "analysisWindow": "Study duration",
                        "imputationRule": "Not specified",
                        "unit": "Utility index / 0-100 scale"
                      }
                    ],
                    "stateMachine": {
                      "id": "4f0d1d90-a0ed-469b-9e31-8c04a410f5c9",
                      "initialState": "Screening",
                      "terminalStates": [
                        "Early Termination",
                        "Completed"
                      ],
                      "states": [
                        "Screening",
                        "Treatment",
                        "Safety Follow Up",
                        "Survival Follow Up",
                        "End Of Study",
                        "Early Termination"
                      ],
                      "transitions": [
                        {
                          "fromState": "Screening",
                          "toState": "Treatment",
                          "trigger": "Progress to Treatment"
                        },
                        {
                          "fromState": "Treatment",
                          "toState": "Safety Follow Up",
                          "trigger": "Progress to Safety Follow Up"
                        },
                        {
                          "fromState": "Safety Follow Up",
                          "toState": "Survival Follow Up",
                          "trigger": "Progress to Survival Follow Up"
                        },
                        {
                          "fromState": "Survival Follow Up",
                          "toState": "End Of Study",
                          "trigger": "Progress to End Of Study"
                        },
                        {
                          "fromState": "Treatment",
                          "toState": "Early Termination",
                          "trigger": "Subject exits to Early Termination"
                        }
                      ],
                      "epochIds": {
                        "Screening": "SCREENING",
                        "Treatment": "TREATMENT",
                        "Safety Follow Up": "SAFETY_FOLLOW_UP",
                        "Survival Follow Up": "SURVIVAL_FOLLOW_UP",
                        "End Of Study": "END_OF_STUDY",
                        "Early Termination": "EARLY_TERMINATION"
                      }
                    },
                    "dosingRegimens": [
                      {
                        "id": "06515a38-d532-4f15-b6fe-2a013768d8d6",
                        "treatmentName": "Atezolizumab",
                        "frequency": "BID",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 1200.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 400.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 15.0,
                            "unit": "mg"
                          }
                        ],
                        "durationDescription": "3 weeks",
                        "doseModifications": [
                          "Dose management for Grade 3 dermatologic events",
                          "Management for Stevens-Johnson syndrome or toxic epidermal necrolysis",
                          "Management for Hepatic Events"
                        ],
                        "sourceText": "or metastatic HCC who have received no prior systemic treatment. This study will enroll approximately 480 patients randomized in a 2:1 ratio to one of two treatment arms:  Arm A (experimental arm): A"
                      },
                      {
                        "id": "5f45a229-d11a-4a47-965e-fdd16dffe041",
                        "treatmentName": "Sorafenib",
                        "frequency": "BID",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 400.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 1200.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 15.0,
                            "unit": "mg"
                          }
                        ],
                        "durationDescription": "3 weeks",
                        "doseModifications": [
                          "Dose reduction for treatment-emergent toxicities"
                        ],
                        "sourceText": "reatment arms:  Arm A (experimental arm): Atezolizumab 1200 mg IV infusion every 3 weeks (Q3W; dosed in 3-week cycles) and bevacizumab 15 mg/kg Q3W (dosed in 3-week cycles)  Arm B (control arm): Sor"
                      },
                      {
                        "id": "10f9bca1-0937-472b-9cbe-111be0c7db21",
                        "treatmentName": "Patients received",
                        "frequency": "Q3W",
                        "route": "Oral",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 1200.0,
                            "unit": "mg"
                          },
                          {
                            "amount": 15.0,
                            "unit": "mg"
                          }
                        ],
                        "sourceText": "with metastatic cancer. Arm A is designed to test the combination of atezolizumab and bevacizumab in patients with locally advanced or metastatic HCC who have not received prior systemic therapy. Pati"
                      },
                      {
                        "id": "6e11ed15-4fe0-4569-b3c2-ce4096cc6ec5",
                        "treatmentName": "Bevacizumab",
                        "frequency": "Q3W",
                        "route": "IV",
                        "startDay": 1,
                        "doseLevels": [
                          {
                            "amount": 15.0,
                            "unit": "mg/kg",
                            "description": "Weight-based dose"
                          }
                        ],
                        "durationDescription": "Until loss of clinical benefit or unacceptable toxicity",
                        "doseModifications": [
                          "Dose modifications for toxicity as per protocol guidelines"
                        ]
                      }
                    ],
                    "visitWindows": [
                      {
                        "id": "3837a6b2-51eb-4199-8d9a-743ac4ecff2d",
                        "visitName": "screening",
                        "targetDay": -14,
                        "windowBefore": 7,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 1,
                        "epoch": "Screening",
                        "sourceText": "Negative HIV test at screening  Documented virology status of hepatitis, as confirmed by screening hepatitis B virus (HBV)"
                      },
                      {
                        "id": "5dbf4b9e-1774-48a2-98b2-7b2e46bfd255",
                        "visitName": "baseline",
                        "targetDay": 0,
                        "windowBefore": 1,
                        "windowAfter": 1,
                        "isRequired": true,
                        "visitNumber": 2,
                        "epoch": "Screening",
                        "sourceText": "Patients discovered to have 2proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate 1 g of protein in 24 hours."
                      },
                      {
                        "id": "74716e68-9048-45ad-a075-960391e79cb0",
                        "visitName": "Early Termination",
                        "targetDay": null,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 3,
                        "sourceText": "heterosexual intercourse) or use contraceptive methods with a failure rate of 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, 6 months after the"
                      },
                      {
                        "id": "a86df8c8-dc45-4221-a0ab-47a7e02bdc71",
                        "visitName": "Visit 1",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 3,
                        "isRequired": true,
                        "visitNumber": 4,
                        "sourceText": "Measurable disease, per RECIST v1.1, must be present outside the CNS.  The patient has no history of intracranial hemorrhage or spinal cord hemorrhage."
                      },
                      {
                        "id": "67a27bb0-246a-46f3-90d4-fca33bc237a0",
                        "visitName": "eot",
                        "targetDay": null,
                        "windowBefore": 28,
                        "windowAfter": 28,
                        "isRequired": true,
                        "visitNumber": 5,
                        "sourceText": "The patient has not undergone stereotactic, whole-brain radiotherapy, and/or neurosurgical resection within 28 days prior to initiation of study treatment. "
                      },
                      {
                        "id": "62ae1e95-5064-4a4d-94c4-4e4095d46cae",
                        "visitName": "End of Study",
                        "targetDay": null,
                        "windowBefore": 3,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 6,
                        "sourceText": "End of Study The end of this study is defined as the date when the last patient, last visit (LPLV) occurs (i.e., last patient in the global and extended China enrollment phases combined) or safety"
                      },
                      {
                        "id": "080a8cba-953c-4377-88a4-4271422c09ff",
                        "visitName": "randomization",
                        "targetDay": 1,
                        "windowBefore": 0,
                        "windowAfter": 0,
                        "isRequired": true,
                        "visitNumber": 7,
                        "sourceText": "Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients who are alive at the time of the analysis data cutoff will be censored at the last "
                      },
                      {
                        "id": "088c8ee5-fbdd-4065-9363-df06ede3287e",
                        "visitName": "Follow-up",
                        "targetDay": 365,
                        "windowBefore": 7,
                        "windowAfter": 7,
                        "isRequired": true,
                        "visitNumber": 8,
                        "sourceText": "follow-up is received from the last patient (global and extended China enrollment phases combined), whichever occurs later. In addition, the Sponsor may decide to terminate the study at any time."
                      }
                    ],
                    "randomizationScheme": {
                      "id": "f5697e56-0a80-4278-b777-4019bca7100c",
                      "ratio": "2:1",
                      "method": "Stratified randomization",
                      "centralRandomization": true,
                      "stratificationFactors": [
                        {
                          "id": "9203b45c-f571-4339-83dd-a4cd3cc90482",
                          "name": "Region",
                          "categories": [
                            "North America",
                            "Europe",
                            "Asia",
                            "Rest of World"
                          ],
                          "isBlocking": false,
                          "sourceText": "geographic region (asia excluding japan vs"
                        },
                        {
                          "id": "2f634c32-f18e-4fbd-bb2a-931137e21e8c",
                          "name": "Geographic region",
                          "categories": [
                            "Asia excluding Japan",
                            "rest of world"
                          ],
                          "isBlocking": false
                        },
                        {
                          "id": "8f19ec8c-636b-4b30-9b91-22d47ff8caec",
                          "name": "Macrovascular invasion and/or extrahepatic spread",
                          "categories": [
                            "presence",
                            "absence"
                          ],
                          "isBlocking": false
                        },
                        {
                          "id": "61facb04-e6f7-4338-8797-a5d0a6330028",
                          "name": "Baseline -fetoprotein",
                          "categories": [
                            "<400 ng/mL",
                            "400 ng/mL"
                          ],
                          "isBlocking": false
                        },
                        {
                          "id": "2feafa0c-c180-4690-a40a-3ac6fde22e20",
                          "name": "Eastern Cooperative Oncology Group Performance Status",
                          "categories": [
                            "0",
                            "1"
                          ],
                          "isBlocking": false
                        }
                      ],
                      "sourceText": "AtezolizumabF. Hoffmann-La Roche Ltd\n4/Protocol YO40245, Version 6\n3.3.7\nRationale for Stratification...................................................... 47\n3.3.7.1\nGeographic Region..............."
                    }
                  }
                }
              },
              {
                "id": "391c0b4c-e4ab-42d4-988f-e75a0a2e88d3",
                "url": "https://protocol2usdm.io/extensions/x-soaFootnotes",
                "valueString": "[\"a. The first dosing date (Cycle 1, Day 1) should occur within 3 business days from randomization, with the exception of the emergence of an adverse event for which dosing may be postponed. All visits and infusions thereafter may be administered with a window of \\u00b1 3 days.\", \"b. Written informed consent can be obtained up to 30 days prior to study entry and is required before performing any study-specific tests or procedures. Results of standard of care tests or examinations performed prior to obtaining informed consent and per protocol relevant window may be used for screening assessments rather than repeating such tests. Screening local laboratory assessments obtained \\u2264 96 hours prior to the initiation of study treatment do not have to be repeated for Cycle 1. Test results should be reviewed prior to administration of study treatment.\", \"c. Patients will be asked to return to the clinic 30 days after the last dose of study treatment for an end-of-treatment visit. After this visit, serious adverse events and protocol defined adverse events of special interest, regardless of attribution, will be recorded until 90 days after the last dose of study treatment or until initiation of another systemic anti-cancer therapy, whichever occurs first. Ongoing adverse events thought to be related to study treatment will be followed until the event has resolved to baseline grade or better, the event is assessed by the investigator as stable, new anti-cancer treatment is initiated, the patient is lost to follow-up, the patient withdraws consent, or it is determined that the study treatment or participation is not the cause of the adverse event. Scans performed within 6 weeks prior to the treatment discontinuation visit do not need to be repeated.\", \"d. Cancer history includes stage, date of diagnosis, and prior anti-tumor treatment. Demographic information includes age and self-reported race/ethnicity. Reproductive status and smoking history should also be captured.\", \"e. A complete physical examination at screening should include the evaluation of head, eye, ear, nose, and throat and cardiovascular, dermatologic, musculoskeletal, respiratory, gastrointestinal, genitourinary, and neurologic systems. Changes in abnormalities noted at baseline should be recorded at the end of the visit. New or worsened abnormalities should be recorded as adverse events if appropriate.\", \"f. A limited physical examination will be performed at other visits to assess changes from baseline abnormalities and any new abnormalities and to evaluate patient-reported symptoms. New or worsened abnormalities should be recorded as adverse events if appropriate.\", \"g. ECOG Performance Status, limited physical examination, local laboratory assessments, and PROs may be obtained \\u2264 96 hours before Day 1 of each cycle.\", \"h. The EORTC QLQ-C30, EORTC QLQ-HCC18, and EQ-5D-5L questionnaires will be completed by all patients on paper starting on Day 1 of Cycle 1 and Day 1 of every cycle thereafter. All PRO questionnaires scheduled for administration during a clinic visit are required to be completed by the patient at the investigational site at the start of the clinic visit before discussion of the patient's health state, lab results or health record, before administration of study treatment, and/or prior to any other study assessment(s). This is to avoid any potential bias to patients' responses to ensure that the validity of the instrument is not compromised and that data quality meets regulatory requirements. Interview assessment by a member of the clinic staff will be allowed if the patient is not able to complete the measure on their own. Study personnel should review all questionnaires for completeness before the patient leaves the investigational site. During survival follow-up, all PRO questionnaires will be completed every 3 months (for 1 year), unless the patient withdraws consent or the Sponsor terminates the study. PRO questionnaires during the survival follow-up period may be completed at the investigational site should the patient come in for a clinic visit or be administered via interview in telephone calls.\", \"i. All measurable and evaluable lesions should be assessed and documented at the screening visit. Radiologic imaging performed during the screening period should consist of 1) CT and/or MRI of the chest/abdomen/pelvis and brain, 2) bone scan or PET scan as clinically indicated, and 3) any other imaging studies (CT scan of the neck, plain films, etc.) as clinically indicated by the treating physician. The same radiographic procedures and technique must be used throughout the study for each patient (e.g., if the patient had CT chest/abdomen/pelvis performed during screening, then she should subsequently undergo CT performed with use of the same radiologic protocol throughout the remainder of the study). Results must be reviewed by the investigator before dosing at the next cycle. Tumor assessments will be performed at baseline, every 6 weeks (\\u00b1 1 week) for the first 54 weeks following the initiation of study treatment, and every 9 weeks (\\u00b1 1 week) thereafter, with additional scans as clinically indicated. All known sites of disease documented at screening should be re-assessed at each subsequent tumor evaluation. Tumor response will be evaluated by the investigator with use of RECIST version 1.1 and imRECIST. In the absence of disease progression, tumor assessments should continue regardless of whether patients discontinue study treatment or start new anti-cancer treatment, unless the patient dies, withdraws consent, or the study is terminated by the Sponsor, whichever occurs first.\", \"j. Vital signs include heart rate, respiratory rate, blood pressure, and temperature. For patients randomized to Arm A, on days of study treatment administration (atezolizumab and bevacizumab), the patient's vital signs should be determined up to 60 minutes before all infusions. Vital signs will be measured at the end of bevacizumab infusion and 2 (\\u00b1 1) hours after end of the infusion and will also be collected during and after every infusion of atezolizumab if clinically indicated.\", \"k. The dose of bevacizumab will be based on the patient's weight (in kilograms) measured \\u2264 14 days prior to baseline (the initiation of study treatment) and will remain the same throughout the study unless there is a weight change of > 10% from baseline. If re-baseline is needed the latest baseline weight should always be used to calculate percent change in weight for all subsequent doses.\", \"l. Patients should be resting and in a supine position for at least 10 minutes prior to each ECG collection.\", \"m. All patients must undergo an EGD and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment.\", \"n. Hematology consists of CBC, including RBC count, hemoglobin, hematocrit, WBC count with differential (neutrophils, eosinophils, lymphocytes, monocytes, basophils, and other cells), and platelet count. A manual differential can be done if clinically indicated.\", \"o. Serum chemistry includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, potassium, magnesium, chloride, glucose, BUN or urea, creatinine, total protein, albumin, phosphorus, calcium, total bilirubin, alkaline phosphatase, ALT, AST, and LDH.\", \"p. All patients will be tested for HIV locally prior to the inclusion into the study and if not in contradiction with local legislation; HIV-positive patients will be excluded from the clinical study. HBsAg, HBcAb, and HBsAb should be collected during screening and tested locally. HBV DNA must be collected prior to Cycle 1, Day 1 in patients who have negative serology for HBsAg and positive serology for anti-HBcAb.\", \"q. Only if patient tests positive for HBsAg, HBcAb, quantitative HBsAg and HBV DNA will be tested during screening; Cycle 5, Day 1; Cycle 9, Day 1; and at treatment discontinuation. Quantitative HBsAg will be tested by central laboratory. If a patient tests positive for HCV antibody at screening, quantitative HCV RNA must be tested locally at screening, Cycle 5 Day 1, Cycle 9 Day 1, and at treatment discontinuation.\", \"r. Urine dipstick includes specific gravity, pH, glucose, protein, ketones, and blood and should be repeated before every cycle during treatment. Urine dipstick for proteinuria must be < 2+ within 7 days prior to initiation of study treatment. Patients discovered to have \\u2265 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours.\", \"s. Serum pregnancy test within 14 days before Cycle 1, Day 1.\", \"t. Urine pregnancy test; if a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test.\", \"u. Concomitant medications include any prescription medications or over-the-counter medications. At screening, any medications the patient has used within the 7 days prior to initiation of study treatment should be documented. At subsequent visits, changes to current medications or medications used since the last documentation of medications will be recorded.\", \"v. After informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protocol-mandated intervention should be reported. After initiation of study drug, all adverse events will be reported until 30 days after the last dose of study treatment or until initiation of another anti-cancer therapy, whichever occurs first. Serious adverse events and adverse events of special interest will continue to be reported until 90 days after the last dose of study treatment or until initiation of new anti-cancer therapy, whichever occurs first. After this period, investigators should report any serious adverse events and adverse events of special interest that are believed to be related to prior treatment with study drug. The investigator should follow each adverse event until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, new systemic anti-cancer treatment is initiated, the patient is lost to follow-up, the patient withdraws consent, or it is determined that the study treatment or participation is not the cause of the adverse event. Every effort should be made to follow all serious adverse events considered to be related to study drug or study-related procedures until a final outcome can be reported.\", \"w. The initial dose of atezolizumab will be delivered over 60 (\\u00b1 15) minutes. If the first infusion is tolerated without infusion-associated adverse events, the second infusion may be delivered over 30 (\\u00b1 10) minutes. If the 30-minute infusion is well-tolerated, all subsequent infusions may be delivered over 30 (\\u00b1 10) minutes. The initial dose of bevacizumab will be delivered over 90 (\\u00b1 15) minutes. If the first infusion is tolerated without infusion-associated adverse events, the second infusion may be delivered over 60 (\\u00b1 10) minutes. If the 60-minute infusion is well-tolerated, all subsequent infusions may be delivered over 30 (\\u00b1 10) minutes. For patients randomized to Arm A, atezolizumab will be administered first followed by bevacizumab, with a minimum of 5 minutes between dosing. In the absence of unacceptable toxicity, patients may continue study treatment until there is evidence of disease progression or lack of clinical benefit.\", \"x. Sorafenib is taken by mouth twice a day continuously.\", \"y. Survival follow-up information will be collected via telephone calls, patient medical records, and/or clinic visits approximately every 3 months (\\u00b1 21 days) until death, loss to follow-up, or until study termination by the Sponsor. All patients will be followed for survival and new anti-cancer therapy (including targeted therapy and immunotherapy) information unless the patient requests to be withdrawn from follow-up; this request must be documented in the source documents and signed by the investigator. If the patient withdraws from study, the study staff may use a public information source (e.g., county records) to obtain information about survival status only.\", \"z. Local laboratory assessments from each cycle must be reviewed prior to study treatment administration for each cycle.\"]",
                "instanceType": "ExtensionAttribute"
              }
            ],
            "administrations": [
              {
                "id": "6def3e30-98c3-4407-999d-de166ce4fc6f",
                "name": "Atezolizumab Administration",
                "instanceType": "Administration",
                "dose": "1200.0 mg / 400.0 mg / 15.0 mg",
                "doseFrequency": "BID",
                "route": {
                  "id": "24f362f4-cb8a-4660-b752-fe0d1f3483c4",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "duration": "3 weeks",
                "description": "or metastatic HCC who have received no prior systemic treatment. This study will enroll approximately 480 patients randomized in a 2:1 ratio to one of two treatment arms:  Arm A (experimental arm): A"
              },
              {
                "id": "14fb41d3-e40f-47fe-8afb-a6024dfc976b",
                "name": "Sorafenib Administration",
                "instanceType": "Administration",
                "dose": "400.0 mg / 1200.0 mg / 15.0 mg",
                "doseFrequency": "BID",
                "route": {
                  "id": "907dbf3d-cf28-4ba0-b276-3d031498cb58",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "duration": "3 weeks",
                "description": "reatment arms:  Arm A (experimental arm): Atezolizumab 1200 mg IV infusion every 3 weeks (Q3W; dosed in 3-week cycles) and bevacizumab 15 mg/kg Q3W (dosed in 3-week cycles)  Arm B (control arm): Sor"
              },
              {
                "id": "36233131-544b-4e60-955d-e6122933e3ee",
                "name": "Patients received Administration",
                "instanceType": "Administration",
                "dose": "1200.0 mg / 15.0 mg",
                "doseFrequency": "Q3W",
                "route": {
                  "id": "4dedbd3c-e03d-4f7f-87a5-413b3ba2b159",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "description": "with metastatic cancer. Arm A is designed to test the combination of atezolizumab and bevacizumab in patients with locally advanced or metastatic HCC who have not received prior systemic therapy. Pati"
              },
              {
                "id": "483e6d57-6faa-4a9f-8220-99a45254e46d",
                "name": "Bevacizumab Administration",
                "instanceType": "Administration",
                "dose": "15.0 mg/kg",
                "doseFrequency": "Q3W",
                "route": {
                  "id": "84b130a8-35bb-4b05-9c4c-a3001411153e",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                },
                "duration": "Until loss of clinical benefit or unacceptable toxicity"
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "91470651-956e-4973-909c-a3203fcded73",
            "text": "A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA",
            "type": {
              "id": "73186f0e-ed14-4414-b22b-7f92c480057c",
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "666a725e-910e-451c-bb59-e4fcc97c39dc",
            "text": "NCT03434379",
            "instanceType": "StudyIdentifier",
            "scopeId": "675b1990-5d79-43d7-a73d-e60073cb666a",
            "type": {
              "code": "C172240",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinicaltrials.gov Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "450a1210-6c06-4cca-a872-f726b915c8f6",
            "text": "YO40245",
            "instanceType": "StudyIdentifier",
            "scopeId": "dc026624-1915-46e6-b2bb-7de3ea14e5a1",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "551359a1-a826-4ba0-97d5-4b5bb68148bd",
            "text": "2017-003691-31",
            "instanceType": "StudyIdentifier",
            "scopeId": "e2570fad-177f-4618-a6c8-3ff3cbfcbb92",
            "type": {
              "code": "C98714",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinical Trial Registry Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "109f5f2d-d841-488c-81fc-28f7c69acd2e",
            "text": "135913",
            "instanceType": "StudyIdentifier",
            "scopeId": "4b068ed9-627a-4463-b93b-502e22421f51",
            "type": {
              "code": "C218685",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "US FDA Investigational New Drug Application Number",
              "instanceType": "Code"
            }
          }
        ],
        "organizations": [
          {
            "id": "dc026624-1915-46e6-b2bb-7de3ea14e5a1",
            "name": "F. Hoffmann-La Roche Ltd",
            "type": {
              "id": "7a308e1e-8436-4917-b1e5-ce56fd6c69a3",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "F. Hoffmann-La Roche Ltd",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "5953be2e-6b27-453c-ab4e-160f24b87f71",
            "name": "Genentech, Inc.",
            "type": {
              "id": "2255ddf4-9796-4c69-acd0-5f80c9d5f340",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "Genentech, Inc.",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "675b1990-5d79-43d7-a73d-e60073cb666a",
            "name": "ClinicalTrials.gov",
            "type": {
              "id": "75f6d197-6e13-4620-a782-bd435789a321",
              "code": "C19326",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Healthcare Facility",
              "instanceType": "Code"
            },
            "identifier": "ClinicalTrials.gov",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "4b068ed9-627a-4463-b93b-502e22421f51",
            "name": "FDA",
            "type": {
              "id": "19da92c8-b672-42ea-ad24-660e6730db83",
              "code": "C25461",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Regulatory Agency",
              "instanceType": "Code"
            },
            "identifier": "FDA",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "dc026624-1915-46e6-b2bb-7de3ea14e5a1",
            "name": "St. Josephs Hospital and Medical Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "1",
            "type": {
              "id": "56aadd07-9f6c-4ac0-97c9-076fa3b34e70",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5953be2e-6b27-453c-ab4e-160f24b87f71",
            "name": "City of Hope",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "2",
            "type": {
              "id": "20ed9d2f-ff25-4648-831b-f08ff0836ee4",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "675b1990-5d79-43d7-a73d-e60073cb666a",
            "name": "Uni of California - San Diego; Cancer Center & Dept of Medicine",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "3",
            "type": {
              "id": "a2021077-3fb7-4720-b30b-d5dffd24894f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4b068ed9-627a-4463-b93b-502e22421f51",
            "name": "Kaiser Permanente Northern California",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "4",
            "type": {
              "id": "8409f5f6-1384-470a-90fb-8b6d9349e051",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "8fe96f27-d652-459f-96d0-f1e17831b7d6",
            "name": "University of California Irvine Medical Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "5",
            "type": {
              "id": "a183b3fb-f41b-4519-90c7-110589d1e695",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a180b648-5b56-4463-ab60-72dedd577efb",
            "name": "Kaiser Permanente Sacramento Medical Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "6",
            "type": {
              "id": "7b4ec804-425f-4c42-b252-99f146ccdee9",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5857a1ad-1ac8-4e4e-9fce-90e9e5767f9c",
            "name": "California Pacific Medical Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "7",
            "type": {
              "id": "1e21a0af-2146-4a7d-bd57-d5721d95f775",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ca4e38d6-79bb-4a59-a569-7ae8f271df63",
            "name": "Kaiser Permanente - San Francisco Medical Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "8",
            "type": {
              "id": "1f8ed233-eb05-4773-85c7-32fef8a4753e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "8131e975-1112-4cfd-9a86-8164ed75080a",
            "name": "University of California Los Angeles",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "9",
            "type": {
              "id": "70d68854-5cc3-409a-8129-417209e8bfa3",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4e3583b5-867d-4697-bd8f-db7e5d3e9a75",
            "name": "Kaiser Permanente - Walnut Creek",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "10",
            "type": {
              "id": "3b036e29-0a85-4e15-b837-b9fa2b6d69af",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "977b29a7-1d89-489b-b4d0-65a09264d2b5",
            "name": "Banner MD Anderson Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "11",
            "type": {
              "id": "d9600475-d249-4bb6-998d-01ccca1a5214",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c89716e9-01c2-4cf7-9060-7ed89c6b77f7",
            "name": "Georgetown University",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "12",
            "type": {
              "id": "cfea4f97-d8c3-4093-8bd7-a30f1242d9f7",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b2cd5ca1-135c-41c4-a280-a1678cc54617",
            "name": "Moffitt Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "13",
            "type": {
              "id": "f7e06d31-47c8-4a36-b1a1-8c49477e5e5c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d323910b-947f-4909-a720-018f34e26a67",
            "name": "Massachusetts General Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "14",
            "type": {
              "id": "62132377-8c81-4328-a588-2086698af597",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ac0ad873-24b0-4561-a72d-f81cc2b87b21",
            "name": "Henry Ford Health System",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "15",
            "type": {
              "id": "fceb898e-6ec8-4e6a-84a2-dad0eb94ebb5",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "cc36d27e-0709-4fb1-bb72-9f496697db68",
            "name": "Washington University; Wash Uni. Sch. Of Med",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "16",
            "type": {
              "id": "39931e78-78f1-4035-bca4-bf3beb586289",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d195491a-1905-463b-9b0d-ccb970df3372",
            "name": "University of New Mexico Comprehensive Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "17",
            "type": {
              "id": "ce3d055c-745f-456f-b3db-8ef7161f3fdf",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "eb91eea3-f14e-4001-b4e9-853fa634ce30",
            "name": "Laura and ISAAC Perlmutter Cancer Center at NYU Langone.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "18",
            "type": {
              "id": "e5b77778-d0e1-4616-b32d-37fa951494e5",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "81ab0857-ef55-48a4-8201-76f73ce707f6",
            "name": "Thomas Jefferson University",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "19",
            "type": {
              "id": "20574f16-ed68-48f1-b44d-ac175756623b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5d60a6b3-e34e-4500-90f5-17fa73526c40",
            "name": "M.D Anderson Cancer Center; Uni of Texas At Houston",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "20",
            "type": {
              "id": "133fff58-7e11-42e9-96c1-9039477f783f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "90cdd09c-564a-4ddd-ad71-5e0985f6214d",
            "name": "Swedish Cancer Inst.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "21",
            "type": {
              "id": "49f67aae-17d7-44de-8642-cd51dc1cd589",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c1d143e2-af6d-4f18-8280-eeafed36727b",
            "name": "Bankstown-Lidcombe Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "22",
            "type": {
              "id": "c820437c-abda-47ad-b7e0-6cb72e8767ef",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1067dd47-1c72-4965-bdab-17e633dfeb52",
            "name": "St George Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "23",
            "type": {
              "id": "b1abd79d-bb1a-4718-8f5c-f07a6bed9f8e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "19254036-22f4-40cb-b0c1-92aa8b3485e4",
            "name": "The Queen Elizabeth Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "24",
            "type": {
              "id": "b5d6be94-6266-4f5f-8a5e-ae790f808d6f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "6aaa464a-2e06-4fa3-80e2-a442a87666d8",
            "name": "Sunshine Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "25",
            "type": {
              "id": "79c25ffd-4b78-4be5-8144-7c1582d23b9a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "43b68be8-a24b-4684-bcf1-b57164d1a18b",
            "name": "Ottawa Hospital Research Institute",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "26",
            "type": {
              "id": "635a8fc7-3c5f-42ae-8ee2-40b76e6fff37",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "13dfa544-2148-48bf-80d2-810594522379",
            "name": "Centre hospitalier de l'Universite de Montreal (CHUM)",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "27",
            "type": {
              "id": "2b7a1706-562b-4c93-946e-9a6f52f99ab4",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "05239203-4ec2-43e7-bddc-25ae8f605cad",
            "name": "Jewish General Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "28",
            "type": {
              "id": "4779800c-5684-4c58-86ec-4dcf8ddbe53d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5f9b4b30-dd19-4cf0-b1b6-b782e5c70fae",
            "name": "McGill University Health Centre - Glen Site",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "29",
            "type": {
              "id": "5e38b224-223e-4a20-ab9a-1bda30277828",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4c5b8d39-15d4-4f33-aed7-85dfc7180012",
            "name": "Peking Union Medical College Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "30",
            "type": {
              "id": "b18f0681-194c-4d40-b29e-89d5b0849252",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "6e0082e8-7f10-4dd6-ba44-6a710ce7dde1",
            "name": "Beijing Friendship Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "31",
            "type": {
              "id": "e7e81639-6231-45d8-bd2e-f022c1762163",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "1f78f090-eef7-4ed7-b601-7783008595f5",
            "name": "Beijing Cancer Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "32",
            "type": {
              "id": "d3486bd7-1b26-4f22-9e3b-499019af5922",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ac0051d2-6a1f-482a-9d94-4ee051a77095",
            "name": "the First Hospital of Jilin University",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "33",
            "type": {
              "id": "6171f062-21e8-4087-900a-3cfa8861bc40",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "dfdd9450-8faf-47fb-a876-89fedb7a5db4",
            "name": "Jilin Cancer Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "34",
            "type": {
              "id": "f1532ecc-d6d5-4770-95ca-050f3ac73d20",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b14f707c-d88d-4621-9a65-4c323ce82142",
            "name": "Hunan Cancer Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "35",
            "type": {
              "id": "680bc3b7-0792-4870-a39c-11321629c89a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "94b6d69e-253d-4e58-80b2-a45f52ef0700",
            "name": "The First People's Hospital of Foshan; Local Ethic Committee",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "36",
            "type": {
              "id": "7530234f-1af1-4551-9732-b2daf4cac1bb",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9af8bb99-9214-45db-9a6a-6ff7dccd43c8",
            "name": "The 900th Hospital of PLA joint service support force",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "37",
            "type": {
              "id": "60ccf603-22d3-4b9f-b057-a85ab05e8170",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "020ba8d7-59b8-4be8-ab45-0d88c66aa47c",
            "name": "Nanfang Hospital, Southern Medical University",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "38",
            "type": {
              "id": "f748e35b-0a3c-409f-b847-d8406ea260bb",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "2dcdca3e-1ddc-44bf-a28f-3bf59b02f183",
            "name": "Sun Yet-sen University Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "39",
            "type": {
              "id": "5f7fb79e-5c2a-456b-8a4e-b0283cc08135",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e893a8fc-982f-493c-abf6-9734e32ad543",
            "name": "The First Affiliated Hospital of College of Medicine, Zhejiang University",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "40",
            "type": {
              "id": "d55540b2-580e-4b03-b632-5b6bc9087454",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "44932624-6910-4c24-a3df-35c185f1fae6",
            "name": "Sir Run Run Shaw Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "41",
            "type": {
              "id": "88d9e88c-ba05-4bd4-9ccd-46d079c6daac",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0659e78c-08ab-475a-a1c1-4225abba63ee",
            "name": "Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "42",
            "type": {
              "id": "57677642-d73e-4797-8dff-6a4b139baff9",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9f6873cf-3d5e-4b29-9f1c-df674849bd58",
            "name": "Harbin Medical University Cancer Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "43",
            "type": {
              "id": "8380c15e-64ee-41bc-a91c-f8a3c9a57129",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "320becb0-4ca6-4fc0-84e2-26e813f42890",
            "name": "The First Affiliated Hospital of Anhui Medical University",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "44",
            "type": {
              "id": "4e14cf98-20b6-4d63-8cfc-0d6767370e04",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "786ba484-bff9-47a2-91db-e68b2080a3cc",
            "name": "Anhui Province Cancer Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "45",
            "type": {
              "id": "8d30b8ae-95a4-4313-835f-ebeda39b11e7",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3a1d7221-f5b5-4abe-867d-22769eff1df9",
            "name": "General Hospital of Jinan Military Command of PLA",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "46",
            "type": {
              "id": "5cc9bc95-5fc9-4e87-989c-67e55650b4c0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "cf0647d1-25c5-4995-97e7-6f6b297b7c27",
            "name": "The 81st Hospital of P.L.A.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "47",
            "type": {
              "id": "be083266-eda8-4bd8-bf99-30dd9d11d9d7",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "39a4ad9c-4253-4798-a3a4-58a867eb6d43",
            "name": "Zhongshan Hospital Fudan University",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "48",
            "type": {
              "id": "223c96e1-da14-4719-9eb9-0b1d6005bc05",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "80cadcc6-d21b-4f0d-9a97-f55173742c21",
            "name": "Fudan University Shanghai Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "49",
            "type": {
              "id": "4380ab0c-eb9b-40b1-8c5c-4d0dbe0c6ba2",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9b7d0700-1fb8-4504-a4cf-02786cdd1c3c",
            "name": "Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "50",
            "type": {
              "id": "656f6a8a-b8bc-4d6d-80b1-02c155fa197c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "dd2d1952-3380-4aba-acf0-dd54b6bacf4b",
            "name": "Masarykuv onkologicky ustav",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "51",
            "type": {
              "id": "421d4221-d3d4-4647-9041-09967c946d11",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b575fa80-af9a-4705-80e4-65efff94aab2",
            "name": "Fakultni nemocnice Olomouc; Onkologicka klinika",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "52",
            "type": {
              "id": "0730f3c0-f6ad-41fc-b462-f278bcca9ca0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "f8e65450-a52f-4dbf-8068-d05a520bdd78",
            "name": "Hopital Claude Huriez;Gastro Enterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "53",
            "type": {
              "id": "e4933aba-c8da-4103-9517-705b7c784c5b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "cd4993b2-12f9-498c-926a-12d5b745cf61",
            "name": "Hopital De La Croix Rousse; Hepatologie Gastro Enterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "54",
            "type": {
              "id": "8b3c629d-0e86-4995-a10e-32cf471602a6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7e81ab51-931e-4b8d-9080-68c672bb1906",
            "name": "Hopital Timone Adultes; Gastro Enterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "55",
            "type": {
              "id": "e0103358-5139-4266-891a-5c28e0be61df",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "365f4304-de98-4285-a5d8-3dc3e76c899d",
            "name": "Hopital Saint-Eloi; Hepatologie-Gastro-Enterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "56",
            "type": {
              "id": "042b1a57-8cc3-489b-a2de-c14f4ad51fb8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "cf3613b5-a5fa-403e-9c37-23a7c2a95caf",
            "name": "Hopital Hotel Dieu Et Hme; Hepatologie Gastro Enterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "57",
            "type": {
              "id": "545f1760-3519-4a5e-bf97-21799bb54a08",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "fce25f12-b94e-41c0-87c3-cf1d263132b2",
            "name": "CHU Nice - Hpital de l'Archet 2; service Hepato gastro enterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "58",
            "type": {
              "id": "50c025dc-70d3-449c-839c-cae301ef7261",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "f9b5af83-998a-4b27-99cd-f72ca3c796b6",
            "name": "Hopital Charles Nicolle; Gastroenterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "59",
            "type": {
              "id": "5625f58c-7bf3-448e-aecd-d0133a048a8a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "6a5c3846-300d-4eb9-9e50-88aa63d4ce54",
            "name": "Hopital Hautepierre; Gastro Enterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "60",
            "type": {
              "id": "d48d6409-30ee-4206-8cdc-7b305c8cbb65",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "f9c18b84-360e-4222-b3bf-bdcf9ffc160c",
            "name": "Hpital d'Adultes; Service hpato-gastro-entrologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "61",
            "type": {
              "id": "ffe45327-9a84-4d94-9e81-93022222561e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0b5716eb-a5fb-4051-a148-5e9b9447c9f8",
            "name": "Institut Gustave Roussy; Gastro-Enterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "62",
            "type": {
              "id": "028a3b20-b8e8-421a-af2a-57beb385d96c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "af3d512b-acf5-41e9-b7f6-1b594dffb693",
            "name": "Campus Virchow-Klinikum Charit Centrum 13; Medizinische Klinik; Abt.Hepatologie u.Gastroenterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "63",
            "type": {
              "id": "9d0b348e-b7db-4b60-8d4d-72cba44d8753",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "f6ab42c3-74c7-4e59-831d-bb8d6d438bfb",
            "name": "Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "64",
            "type": {
              "id": "a234e8fe-882f-41b0-a85d-4260af673c29",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "27de2049-d125-4298-b33c-5d4f5610b8ab",
            "name": "Universitaetsklinikum Hamburg-Eppendorf; I. Medizinische Klinik - Gastroenterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "65",
            "type": {
              "id": "f7561ecf-1319-4241-b30c-a64749f50126",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b2786822-53f6-4c0a-a422-e6e87f54f401",
            "name": "Med. Hochschule Hannover; Gastroenterologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "66",
            "type": {
              "id": "a89af99c-efc2-42fb-b72f-aa76a3317332",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c639dc2e-c7e8-4015-93f1-08b3668c7a11",
            "name": "Universittsklinikum Leipzig Medizinische Klinik II Gastroenterolog. u. Hepatolog.",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "67",
            "type": {
              "id": "5568c99c-5b43-4989-a39e-c7b5a01f0304",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "81cc24e8-575d-46cc-aaea-8187859c51b7",
            "name": "Uniklinik Mainz; I. Medizinische Klinik",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "68",
            "type": {
              "id": "931b3429-014a-4efa-b238-4c66d41dccd6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "3af83173-a155-4b79-99de-b6f8b95bee86",
            "name": "Klinikum der Uni Regensburg; Klinik f.Innere Medizin I Abt. Hmatologie und Internistische Onkologie",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "69",
            "type": {
              "id": "84d3bea5-169f-4066-9294-28d2cf67b3a3",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5f3a246b-a7c3-4a00-b079-1e49b035fee7",
            "name": "Queen Mary Hospital; Dept. Of Haematology & Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "70",
            "type": {
              "id": "d44eb426-0cfc-4003-94f8-eab643bc0bdf",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "eec246cb-4130-44e1-8789-8a4667707978",
            "name": "Prince of Wales Hosp; Dept. Of Clinical Onc",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "71",
            "type": {
              "id": "1403670a-cd43-485d-9ea7-2abd18c1a5ed",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0b34c4e6-ee94-46c0-acd7-d3a8b37b5fad",
            "name": "Az. Osp. Rummo; Oncologia Medica",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "72",
            "type": {
              "id": "3e27dfc9-329f-4bc5-91a0-46e1452c1bc8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5e163c50-984c-465d-a533-97d54ab3c7a2",
            "name": "IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "73",
            "type": {
              "id": "73aa1c7b-3cf8-4277-9b25-fa8a254cd268",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "cdc46449-b9c2-4a3c-8111-f287e2b40f7a",
            "name": "Az. Osp. S. Luigi Gonzaga; Divisione Di Oncologia Medica",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "74",
            "type": {
              "id": "f730d9a2-5997-43ba-97bc-56acc00af8cf",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "720ae52d-bed6-4357-a56a-c94f16e105cb",
            "name": "A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "75",
            "type": {
              "id": "92e2eb9c-4222-4953-86af-8785880a8d96",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "9b23e35f-548f-4e72-8a4e-bd79872f846c",
            "name": "Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria ? Polo Oncologico",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "76",
            "type": {
              "id": "904f131e-423b-43cf-882c-9d24e75d03e9",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c0820725-2d26-4e4e-8c65-8e80b7202fc4",
            "name": "IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "77",
            "type": {
              "id": "3be09893-9dbc-4187-9649-4bd7f39e6bd0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "6d7f6ab8-7bcf-4151-8112-886dc672861a",
            "name": "Chiba University Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "78",
            "type": {
              "id": "539e33c5-65f8-4eb8-af75-3159a65f1e6d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "f50c6d98-e732-4b71-9cef-ac226c6ab24b",
            "name": "National Cancer Center Hospital East",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "79",
            "type": {
              "id": "264c5cc1-f615-4498-8beb-adb98d185357",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "6a83b7b7-6969-4c38-b5f6-895a0d82b720",
            "name": "Kurume University Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "80",
            "type": {
              "id": "8dbba2c6-65b1-4aa1-97e6-24dae8127c9b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "184ea649-9805-4590-9ace-b297f1d985ed",
            "name": "Sapporo Kosei Genaral Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "81",
            "type": {
              "id": "5de1b3aa-07e2-4983-982e-0eb742d3093a",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c9966309-cef9-464c-a956-593eb25e39da",
            "name": "Hokkaido University Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "82",
            "type": {
              "id": "3bde5c65-deb2-44ad-a23b-3ab9df3fa3f0",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "828ba241-0f6c-40eb-81d5-9e710d80abe5",
            "name": "Kanazawa University Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "83",
            "type": {
              "id": "64aae746-8a10-4402-8a8b-1c2a487cfcf8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "c9b3c774-17ee-48ce-8cdd-f07e35c9c589",
            "name": "Kitasato University Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "84",
            "type": {
              "id": "7d071fe3-6250-490b-83b1-b9f92c1b675c",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0f03b5c5-448a-4c79-ac26-7c5b3d09c9e1",
            "name": "Kumamoto University Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "85",
            "type": {
              "id": "f27dd752-db26-4f9d-a1a2-ffe798db357e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "75c8749f-3cc1-477a-962e-1ad35ba999e3",
            "name": "Osaka Metropolitan University Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "86",
            "type": {
              "id": "877a268d-135f-4d96-bc4f-4013b79f0d19",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "fe660a29-d160-4f59-a7d3-656000a823a6",
            "name": "Kindai University Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "87",
            "type": {
              "id": "c581e057-5f40-454d-b219-1e2c14bd29d8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ea1eb071-c4c6-4215-a96a-fb910fa12a25",
            "name": "Saga-ken Medical Centre Koseikan",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "88",
            "type": {
              "id": "52506810-9fb1-4496-aaa1-c59b89cd9f3f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "748bdc8c-faac-4671-aff2-e688fd102f8e",
            "name": "Shizuoka Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "89",
            "type": {
              "id": "0f1f2a48-6d0e-490e-a862-7bcee41090dc",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b236d452-b8aa-4c48-bd32-688bc6d36d41",
            "name": "Japanese Red Cross Musashino Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "90",
            "type": {
              "id": "64682c0d-e282-4c3e-b832-9dccac3fac52",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "4d400187-4916-44ca-86c0-637c3c269f68",
            "name": "Copernicus Podmiot Medyczny Sp. z o.o. Wojewodzkie Centrum Onkologii",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "91",
            "type": {
              "id": "e0edded8-7dfd-4003-9eff-cad2cd6fb95f",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "5dd69e30-bbf1-415d-86a6-0107d959428a",
            "name": "ID Clinic",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "92",
            "type": {
              "id": "197641b4-63a1-4106-bfad-eac9202a7406",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e3e9590e-ffda-4ae6-8f18-5bf56f2098f6",
            "name": "SP ZOZ MSWiA z WARMINSKO-MAZURSKIM CENTRUM ONKOLOGII; CLINICAL ONCOLOGY, CLINICAL IMMUNOLOGY",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "93",
            "type": {
              "id": "80d855ec-0585-4162-9c72-74f4676e2d2e",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "308956f2-7d83-4afc-a56e-40ae8d642f2a",
            "name": "Narodowy Instytut Onkologii im. Marii Sk?odowskiej-Curie - Pa?stwowy Instytut Badawczy",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "94",
            "type": {
              "id": "123157be-cab7-45c0-a8da-812370f02bd7",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "54411576-ef65-4094-971c-1760a524b6d9",
            "name": "Dolno?l?skie Centrum Onkologii; Oddzia? Onkologii Klinicznej i Chemioterapii",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "95",
            "type": {
              "id": "a78494af-775f-41ee-9e30-46d041f30261",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "21b3f2ef-47ce-401f-8d89-48f75f360695",
            "name": "FSBI \"National Medical Research Center of Oncology N.N. Blokhin?; Clinical Biotechnologies",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "96",
            "type": {
              "id": "bb33d2d2-c2d7-4c7c-bbbd-7c70e1bc7fb4",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "ee4ef1d6-abd9-43c1-9ff9-c6bbc588c538",
            "name": "GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "97",
            "type": {
              "id": "7cbac305-49c4-4ccb-bfd0-41661b7e4e62",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "96a416df-2c97-4ec7-9980-2fcdc154e4b1",
            "name": "National Cancer Centre",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "98",
            "type": {
              "id": "975a4ad7-e907-4c78-a4ce-31e91c5776eb",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "36d4a223-f38b-44f4-8c9e-1972559ef62f",
            "name": "Tan Tock Seng Hospital; Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "99",
            "type": {
              "id": "d9a37f57-3d38-4c87-a76c-518fb8279f5b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7a945c64-4077-4448-aced-41bba8697f36",
            "name": "Chonnam National University Hwasun Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "100",
            "type": {
              "id": "dfd6cc9b-0bfc-4ae3-a073-01b1b30c433d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "b4e692e7-667a-4b4b-abc1-4e720f1f853d",
            "name": "Seoul National University Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "101",
            "type": {
              "id": "5a260fe4-3986-4f80-8cbf-6238a12a14b2",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "f25be671-0e64-48de-a26a-d42d832ca503",
            "name": "Severance Hospital, Yonsei University Health System",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "102",
            "type": {
              "id": "360fe53c-a80c-4b24-98be-098b5cdbb50b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a69d8367-574b-4e12-9f69-fb9a21b29de7",
            "name": "Asan Medical Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "103",
            "type": {
              "id": "f78fe3e0-8b48-4027-a87e-40c3db50e607",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "45715435-60e3-4043-91c8-591d029bbae8",
            "name": "Samsung Medical Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "104",
            "type": {
              "id": "af6422b7-547b-4863-bce6-b95a89aebe30",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "33945e80-e42a-45f9-88af-12d6b45361a1",
            "name": "Ulsan University Hosiptal",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "105",
            "type": {
              "id": "1df87352-dffa-44b3-b52b-8e66b164d1f8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "23748e5f-f6aa-4f2f-9dda-b6a6a19b402d",
            "name": "Hospital Universitari Vall d'Hebron; Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "106",
            "type": {
              "id": "291496eb-c439-41bd-a5f2-705ea7ffe467",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "438a760f-141d-49d6-a2ec-13c960c9321a",
            "name": "Hospital Clinico San Carlos; Servicio de Oncologia",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "107",
            "type": {
              "id": "0e3ebfd4-d004-4271-8532-eb53c844476d",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a3032da6-943a-42f4-866c-71ab7db02b46",
            "name": "Hospital Universitario La Paz; Servicio de Oncologia",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "108",
            "type": {
              "id": "5ce3d5d2-bb33-4ca1-ace1-6aa7b07e641b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "e4c80eb7-4a64-49bf-92b8-fe145e8e5e97",
            "name": "Centro Integral Oncologico Clara Campal; Servicio de Oncologa",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "109",
            "type": {
              "id": "224b7644-9958-456a-af82-22ca9a91cedf",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7a71e546-3505-48ae-b4bf-1480a319b2cf",
            "name": "Hospital Universitario Miguel Servet; Servicio de Oncologia Medica",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "110",
            "type": {
              "id": "688366b6-4d3f-4b40-a6ba-7bc34c2462fd",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "0d851b26-e109-4037-9f80-cd9b1ed2302d",
            "name": "National Cheng Kung University Hospital; Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "111",
            "type": {
              "id": "230d5e87-4802-4661-bd95-97cdddbea6ec",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "59e831c6-882e-4672-8a81-5c79e483b536",
            "name": "Chi-Mei Medical Centre; Hematology & Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "112",
            "type": {
              "id": "7511ff70-d167-45ab-97c0-1e187cfed3ec",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "802a86d9-4ccf-4f78-b38a-4205cc380af0",
            "name": "Veterans General Hospital; Cancer Center",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "113",
            "type": {
              "id": "d524861a-a29e-4685-b676-bacd807d16b9",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "65044fcd-8c83-4387-b746-b923e0b4595f",
            "name": "National Taiwan Uni Hospital; Dept of Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "114",
            "type": {
              "id": "070e143e-3725-4e76-acf9-623fadada817",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7a0f2096-b7d0-4880-9de7-f9fd9cf2113b",
            "name": "Chang Gung Memorial Hospital-Linkou; Dept of Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "115",
            "type": {
              "id": "87fc4e35-25c0-4a64-b118-74bc57ee114b",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "a5f087be-a9c9-4770-a512-750acf1f3167",
            "name": "Beatson West of Scotland Cancer Centre",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "116",
            "type": {
              "id": "b29c92d1-e6ee-47bf-954a-38fbaba9b7d8",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "bec7dd56-9000-40aa-af49-896a5f1854fc",
            "name": "Royal Free Hospital; Dept of Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "117",
            "type": {
              "id": "ef21a47b-d1b9-43ab-8562-90c26e1ffef6",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "7f1e175c-e265-4495-89fa-2448b62e46ea",
            "name": "King'S College Hospital",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "118",
            "type": {
              "id": "13f7c1f0-0d6e-43a4-8c1e-0ce41a738303",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          },
          {
            "id": "d993914f-a7b4-4c7f-b3bc-cc278e8c527f",
            "name": "Christie Hospital Nhs Trust; Medical Oncology",
            "identifierScheme": "SITE_NUMBER",
            "identifier": "119",
            "type": {
              "id": "748fc0a7-abc9-4357-a1b9-ba98648388ef",
              "code": "C70793",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-03-29",
              "decode": "Clinical Study Site",
              "instanceType": "Code"
            },
            "instanceType": "Organization"
          }
        ],
        "studyPhase": {
          "id": "c284e829-6956-43cd-a55d-cfe78e1aa56c",
          "code": "Phase3",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Phase3",
          "instanceType": "Code"
        },
        "eligibilityCriterionItems": [
          {
            "id": "27e7cd76-87d5-4416-a9ff-f741aad44a90",
            "name": "Informed Consent",
            "text": "Signed Informed Consent Form",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "88e5b1d2-8aa2-42c4-b720-3fc9b2439cde",
            "name": "Age Requirement",
            "text": "Age 18 years at time of signing Informed Consent Form",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ebc6e647-9746-4c9c-a366-7ebc11906b82",
            "name": "Compliance",
            "text": "Ability to comply with the study protocol, in the investigator's judgment",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "6a76a9c7-c9cc-4324-9c7b-e9341b0d7aaa",
            "name": "HCC Diagnosis",
            "text": "Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients. Patients without cirrhosis require histological confirmation of diagnosis.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "09813e2e-7edf-4b6f-8f90-c1b019f601f0",
            "name": "Disease Status",
            "text": "Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "cd6d42d9-58c0-4ba9-aa79-d8a9ae991c42",
            "name": "Prior Systemic Therapy",
            "text": "No prior systemic therapy (including systemic investigational agents) for HCC. Previous use of herbal therapies/traditional Chinese medicines with anti-cancer activity included in the label is allowed, provided that these medications are discontinued prior to randomization.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "76742451-36a3-4893-9594-6bc67258a599",
            "name": "Measurable Disease",
            "text": "At least 1 measurable (per RECIST 1.1) untreated lesion",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "f1598a54-96f9-4945-a003-4831591d5ff5",
            "name": "Prior Local Therapy",
            "text": "Patients who received prior local therapy (e.g., radiofrequency ablation, percutaneous ethanol or acetic acid injection, cryoablation, high-intensity focused ultrasound, transarterial chemoembolization, transarterial embolization, etc.) are eligible provided the target lesion(s) have not been previously treated with local therapy or the target lesion(s) within the field of local therapy have subsequently progressed in accordance with RECIST v1.1",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "c3d7cbc6-1f73-4dbd-a499-2d1499fdd984",
            "name": "Tumor Tissue",
            "text": "Pretreatment tumor tissue sample (if available). If tumor tissue is available, a formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or approximately 1015 slides containing unstained, freshly cut, serial sections should be submitted along with an associated pathology report within 4 weeks of randomization. If FFPE specimens described above are not available, any type of specimens (including fine-needle aspiration, cell pellet specimens [e.g., from pleural effusion], and lavage samples) are also acceptable. This specimen should be accompanied by the associated pathology report. If tumor tissue is not available (e.g., depleted because of prior diagnostic testing), patients are still eligible.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "dda1358d-3424-4009-b758-4d2687bcb75a",
            "name": "ECOG Performance Status",
            "text": "Eastern Cooperative Oncology Group Performance Status of 0 or 1 within 7 days prior to randomization",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "2d51ae4d-6057-41c2-a194-a2358810b3ab",
            "name": "Child-Pugh Class",
            "text": "Child-Pugh Class A within 7 days prior to randomization",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "38aef12f-f0ea-42c5-93a9-61e8fd83bf5e",
            "name": "Hematologic and End-organ Function",
            "text": "Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 7 days prior to randomization, unless otherwise specified: ANC 1.5 109/L (1500/L) without granulocyte colony-stimulating factor support; Lymphocyte count 0.5 109/L (500/L); Platelet count 75109/L (75,000/L) without transfusion; Hemoglobin 90 g/L (9 g/dL); AST, ALT, and alkaline phosphatase (ALP) 5upper limit of normal (ULN); Serum bilirubin 3ULN; Serum creatinine 1.5ULN or creatinine clearance 50 mL/min (calculated using the Cockcroft-Gault formula); Serum albumin 28 g/L (2.8 g/dL) without transfusion; For patients not receiving therapeutic anticoagulation: INR or aPTT 2ULN; Urine dipstick for proteinuria 2(within 7 days prior to initiation of study treatment).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "914cd7bd-5004-424f-a7b4-ff461b49e4e8",
            "name": "Toxicity Resolution",
            "text": "Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade 1 prior to study entry, with the exception of alopecia",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "123669be-0a8c-4fa1-92d0-e04ec7a9276a",
            "name": "HIV Status",
            "text": "Negative HIV test at screening",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "3ffe45c5-a292-4f7c-9d81-89592fa34ee4",
            "name": "Hepatitis Virology",
            "text": "Documented virology status of hepatitis, as confirmed by screening hepatitis B virus (HBV) and hepatitis C virus (HCV) serology test",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "683b5e04-8873-4b8f-87a1-34ae9d9c0c9e",
            "name": "Active HBV Management",
            "text": "For patients with active HBV: HBV DNA 500 IU/mL obtained within 28 days prior to initiation of study treatment, and Anti-HBV treatment (per local standard of care; e.g., entecavir) for a minimum of 14 days prior to study entry and willingness to continue treatment for the length of the study",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "0cc2ee64-3655-47bc-8212-da6b640cd1d3",
            "name": "Contraception - Women",
            "text": "For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 6 months after the last dose of sorafenib. Women must refrain from donating eggs during this same period.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "5eaf7e96-6728-478c-a36d-cebde93e244b",
            "name": "Contraception - Men",
            "text": "For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of 1% per year during the treatment period and for 6 months after the last dose of bevacizumab or 3 months after the last dose of sorafenib. Men must refrain from donating sperm during this same period. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of bevacizumab or 3 months after the last dose of sorafenib to avoid exposing the embryo.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "6958a4ee-765c-44c3-bb38-01c8ca381fa6",
            "name": "China Enrollment Phase",
            "text": "For the extended China enrollment phase: Chinese ancestry and residence in Mainland China, Hong Kong, or Taiwan with enrollment at sites recognized by the China Center for Drug Evaluation",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "3896273f-15b6-4b7c-8a31-b22f855950b6",
            "name": "Leptomeningeal Disease",
            "text": "History of leptomeningeal disease",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "41c260f1-dcc7-4f4f-bd1d-5afa8b2206c0",
            "name": "Autoimmune Disease",
            "text": "Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjgren syndrome, Guillain-Barr syndrome, or multiple sclerosis, with specific exceptions for hypothyroidism, Type 1 diabetes, and certain dermatologic conditions.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "7940ff64-ca19-4661-ba97-f19b38f17d55",
            "name": "Pulmonary Conditions",
            "text": "History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "c34986ef-105d-4138-b689-86b6cf112fd5",
            "name": "Active Tuberculosis",
            "text": "Known active tuberculosis",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "fd831336-84bd-43f1-9608-f8593c04d52b",
            "name": "Cardiovascular Disease",
            "text": "Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment), unstable arrhythmia, or unstable angina",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "7e8f5c74-0700-4250-8e3c-6c0e481c03c3",
            "name": "QT Interval",
            "text": "History of congenital long QT syndrome or corrected QT interval 500 ms (calculated with use of the Fridericia method) at screening",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "2e1fb6c8-7524-454f-9241-093d4d0dce61",
            "name": "Electrolyte Disorder",
            "text": "History of uncorrectable electrolyte disorder affecting serum levels of potassium, calcium, or magnesium",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "b421661a-2c6b-41d6-8e7b-10b3d4eef684",
            "name": "Major Surgery",
            "text": "Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a049e4ad-b6b1-4088-ba96-53d6aedb1978",
            "name": "Other Malignancy",
            "text": "History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival [OS] rate 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "9bb990f7-6299-48ec-9fdd-5fc03a07c6f0",
            "name": "Severe Infection",
            "text": "Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion of the investigator, could impact patient safety",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "f63cd517-49c4-4361-a9f8-bd101d8e0ff1",
            "name": "Antibiotic Treatment",
            "text": "Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment. Patients receiving prophylactic antibiotics are eligible.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "54084945-ee57-472f-bc24-d15b29b708b8",
            "name": "Transplantation",
            "text": "Prior allogeneic stem cell or solid organ transplantation",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "bd7c6666-0439-4eaa-aa6b-2f12efa5eca2",
            "name": "Other Contraindications",
            "text": "Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "95abc6ee-7000-45d0-a077-87b5f1709220",
            "name": "Live Vaccine",
            "text": "Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the last dose of atezolizumab",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "0b8b66c9-d85c-40e9-b9e3-57d78af35db5",
            "name": "Anaphylactic Reactions",
            "text": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "df9a5c43-5160-48d0-a9e4-10bcb8809d8a",
            "name": "Hypersensitivity",
            "text": "Known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulation",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "78c2180f-0bc0-47ea-8dca-4aee49411b91",
            "name": "Pregnancy and Breastfeeding",
            "text": "Pregnant or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 6 months after the last dose of sorafenib. Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "7dec73d2-1a19-42c1-b97b-460cc98f7206",
            "name": "Specific HCC Types",
            "text": "Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "f96e78ac-91c3-42c3-acc1-2f11cf23519c",
            "name": "Varices",
            "text": "Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding. Patients must undergo an EGD, and all size of varices must be assessed and treated per local standard of care prior to enrollment.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1dc15812-dc82-4dc4-a929-e5feccec942e",
            "name": "Prior Bleeding Event",
            "text": "A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a5ae7fc0-27f0-488d-9eb5-f23f89f6ce60",
            "name": "Ascites",
            "text": "Moderate or severe ascites",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "578b4a62-41a4-499e-9aa1-bfaf46f17750",
            "name": "Hepatic Encephalopathy",
            "text": "History of hepatic encephalopathy",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "31cf676d-ae1f-4478-825b-ffcc28dc1fbc",
            "name": "HBV and HCV Coinfection",
            "text": "Coinfection of HBV and HCV. Patients with a history of HCV infection but who are negative for HCV RNA by PCR will be considered non-infected with HCV.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "114c5965-4e50-4cf2-8637-9332aa48a5e8",
            "name": "CNS Metastases",
            "text": "Symptomatic, untreated, or actively progressing CNS metastases. Asymptomatic patients with treated CNS lesions are eligible under specific conditions (measurable disease outside CNS, no hemorrhage history, limited location, no interim progression, no recent radiotherapy/surgery, no ongoing corticosteroids).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "c0dee62f-9df1-403b-9a3a-d9d261d42e70",
            "name": "Tumor-related Pain",
            "text": "Uncontrolled tumor-related pain. Patients requiring pain medication must be on a stable regimen at study entry.",
            "instanceType": "EligibilityCriterionItem"
          }
        ],
        "studyInterventions": [
          {
            "id": "21446bee-488b-4664-ac7d-8e9679c65fb8",
            "name": "Atezolizumab",
            "type": {
              "id": "59936cc2-8edd-4386-80c4-92d448149876",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "9b517b3b-5b75-4805-b3c7-c015e12fd889",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Humanized IgG1 monoclonal antibody that targets PD-L1",
            "productIds": [
              "ddde6217-effd-4c1e-a7b5-7e31ee81d613"
            ],
            "administrationIds": [
              "4089673c-4b0e-40d3-b514-f4304e3f835f",
              "390ffdd1-663c-4df6-bdfa-084973579f61"
            ]
          },
          {
            "id": "87cd725b-04ba-43ff-a0bc-d27ad010d16a",
            "name": "Bevacizumab",
            "type": {
              "id": "53f554de-3349-4c81-927e-b96f37922c93",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "cdd41a46-997e-4e48-8e87-172bc33f481c",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Anti-VEGF therapy used in combination with atezolizumab",
            "productIds": [
              "a59bfce7-95f5-40a2-98f9-90728e390bb7"
            ],
            "administrationIds": [
              "118fc8d8-0dd6-4002-9cc1-fcd65138e68a",
              "2963953f-047a-445c-954d-89e320f0307a"
            ]
          },
          {
            "id": "c4b21f71-d39a-4494-885e-568c285b8eb2",
            "name": "Sorafenib",
            "type": {
              "id": "4bbe5c1e-dab4-4b44-8787-f68ef1838d29",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "role": {
              "id": "85e85f16-3fea-4d5b-9280-c70d12255158",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Oral multi-kinase inhibitor used as the standard of care control",
            "productIds": [
              "31629f25-4ab7-43c7-8e6f-e8344cfaf97a"
            ],
            "administrationIds": [
              "06ccd58b-4217-4ea7-baea-202fc733d349",
              "efcd809f-cfd6-4a40-ac57-aa1bc86df138"
            ]
          },
          {
            "id": "b39f14bc-216a-4e12-afe3-e6d7c3d355f2",
            "name": "Entecavir",
            "type": {
              "id": "c1b8a610-0115-449e-bfdf-5aff40aba55e",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "d991320f-b0f1-499b-91c4-7d5f3704c9ef",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Example of anti-HBV treatment required for patients with active HBV"
          },
          {
            "id": "5bd9e37b-7dc6-4102-b742-25d00843e8d4",
            "name": "Herbal therapies/traditional Chinese medicines",
            "type": {
              "id": "86d1dfe8-6c55-41d7-8f0c-46b0400be855",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "889fb7cd-4fe5-4ca5-9f43-d2c14b834302",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Must be discontinued prior to randomization"
          },
          {
            "id": "40a8b6a9-e891-49fe-b153-73ec128eb78a",
            "name": "Corticosteroids",
            "type": {
              "id": "1560cd87-deb8-4029-92ac-181bbc0d0879",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "2212c4a4-1b38-4bd7-b23c-0e022611aa93",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Systemic immunosuppressive medication; prohibited within 2 weeks prior to initiation except for specific low-dose or acute cases"
          },
          {
            "id": "3485eb80-164d-4415-9992-6e312c98f641",
            "name": "Aspirin (>325 mg/day)",
            "type": {
              "id": "7abdff0c-5500-4f77-bf71-f594678ff8df",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "1c7a1096-bef8-4fed-a87f-9b8db0d4fe38",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited within 10 days of first dose"
          },
          {
            "id": "31dc0d90-a60b-49cc-a816-5d235f93f3f8",
            "name": "Strong CYP3A4 inducers",
            "type": {
              "id": "b252df49-47a7-494d-8284-cdde5d741533",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "19eb589e-ed4a-4076-bc13-345c0442a3a2",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited within 14 days prior to initiation (e.g., rifampin, St. John's wort)"
          }
        ],
        "administrableProducts": [
          {
            "id": "ddde6217-effd-4c1e-a7b5-7e31ee81d613",
            "name": "Atezolizumab (RO5541267)",
            "administrableDoseForm": {
              "id": "3a73032e-d12a-4105-8b4e-f23ed6f420ad",
              "code": "C42945",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Injection",
              "instanceType": "Code",
              "standardCode": {
                "id": "f40c73e9-0b9b-4eb8-a669-0ff5eed0b7bc",
                "code": "C42945",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Injection",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "772ec79d-5b36-4fe4-a57a-74ea9abcc289",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "Not specified",
            "substanceIds": [
              "7ea56a21-406e-4ad1-aee8-b75529654a77"
            ],
            "manufacturer": "F. Hoffmann-La Roche Ltd"
          },
          {
            "id": "a59bfce7-95f5-40a2-98f9-90728e390bb7",
            "name": "Bevacizumab (RO4876646)",
            "administrableDoseForm": {
              "id": "5c4d31e7-d16f-489e-b1d1-09f2451ed77a",
              "code": "C42945",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Injection",
              "instanceType": "Code",
              "standardCode": {
                "id": "9f9a7adb-3122-41d1-b48f-ebc2e7955d00",
                "code": "C42945",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Injection",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "e8b47dca-ea6f-4ba2-a251-3cc936ed02ba",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "Not specified",
            "substanceIds": [
              "ddad6715-11a5-4cf8-a6dd-75d2cdb8f6d3"
            ],
            "manufacturer": "F. Hoffmann-La Roche Ltd"
          },
          {
            "id": "31629f25-4ab7-43c7-8e6f-e8344cfaf97a",
            "name": "Sorafenib",
            "administrableDoseForm": {
              "id": "0c0af308-6cef-499c-bcdb-9da6f8a6f70d",
              "code": "C42998",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Tablet",
              "instanceType": "Code",
              "standardCode": {
                "id": "3ef058aa-e752-475a-be04-77162ee59c24",
                "code": "C42998",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Tablet",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "9d7d8b03-0d3f-424d-9d4d-4f7d19598b86",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "Not specified",
            "substanceIds": [
              "a0980589-6d28-40f4-8502-74081b77c892"
            ],
            "manufacturer": "Not specified"
          }
        ],
        "narrativeContents": [
          {
            "id": "5799633c-82cb-49f2-a096-d3a2406f945b",
            "name": "PROTOCOL SYNOPSIS",
            "text": "PROTOCOL SYNOPSIS",
            "order": 0,
            "instanceType": "NarrativeContent",
            "sectionTitle": "PROTOCOL SYNOPSIS",
            "sectionType": {
              "id": "27ffaa55-64db-423e-883d-f3840fdc9f18",
              "code": "Synopsis",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Synopsis",
              "instanceType": "Code"
            }
          },
          {
            "id": "664ee37a-964f-4d18-b887-1afbde9bf25e",
            "name": "BACKGROUND",
            "text": "BACKGROUND",
            "order": 1,
            "instanceType": "NarrativeContent",
            "sectionNumber": "1",
            "sectionTitle": "BACKGROUND",
            "sectionType": {
              "id": "f768fdc5-f452-4db0-b67d-0c086d71f114",
              "code": "Introduction",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Introduction",
              "instanceType": "Code"
            },
            "childIds": [
              "417b99e3-49c0-4356-8055-c09c4270f7b5",
              "054aa110-76d0-429c-abeb-d4237b70bb4f",
              "fc2f2fc1-0f7a-402d-a85b-24c511f6a26c",
              "39c95050-eed1-474c-9534-6dc9f49bd489",
              "3fe57c08-24b9-4589-b357-c290714da4f7",
              "84afec27-6aa7-44a4-8f25-c9313e16ac68",
              "e667d90b-b451-42fd-88f1-478461a19b33",
              "2637a169-3b73-405c-8ee6-cb256c230cb0",
              "5d0e7f9a-4293-4b47-8f80-3232b2b79321",
              "67e3917f-066c-4193-a87d-38fe3b05a977",
              "00bdfefc-42d2-4f11-a2f9-1b2cbedd0ec8",
              "fc77b46e-9cf2-4171-b7de-e8b85fc69743"
            ]
          },
          {
            "id": "308ed2ad-0d85-447c-8563-d6ae77a54dac",
            "name": "OBJECTIVES AND ENDPOINTS",
            "text": "OBJECTIVES AND ENDPOINTS",
            "order": 2,
            "instanceType": "NarrativeContent",
            "sectionNumber": "2",
            "sectionTitle": "OBJECTIVES AND ENDPOINTS",
            "sectionType": {
              "id": "7e09dcf5-0148-4871-b126-33af22d4f6a1",
              "code": "Objectives",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Objectives",
              "instanceType": "Code"
            }
          },
          {
            "id": "56461abe-a3c2-4f5b-917a-bcfdba2927ae",
            "name": "STUDY DESIGN",
            "text": "STUDY DESIGN",
            "order": 3,
            "instanceType": "NarrativeContent",
            "sectionNumber": "3",
            "sectionTitle": "STUDY DESIGN",
            "sectionType": {
              "id": "9d8a9362-c491-4a23-acc2-2b94d3b59fe5",
              "code": "Study Design",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Design",
              "instanceType": "Code"
            },
            "childIds": [
              "218dc77f-daaa-4aaf-b35d-c47f515ebfaa",
              "9ad9727a-2f30-4753-b992-fbc588607e92",
              "b0733f2b-cbc3-484e-9e7d-4c17b07d11da",
              "31a8eecd-9d27-4506-845f-f7bc8f49e4d1",
              "ef6d2765-a79a-4c8b-8a24-ae20f2e29abb",
              "731f4fd6-0463-43ab-807c-06d642795f84",
              "334b5e32-07f0-4619-b2c8-1070303680b9",
              "8dfa9fb6-6c29-40dd-906b-67d61a369fa5",
              "34753259-36eb-4395-a42d-69807ba3f784",
              "d6bf8165-b521-4cdf-bb7b-cdf50734b733",
              "507f9deb-3a1c-4ea3-addd-a60337a74b3c"
            ]
          },
          {
            "id": "8e4046f3-4de9-45ca-aac6-0a4735d2e96e",
            "name": "Dissemination of Data and Protection of Trade Secrets",
            "text": "Dissemination of Data and Protection of Trade Secrets",
            "order": 4,
            "instanceType": "NarrativeContent",
            "sectionNumber": "9.5",
            "sectionTitle": "Dissemination of Data and Protection of Trade Secrets",
            "sectionType": {
              "id": "8f3d045d-b535-43b1-aa7f-ca932e6aee41",
              "code": "Ethics",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Ethics",
              "instanceType": "Code"
            }
          },
          {
            "id": "197546be-9acc-44fa-844a-8a019de1fb35",
            "name": "Protocol Amendments",
            "text": "Protocol Amendments",
            "order": 5,
            "instanceType": "NarrativeContent",
            "sectionNumber": "9.6",
            "sectionTitle": "Protocol Amendments",
            "sectionType": {
              "id": "1734a25e-3878-42c5-943b-ae8e4df88628",
              "code": "Other",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Other",
              "instanceType": "Code"
            }
          },
          {
            "id": "ef0a2561-e1b4-49c5-9889-b9ae4601fc6d",
            "name": "REFERENCES",
            "text": "REFERENCES",
            "order": 6,
            "instanceType": "NarrativeContent",
            "sectionNumber": "10",
            "sectionTitle": "REFERENCES",
            "sectionType": {
              "id": "def01501-19db-40f3-b49e-22026003106b",
              "code": "References",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "References",
              "instanceType": "Code"
            }
          },
          {
            "id": "1f9ebf83-6eca-4ac0-b30a-46c2db7a55ec",
            "name": "Schedule of Activities",
            "text": "Schedule of Activities",
            "order": 7,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 1",
            "sectionTitle": "Schedule of Activities",
            "sectionType": {
              "id": "73771f3f-fcd9-4eb9-a255-6bf02baad087",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "0227efa1-5fdc-4d6b-9d4c-ba10bd402f9b",
            "name": "Schedule of Biomarker, Pharmacokinetic, and Immunogenicity Samples",
            "text": "Schedule of Biomarker, Pharmacokinetic, and Immunogenicity Samples",
            "order": 8,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 2",
            "sectionTitle": "Schedule of Biomarker, Pharmacokinetic, and Immunogenicity Samples",
            "sectionType": {
              "id": "62616ff6-a532-4b2e-b562-36f5e39de6d2",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "24d86042-ef93-4660-971c-e030c91bbe33",
            "name": "Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
            "text": "Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
            "order": 9,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 3",
            "sectionTitle": "Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)",
            "sectionType": {
              "id": "21ce8715-c4ee-457f-b11c-b3bcc4817cf0",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "eefc5e6e-a7ac-49a6-ae44-8e9e7bc87cf7",
            "name": "Immune-Modified Response Evaluation Criteria in Solid Tumors (imRECIST)",
            "text": "Immune-Modified Response Evaluation Criteria in Solid Tumors (imRECIST)",
            "order": 10,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 4",
            "sectionTitle": "Immune-Modified Response Evaluation Criteria in Solid Tumors (imRECIST)",
            "sectionType": {
              "id": "378d9f7e-da91-4bbb-b045-2cf78dd0fba6",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "b052ce3a-bcc7-4ea4-bb3f-cb155c991fee",
            "name": "European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire: EORTC QLQ-C30",
            "text": "European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire: EORTC QLQ-C30",
            "order": 11,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 5",
            "sectionTitle": "European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire: EORTC QLQ-C30",
            "sectionType": {
              "id": "279d7e7f-6435-4bf8-94da-960a39223622",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "28309b80-75b6-4fd8-b83b-9c90b8dae06b",
            "name": "EORTC QLQ-HCC18 Module",
            "text": "EORTC QLQ-HCC18 Module",
            "order": 12,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 6",
            "sectionTitle": "EORTC QLQ-HCC18 Module",
            "sectionType": {
              "id": "96fb90b7-78f1-4c90-9b5f-918b963aa318",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "460f19e5-d188-46f1-9e65-16d74a6640c3",
            "name": "EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)",
            "text": "EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)",
            "order": 13,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 7",
            "sectionTitle": "EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)",
            "sectionType": {
              "id": "7e8def5f-e385-4954-84ff-ba61b96bf3d7",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "3fba2bdf-f390-4d6c-8a2f-2bfd75e75cea",
            "name": "Preexisting Autoimmune Diseases and Immune Deficiencies",
            "text": "Preexisting Autoimmune Diseases and Immune Deficiencies",
            "order": 14,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 8",
            "sectionTitle": "Preexisting Autoimmune Diseases and Immune Deficiencies",
            "sectionType": {
              "id": "2d119e80-6a69-4747-976d-7d6a72304d50",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "f5afacc8-b569-4053-b514-ffe11b882dd7",
            "name": "Anaphylaxis Precautions",
            "text": "Anaphylaxis Precautions",
            "order": 15,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 9",
            "sectionTitle": "Anaphylaxis Precautions",
            "sectionType": {
              "id": "a5926a7c-762a-4c34-9368-ba1a8a475035",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          },
          {
            "id": "89007ce2-9929-477d-ae9b-85a6b2db9c81",
            "name": "Child-Pugh Classification",
            "text": "Child-Pugh Classification",
            "order": 16,
            "instanceType": "NarrativeContent",
            "sectionNumber": "Appendix 10",
            "sectionTitle": "Child-Pugh Classification",
            "sectionType": {
              "id": "5733abd8-b01b-404f-91e8-a4c72efd369a",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            }
          }
        ],
        "narrativeContentItems": [
          {
            "id": "417b99e3-49c0-4356-8055-c09c4270f7b5",
            "name": "Background on Hepatocellular Carcinoma",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.1",
            "sectionTitle": "Background on Hepatocellular Carcinoma"
          },
          {
            "id": "054aa110-76d0-429c-abeb-d4237b70bb4f",
            "name": "Current Systemic Treatment for Advanced Hepatocellular Carcinoma",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2",
            "sectionTitle": "Current Systemic Treatment for Advanced Hepatocellular Carcinoma"
          },
          {
            "id": "fc2f2fc1-0f7a-402d-a85b-24c511f6a26c",
            "name": "Background on Atezolizumab",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.3",
            "sectionTitle": "Background on Atezolizumab"
          },
          {
            "id": "39c95050-eed1-474c-9534-6dc9f49bd489",
            "name": "Background on Bevacizumab",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.4",
            "sectionTitle": "Background on Bevacizumab"
          },
          {
            "id": "3fe57c08-24b9-4589-b357-c290714da4f7",
            "name": "Overview of Clinical Development Program in Hepatocellular Carcinoma",
            "text": "",
            "order": 4,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.5",
            "sectionTitle": "Overview of Clinical Development Program in Hepatocellular Carcinoma"
          },
          {
            "id": "84afec27-6aa7-44a4-8f25-c9313e16ac68",
            "name": "Atezolizumab Monotherapy",
            "text": "",
            "order": 5,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.5.1",
            "sectionTitle": "Atezolizumab Monotherapy"
          },
          {
            "id": "e667d90b-b451-42fd-88f1-478461a19b33",
            "name": "Bevacizumab Monotherapy",
            "text": "",
            "order": 6,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.5.2",
            "sectionTitle": "Bevacizumab Monotherapy"
          },
          {
            "id": "2637a169-3b73-405c-8ee6-cb256c230cb0",
            "name": "Study Rationale and Benefit-Risk Assessment",
            "text": "",
            "order": 7,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.6",
            "sectionTitle": "Study Rationale and Benefit-Risk Assessment"
          },
          {
            "id": "5d0e7f9a-4293-4b47-8f80-3232b2b79321",
            "name": "Rationale for the Combination of Anti-PD-L1 and Anti-VEGF Therapy in Hepatocellular Carcinoma",
            "text": "",
            "order": 8,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.6.1",
            "sectionTitle": "Rationale for the Combination of Anti-PD-L1 and Anti-VEGF Therapy in Hepatocellular Carcinoma"
          },
          {
            "id": "67e3917f-066c-4193-a87d-38fe3b05a977",
            "name": "Clinical Data of Atezolizumab in Combination with Bevacizumab in Hepatocellular Carcinoma",
            "text": "",
            "order": 9,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.6.2",
            "sectionTitle": "Clinical Data of Atezolizumab in Combination with Bevacizumab in Hepatocellular Carcinoma"
          },
          {
            "id": "00bdfefc-42d2-4f11-a2f9-1b2cbedd0ec8",
            "name": "COVID-19 Considerations",
            "text": "",
            "order": 10,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.6.3",
            "sectionTitle": "COVID-19 Considerations"
          },
          {
            "id": "fc77b46e-9cf2-4171-b7de-e8b85fc69743",
            "name": "Summary",
            "text": "",
            "order": 11,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.6.4",
            "sectionTitle": "Summary"
          },
          {
            "id": "218dc77f-daaa-4aaf-b35d-c47f515ebfaa",
            "name": "Description of the Study",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.1",
            "sectionTitle": "Description of the Study"
          },
          {
            "id": "9ad9727a-2f30-4753-b992-fbc588607e92",
            "name": "Overview of Study Design",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.1.1",
            "sectionTitle": "Overview of Study Design"
          },
          {
            "id": "b0733f2b-cbc3-484e-9e7d-4c17b07d11da",
            "name": "Independent Data Monitoring Committee",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.1.2",
            "sectionTitle": "Independent Data Monitoring Committee"
          },
          {
            "id": "31a8eecd-9d27-4506-845f-f7bc8f49e4d1",
            "name": "End of Study",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.2",
            "sectionTitle": "End of Study"
          },
          {
            "id": "ef6d2765-a79a-4c8b-8a24-ae20f2e29abb",
            "name": "Rationale for Study Design",
            "text": "",
            "order": 4,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.3",
            "sectionTitle": "Rationale for Study Design"
          },
          {
            "id": "731f4fd6-0463-43ab-807c-06d642795f84",
            "name": "Rationale for Atezolizumab Dose and Schedule",
            "text": "",
            "order": 5,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.3.1",
            "sectionTitle": "Rationale for Atezolizumab Dose and Schedule"
          },
          {
            "id": "334b5e32-07f0-4619-b2c8-1070303680b9",
            "name": "Rationale for Bevacizumab Dose and Schedule",
            "text": "",
            "order": 6,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.3.2",
            "sectionTitle": "Rationale for Bevacizumab Dose and Schedule"
          },
          {
            "id": "8dfa9fb6-6c29-40dd-906b-67d61a369fa5",
            "name": "Rationale for Patient Population",
            "text": "",
            "order": 7,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.3.3",
            "sectionTitle": "Rationale for Patient Population"
          },
          {
            "id": "34753259-36eb-4395-a42d-69807ba3f784",
            "name": "Rationale for Control Arm",
            "text": "",
            "order": 8,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.3.4",
            "sectionTitle": "Rationale for Control Arm"
          },
          {
            "id": "d6bf8165-b521-4cdf-bb7b-cdf50734b733",
            "name": "Rationale for Open-Label Study",
            "text": "",
            "order": 9,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.3.5",
            "sectionTitle": "Rationale for Open-Label Study"
          },
          {
            "id": "507f9deb-3a1c-4ea3-addd-a60337a74b3c",
            "name": "Rationale for Overall Survival and Progression-Free Survival as Co-Primary Endpoints",
            "text": "",
            "order": 10,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.3.6",
            "sectionTitle": "Rationale for Overall Survival and Progression-Free Survival as Co-Primary Endpoints"
          }
        ],
        "abbreviations": [
          {
            "id": "8ee29a03-f96c-482d-b1dd-21dd70e7e4cd",
            "abbreviatedText": "16W-DCR",
            "expandedText": "disease-control rate at 16 weeks",
            "instanceType": "Abbreviation"
          },
          {
            "id": "4735b197-b1ce-4a4f-809f-8f2c14ca9840",
            "abbreviatedText": "AASLD",
            "expandedText": "American Association for the Study of Liver Diseases",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2b1b6321-6a78-42a0-8b26-c8b99621be90",
            "abbreviatedText": "ADA",
            "expandedText": "anti-drug antibody",
            "instanceType": "Abbreviation"
          },
          {
            "id": "d92799ff-eaed-42f3-8287-af6f572f86b2",
            "abbreviatedText": "AFP",
            "expandedText": "-fetoprotein",
            "instanceType": "Abbreviation"
          },
          {
            "id": "5466cd18-8d31-430e-8fc5-7d85ff963e6a",
            "abbreviatedText": "ALP",
            "expandedText": "alkaline phosphatase",
            "instanceType": "Abbreviation"
          },
          {
            "id": "1019d0ce-1cc4-4b25-81ec-6df124f5b4e3",
            "abbreviatedText": "ALT",
            "expandedText": "alanine aminotransferase",
            "instanceType": "Abbreviation"
          },
          {
            "id": "b02f73cf-a022-44c4-bfd3-b026df0b8012",
            "abbreviatedText": "ANC",
            "expandedText": "absolute neutrophil count",
            "instanceType": "Abbreviation"
          },
          {
            "id": "bac6c005-e715-472c-90f7-d774dbc2e8c1",
            "abbreviatedText": "APASL",
            "expandedText": "Asian-Pacific Association for the Study of the Liver",
            "instanceType": "Abbreviation"
          },
          {
            "id": "fe161aa7-82bb-44bf-8b07-1823bea6bd65",
            "abbreviatedText": "ASCO",
            "expandedText": "American Society of Clinical Oncology",
            "instanceType": "Abbreviation"
          },
          {
            "id": "1dfc4a4a-3c45-4d89-8518-fe676d766e8b",
            "abbreviatedText": "AST",
            "expandedText": "aspartate aminotransferase",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2b3ef63d-63ef-45c5-bbe0-e75a63b31813",
            "abbreviatedText": "BID",
            "expandedText": "twice a day",
            "instanceType": "Abbreviation"
          },
          {
            "id": "6fa9de19-9bb1-4e44-946c-d382e88fa18e",
            "abbreviatedText": "BP",
            "expandedText": "blood pressure",
            "instanceType": "Abbreviation"
          },
          {
            "id": "b3b57fec-efdb-4e98-bc4b-52645db79cc7",
            "abbreviatedText": "CDE",
            "expandedText": "Center of Drug Evaluation (China)",
            "instanceType": "Abbreviation"
          },
          {
            "id": "7fa675a2-bbfb-40d7-adc0-fc4eb4bb2523",
            "abbreviatedText": "COPD",
            "expandedText": "chronic obstructive pulmonary disease",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2849ddc9-5005-4e1a-8e33-6b1a9625f2f3",
            "abbreviatedText": "CR",
            "expandedText": "complete response",
            "instanceType": "Abbreviation"
          },
          {
            "id": "c2f265de-4a35-4274-bf9b-26c3afecc18e",
            "abbreviatedText": "CRC",
            "expandedText": "carcinoma of the colon or rectum",
            "instanceType": "Abbreviation"
          },
          {
            "id": "c6630978-3713-41bd-b76e-d11fe956f9bf",
            "abbreviatedText": "CSR",
            "expandedText": "Clinical Study Report",
            "instanceType": "Abbreviation"
          },
          {
            "id": "02ffd2cb-687b-4d8b-af18-d1017355f729",
            "abbreviatedText": "CT",
            "expandedText": "computed tomography",
            "instanceType": "Abbreviation"
          },
          {
            "id": "b2edbb9b-f43b-4d50-8b11-9bfb3bfb249b",
            "abbreviatedText": "DOR",
            "expandedText": "duration of response",
            "instanceType": "Abbreviation"
          },
          {
            "id": "6aacc485-43e3-42e7-8ec6-e22a519c4748",
            "abbreviatedText": "EC",
            "expandedText": "Ethics Committee",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2c50da7e-8266-4d76-8055-790b625cf5ad",
            "abbreviatedText": "ECOG",
            "expandedText": "Eastern Cooperative Oncology Group",
            "instanceType": "Abbreviation"
          },
          {
            "id": "08bb2004-8b68-4572-ba19-5799d0b0ce4c",
            "abbreviatedText": "eCRF",
            "expandedText": "electronic Case Report Form",
            "instanceType": "Abbreviation"
          },
          {
            "id": "f8f2c4bb-d26c-47e0-b3b1-271310eef5da",
            "abbreviatedText": "EDC",
            "expandedText": "electronic data capture",
            "instanceType": "Abbreviation"
          },
          {
            "id": "632fdfdd-58ec-4a45-8a84-c8b06b6de4c5",
            "abbreviatedText": "EGD",
            "expandedText": "esophagogastroduodenoscopy",
            "instanceType": "Abbreviation"
          },
          {
            "id": "e2ec6242-6a6a-4d55-ac42-9dba45a97e6e",
            "abbreviatedText": "EOC",
            "expandedText": "epithelial ovarian cancer",
            "instanceType": "Abbreviation"
          },
          {
            "id": "9e08b57f-b7cc-4693-bbe3-0c6cb9f6b2ed",
            "abbreviatedText": "EORTC",
            "expandedText": "European Organisation for Research and Treatment of Cancer",
            "instanceType": "Abbreviation"
          },
          {
            "id": "012d97f4-cd26-47e5-9e19-14fb1abe9881",
            "abbreviatedText": "EQ-5D-5L",
            "expandedText": "EuroQol 5-Dimension, 5-Level Questionnaire",
            "instanceType": "Abbreviation"
          },
          {
            "id": "cb1ff800-73b0-4765-9ca6-cef91517531f",
            "abbreviatedText": "FDA",
            "expandedText": "(U.S.) Food and Drug Administration",
            "instanceType": "Abbreviation"
          },
          {
            "id": "ea34b425-cc76-4f2c-8f9d-75eaaea5c687",
            "abbreviatedText": "FFPE",
            "expandedText": "formalin-fixed, paraffin-embedded",
            "instanceType": "Abbreviation"
          },
          {
            "id": "4c18460b-0530-4440-94cc-a4a7737e382b",
            "abbreviatedText": "FPI",
            "expandedText": "first patient in",
            "instanceType": "Abbreviation"
          },
          {
            "id": "4d6991bc-46c4-4fb2-832e-a3b869eebe21",
            "abbreviatedText": "FTC",
            "expandedText": "fallopian tube cancer",
            "instanceType": "Abbreviation"
          },
          {
            "id": "472d2a2d-7ba3-4646-8bb9-912aacca2028",
            "abbreviatedText": "GBM",
            "expandedText": "glioblastoma multiforme",
            "instanceType": "Abbreviation"
          },
          {
            "id": "4574a4fd-0fa0-4778-ae90-472edde0de5d",
            "abbreviatedText": "GHS",
            "expandedText": "global health status",
            "instanceType": "Abbreviation"
          },
          {
            "id": "21d6e23a-96b5-4267-b4c4-c8dbf4eb8ab9",
            "abbreviatedText": "GI",
            "expandedText": "gastrointestinal",
            "instanceType": "Abbreviation"
          },
          {
            "id": "fa3586f7-2db5-4bd1-a291-9a57eb7f1f58",
            "abbreviatedText": "HBcAb",
            "expandedText": "hepatitis B core antibody",
            "instanceType": "Abbreviation"
          },
          {
            "id": "bd41f2e8-214a-46ee-ab82-98c8f81b7deb",
            "abbreviatedText": "HBsAg",
            "expandedText": "hepatitis B surface antigen",
            "instanceType": "Abbreviation"
          },
          {
            "id": "248f1224-8082-436a-a6eb-7f177c9c10f2",
            "abbreviatedText": "HBV",
            "expandedText": "hepatitis B virus",
            "instanceType": "Abbreviation"
          },
          {
            "id": "fb1f5237-ce18-4a4f-8dc1-7f48e686bcf7",
            "abbreviatedText": "HCC",
            "expandedText": "hepatocellular carcinoma",
            "instanceType": "Abbreviation"
          },
          {
            "id": "f93f37e1-45e6-4826-ab43-30241119f011",
            "abbreviatedText": "HCV",
            "expandedText": "hepatitis C virus",
            "instanceType": "Abbreviation"
          },
          {
            "id": "2d36b0ed-3de5-492f-8402-f28af8751d44",
            "abbreviatedText": "HIPAA",
            "expandedText": "Health Insurance Portability and Accountability Act",
            "instanceType": "Abbreviation"
          },
          {
            "id": "7c3ed837-1f16-42e0-846f-9ea20b6cad6c",
            "abbreviatedText": "ICF",
            "expandedText": "Informed Consent Form",
            "instanceType": "Abbreviation"
          },
          {
            "id": "dc7ef489-1683-427e-9a87-e2c556a34c83",
            "abbreviatedText": "imRECIST",
            "expandedText": "Immune-Modified Response Evaluation Criteria in Solid Tumors",
            "instanceType": "Abbreviation"
          },
          {
            "id": "cfbc4ab5-85f9-4577-93d5-d6b54386a40a",
            "abbreviatedText": "IRF",
            "expandedText": "Independent Review Facility",
            "instanceType": "Abbreviation"
          },
          {
            "id": "3e074c04-10a6-42e3-af70-244556d34ac7",
            "abbreviatedText": "NCI CTCAE",
            "expandedText": "National Cancer Institute Common Terminology Criteria for Adverse Events",
            "instanceType": "Abbreviation"
          },
          {
            "id": "60ef23bf-f992-41c2-96cd-7b0dcab9f784",
            "abbreviatedText": "OR",
            "expandedText": "objective response",
            "instanceType": "Abbreviation"
          },
          {
            "id": "1a6e233e-1d3c-4d8e-be1f-35a545c81e74",
            "abbreviatedText": "OS",
            "expandedText": "overall survival",
            "instanceType": "Abbreviation"
          },
          {
            "id": "74bfe470-b80a-47ba-b648-41571332c586",
            "abbreviatedText": "PD-L1",
            "expandedText": "programmed death-ligand 1",
            "instanceType": "Abbreviation"
          },
          {
            "id": "582358c7-7df5-4ae8-aa9e-0d71e17fa24a",
            "abbreviatedText": "PFS",
            "expandedText": "progression-free survival",
            "instanceType": "Abbreviation"
          },
          {
            "id": "01216673-ced4-4298-8017-3d5bb44d55b9",
            "abbreviatedText": "QLQ-C30",
            "expandedText": "Quality-of-Life Questionnaire",
            "instanceType": "Abbreviation"
          },
          {
            "id": "55f265e7-ae12-4728-8674-49a9d85b700a",
            "abbreviatedText": "RECIST v1.1",
            "expandedText": "Response Evaluation Criteria in Solid Tumors, Version 1.1",
            "instanceType": "Abbreviation"
          },
          {
            "id": "c06ec141-4e3c-4ad2-b996-084ac2874360",
            "abbreviatedText": "TTP",
            "expandedText": "time to progression",
            "instanceType": "Abbreviation"
          },
          {
            "id": "1a409569-8051-4a4d-a8d4-aa983c60b7aa",
            "abbreviatedText": "ULN",
            "expandedText": "upper limit of normal",
            "instanceType": "Abbreviation"
          },
          {
            "id": "bdc8912c-e885-48cc-ab5a-f9014b9af89a",
            "abbreviatedText": "VEGF",
            "expandedText": "vascular endothelial growth factor",
            "instanceType": "Abbreviation"
          }
        ],
        "amendments": [
          {
            "id": "838e23bb-3336-4610-87b6-43ce6fefea8e",
            "number": "6",
            "name": "Amendment 6",
            "scope": {
              "id": "0bfb561b-424b-4ddc-a2d0-615b362b2b83",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "91719f43-1591-4bb4-9826-d42e786f81ca",
              "code": {
                "id": "4c1024c5-15c1-4f4e-a906-6741dabb5766",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "1a2eb0c8-c040-4062-a86e-5b441effa892",
                "type": {
                  "id": "f84f4047-bf85-40a4-a3ca-f9ffe8f70ed5",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Protocol YO40245 has been amended primarily to align with updates in the Atezolizumab Investigators Brochure, Version 17. Key changes include clarifying the descriptive nature of subsequent OS analyses, adding Severe Cutaneous Adverse Reactions (SCARs) as a risk, updating management guidelines for dermatologic and hepatic events, and incorporating COVID-19 considerations and risk language.",
            "effectiveDate": "2021-02-01",
            "reasonIds": [
              "74e54b66-668a-483d-bb73-4e9dc8942a24",
              "486a9163-52fb-4ff5-a54d-d927d3e64a7c",
              "46488979-7abc-4abb-9f33-f0e9152bc68a",
              "bf2f1464-4f4b-4280-aca8-f12bd20e0b8c"
            ],
            "previousVersion": "5",
            "newVersion": "6"
          },
          {
            "id": "da0db8fa-0c74-4d2a-8b3c-d4ccfcb49356",
            "number": "5",
            "name": "Amendment 5",
            "scope": {
              "id": "faf4f50d-8937-46e0-93bb-65f043af19ce",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "e81c54db-25f3-4ee0-8269-5f57aa74d9f0",
              "code": {
                "id": "14081983-6fcc-40da-bc7f-8caf94052b9d",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "2c0b9c5e-ad97-4538-9693-aeb2734aae4e",
                "type": {
                  "id": "f1cb5580-6072-4a33-8a5c-64c2a877223e",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Not provided in the document text beyond the date and version reference.",
            "effectiveDate": "2020-01-15",
            "previousVersion": "4",
            "newVersion": "5"
          },
          {
            "id": "9793c4d2-8ab5-4ec7-8c37-c6e1b26195f9",
            "number": "4",
            "name": "Amendment 4",
            "scope": {
              "id": "47e92999-977e-4fab-86d4-f5e19dec4b47",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "9d9a2785-6b6d-4073-88b0-6613a28ee8d0",
              "code": {
                "id": "0614cc2a-aee5-4933-8a6b-1c9c38bc9593",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "c76615bb-dc0f-4bd3-8060-4d9b300a338d",
                "type": {
                  "id": "b3c46af4-c789-4dc4-9a7a-17435132e471",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Not provided in the document text beyond the date and version reference.",
            "effectiveDate": "2019-02-20",
            "previousVersion": "3",
            "newVersion": "4"
          },
          {
            "id": "a45f5890-ed12-49cb-9a3f-3cf80de0e3a1",
            "number": "3",
            "name": "Amendment 3",
            "scope": {
              "id": "f718c689-cb69-4847-a125-00c0ab2393c3",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "5baa208e-8adf-494e-b663-d08f364fb8d9",
              "code": {
                "id": "a46685cd-6f3e-497f-b090-27cea56530de",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "3d899cd3-9602-4b4f-8012-819d22281d82",
                "type": {
                  "id": "60266de1-3e33-4ffd-b4b0-e7d0944d58b4",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Not provided in the document text beyond the date and version reference.",
            "effectiveDate": "2018-09-15",
            "previousVersion": "2",
            "newVersion": "3"
          },
          {
            "id": "cd9e69b1-b62e-4ad5-a442-4278770b7264",
            "number": "2",
            "name": "Amendment 2",
            "scope": {
              "id": "f5605316-8a59-4fbd-9310-4f9c836b3dcb",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "a4e0605a-bf49-4201-8094-2db364038a5c",
              "code": {
                "id": "f4d4dc45-ca5a-4bd9-a8d1-1b85cf4353df",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "dbd5a9e4-4cd5-4b90-b8ff-98084dc05bac",
                "type": {
                  "id": "f7513ffc-5ebb-4ef2-8867-a0c6d23c78b7",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Not provided in the document text beyond the date and version reference.",
            "effectiveDate": "2018-03-14",
            "previousVersion": "1",
            "newVersion": "2"
          }
        ],
        "medicalDevices": [
          {
            "id": "4c48d8b1-c1d6-439c-bb81-c5b6e8e7c26e",
            "name": "Indwelling Catheter",
            "instanceType": "MedicalDevice",
            "label": "PleurX",
            "description": "Indwelling catheter for drainage of pleural effusion or ascites",
            "deviceType": {
              "id": "cc58f0e1-d51b-4989-a294-0fc49cf3173d",
              "code": "Monitoring Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Monitoring Device",
              "instanceType": "Code"
            },
            "manufacturer": "BD",
            "modelNumber": "PleurX"
          },
          {
            "id": "1061362d-284b-4ff7-a679-0879d574e731",
            "name": "Venous Access Device",
            "instanceType": "MedicalDevice",
            "label": "Vascular Access Device",
            "description": "Device for long-term intravenous administration",
            "deviceType": {
              "id": "fa479feb-89ab-43f6-b20e-11f9b2a4c190",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            },
            "manufacturer": "Not Specified",
            "modelNumber": "Not Specified"
          },
          {
            "id": "8c301f71-2e15-4e22-8824-d1bd73e47709",
            "name": "Computed Tomography Scanner",
            "instanceType": "MedicalDevice",
            "label": "CT Scanner",
            "description": "Imaging equipment for tumor assessment",
            "deviceType": {
              "id": "3cdfcbeb-fa8e-4a8b-b95e-ce5c072334d3",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            },
            "manufacturer": "Not Specified",
            "modelNumber": "Not Specified"
          }
        ],
        "conditions": [
          {
            "id": "4acbf905-d2b9-4a9d-8b25-4a26e9ba4143",
            "name": "Adequate Hematologic Function",
            "instanceType": "Condition",
            "description": "Laboratory thresholds for ANC, Platelets, and Hemoglobin",
            "text": "ANC >= 1.5 x 10^9/L, Platelets >= 75 x 10^9/L, Hemoglobin >= 90 g/L"
          },
          {
            "id": "b7b3c554-ab9a-4bfa-a093-1aaa9a5fe752",
            "name": "Liver Function Thresholds",
            "instanceType": "Condition",
            "description": "AST, ALT, and Bilirubin limits",
            "text": "AST, ALT, and ALP <= 5x ULN; Serum bilirubin <= 3x ULN"
          },
          {
            "id": "6e9371af-9a62-4e8c-a54a-30d0ced58996",
            "name": "Proteinuria Management",
            "instanceType": "Condition",
            "description": "Criteria for 24-hour urine collection",
            "text": "If dipstick >= 2+, 24-hour urine must demonstrate < 1g protein"
          }
        ],
        "studySites": [
          {
            "id": "dd30bc24-2c7a-4c52-8e95-2db2519b4da5",
            "name": "St. Josephs Hospital and Medical Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "1",
            "organizationId": "dc026624-1915-46e6-b2bb-7de3ea14e5a1",
            "country": "United States"
          },
          {
            "id": "33eeee20-37c2-4af2-aab5-940dca6dcca2",
            "name": "City of Hope",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "2",
            "organizationId": "5953be2e-6b27-453c-ab4e-160f24b87f71",
            "country": "United States"
          },
          {
            "id": "6bf360fe-60c7-4598-865d-234cc149015d",
            "name": "Uni of California - San Diego; Cancer Center & Dept of Medicine",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "3",
            "organizationId": "675b1990-5d79-43d7-a73d-e60073cb666a",
            "country": "United States"
          },
          {
            "id": "83ab5542-6566-41ef-b21c-5db06f9d1256",
            "name": "Kaiser Permanente Northern California",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "4",
            "organizationId": "4b068ed9-627a-4463-b93b-502e22421f51",
            "country": "United States"
          },
          {
            "id": "cb2dcc00-0989-47cf-a13a-b9b52ba6f4ac",
            "name": "University of California Irvine Medical Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "5",
            "organizationId": "8fe96f27-d652-459f-96d0-f1e17831b7d6",
            "country": "United States"
          },
          {
            "id": "00c04bc0-d2b8-446f-a6fe-5ef5393d7354",
            "name": "Kaiser Permanente Sacramento Medical Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "6",
            "organizationId": "a180b648-5b56-4463-ab60-72dedd577efb",
            "country": "United States"
          },
          {
            "id": "90228a76-7d18-4714-ab42-0585ba731a29",
            "name": "California Pacific Medical Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "7",
            "organizationId": "5857a1ad-1ac8-4e4e-9fce-90e9e5767f9c",
            "country": "United States"
          },
          {
            "id": "a07f729a-780f-4458-a5d4-38f05d765da1",
            "name": "Kaiser Permanente - San Francisco Medical Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "8",
            "organizationId": "ca4e38d6-79bb-4a59-a569-7ae8f271df63",
            "country": "United States"
          },
          {
            "id": "117f236e-890b-46e2-a4dc-ead5c041307b",
            "name": "University of California Los Angeles",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "9",
            "organizationId": "8131e975-1112-4cfd-9a86-8164ed75080a",
            "country": "United States"
          },
          {
            "id": "b9dc267f-e233-460f-95ef-470177a2c7da",
            "name": "Kaiser Permanente - Walnut Creek",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "10",
            "organizationId": "4e3583b5-867d-4697-bd8f-db7e5d3e9a75",
            "country": "United States"
          },
          {
            "id": "e5dec6b3-eb63-492a-b716-d45ffb39ba32",
            "name": "Banner MD Anderson Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "11",
            "organizationId": "977b29a7-1d89-489b-b4d0-65a09264d2b5",
            "country": "United States"
          },
          {
            "id": "b9cc4366-5bfd-48c9-aa8e-920468d9ae38",
            "name": "Georgetown University",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "12",
            "organizationId": "c89716e9-01c2-4cf7-9060-7ed89c6b77f7",
            "country": "United States"
          },
          {
            "id": "9cd7d2b6-3917-44e6-a4c7-d479a3c66d63",
            "name": "Moffitt Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "13",
            "organizationId": "b2cd5ca1-135c-41c4-a280-a1678cc54617",
            "country": "United States"
          },
          {
            "id": "0760d5cc-20ce-455a-9086-bfcc620c5303",
            "name": "Massachusetts General Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "14",
            "organizationId": "d323910b-947f-4909-a720-018f34e26a67",
            "country": "United States"
          },
          {
            "id": "e643672a-ec80-4a9f-a68a-f2a512e2983a",
            "name": "Henry Ford Health System",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "15",
            "organizationId": "ac0ad873-24b0-4561-a72d-f81cc2b87b21",
            "country": "United States"
          },
          {
            "id": "9dfd2d5c-332b-4bce-9aa7-b62dc13f63af",
            "name": "Washington University; Wash Uni. Sch. Of Med",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "16",
            "organizationId": "cc36d27e-0709-4fb1-bb72-9f496697db68",
            "country": "United States"
          },
          {
            "id": "3d5b6164-7b5e-4db1-b147-3c64f18d32d2",
            "name": "University of New Mexico Comprehensive Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "17",
            "organizationId": "d195491a-1905-463b-9b0d-ccb970df3372",
            "country": "United States"
          },
          {
            "id": "a539437a-33e6-4679-9a52-3d486f6cfb4d",
            "name": "Laura and ISAAC Perlmutter Cancer Center at NYU Langone.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "18",
            "organizationId": "eb91eea3-f14e-4001-b4e9-853fa634ce30",
            "country": "United States"
          },
          {
            "id": "3e0af50e-2018-4c5d-bea8-d66541e5322d",
            "name": "Thomas Jefferson University",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "19",
            "organizationId": "81ab0857-ef55-48a4-8201-76f73ce707f6",
            "country": "United States"
          },
          {
            "id": "50c1f610-e0b9-4cb6-a00a-67dc43aa1b18",
            "name": "M.D Anderson Cancer Center; Uni of Texas At Houston",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "20",
            "organizationId": "5d60a6b3-e34e-4500-90f5-17fa73526c40",
            "country": "United States"
          },
          {
            "id": "b2390431-3353-4e47-b19d-b7261931bc34",
            "name": "Swedish Cancer Inst.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "21",
            "organizationId": "90cdd09c-564a-4ddd-ad71-5e0985f6214d",
            "country": "United States"
          },
          {
            "id": "c710589c-932b-4477-95c6-a5e6f748b652",
            "name": "Bankstown-Lidcombe Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "22",
            "organizationId": "c1d143e2-af6d-4f18-8280-eeafed36727b",
            "country": "Australia"
          },
          {
            "id": "7f8fa2a0-4f89-4f94-839b-a1adaf981e80",
            "name": "St George Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "23",
            "organizationId": "1067dd47-1c72-4965-bdab-17e633dfeb52",
            "country": "Australia"
          },
          {
            "id": "0dbaf46b-7a4f-4dc8-a0b4-dd87b8fd77b2",
            "name": "The Queen Elizabeth Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "24",
            "organizationId": "19254036-22f4-40cb-b0c1-92aa8b3485e4",
            "country": "Australia"
          },
          {
            "id": "15d83e15-baf4-47e8-9c0d-9a828b5d9a1e",
            "name": "Sunshine Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "25",
            "organizationId": "6aaa464a-2e06-4fa3-80e2-a442a87666d8",
            "country": "Australia"
          },
          {
            "id": "b6121ec0-0173-4aff-bafa-ad0b60665ef8",
            "name": "Ottawa Hospital Research Institute",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "26",
            "organizationId": "43b68be8-a24b-4684-bcf1-b57164d1a18b",
            "country": "Canada"
          },
          {
            "id": "88d94f37-a00d-4960-ac41-c114349d1980",
            "name": "Centre hospitalier de l'Universite de Montreal (CHUM)",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "27",
            "organizationId": "13dfa544-2148-48bf-80d2-810594522379",
            "country": "Canada"
          },
          {
            "id": "233572b2-874c-42e2-a4ef-5b48b54ca87b",
            "name": "Jewish General Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "28",
            "organizationId": "05239203-4ec2-43e7-bddc-25ae8f605cad",
            "country": "Canada"
          },
          {
            "id": "aeb1d541-1c66-416e-83ed-9121fd3f41bf",
            "name": "McGill University Health Centre - Glen Site",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "29",
            "organizationId": "5f9b4b30-dd19-4cf0-b1b6-b782e5c70fae",
            "country": "Canada"
          },
          {
            "id": "6ec9400d-ba33-4869-b1d0-07e4cebfec8b",
            "name": "Peking Union Medical College Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "30",
            "organizationId": "4c5b8d39-15d4-4f33-aed7-85dfc7180012",
            "country": "China"
          },
          {
            "id": "2f91379b-9260-4c2a-94cd-a2843e3887ac",
            "name": "Beijing Friendship Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "31",
            "organizationId": "6e0082e8-7f10-4dd6-ba44-6a710ce7dde1",
            "country": "China"
          },
          {
            "id": "6177639c-c57c-47d1-b0b4-b1790903c524",
            "name": "Beijing Cancer Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "32",
            "organizationId": "1f78f090-eef7-4ed7-b601-7783008595f5",
            "country": "China"
          },
          {
            "id": "fb8d93d8-fa35-4400-a468-98791085c839",
            "name": "the First Hospital of Jilin University",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "33",
            "organizationId": "ac0051d2-6a1f-482a-9d94-4ee051a77095",
            "country": "China"
          },
          {
            "id": "96ab96ce-cb65-4cf2-9f3b-f391de916d3a",
            "name": "Jilin Cancer Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "34",
            "organizationId": "dfdd9450-8faf-47fb-a876-89fedb7a5db4",
            "country": "China"
          },
          {
            "id": "2dfb59ba-bc29-4f46-9116-541ed1e67f62",
            "name": "Hunan Cancer Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "35",
            "organizationId": "b14f707c-d88d-4621-9a65-4c323ce82142",
            "country": "China"
          },
          {
            "id": "3d5ff19c-6ed3-44e0-9c9a-ac8f8cb0e207",
            "name": "The First People's Hospital of Foshan; Local Ethic Committee",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "36",
            "organizationId": "94b6d69e-253d-4e58-80b2-a45f52ef0700",
            "country": "China"
          },
          {
            "id": "2710ca34-e125-4e65-841d-9fd26a0022e9",
            "name": "The 900th Hospital of PLA joint service support force",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "37",
            "organizationId": "9af8bb99-9214-45db-9a6a-6ff7dccd43c8",
            "country": "China"
          },
          {
            "id": "ba91ea84-40b4-41c7-b62e-25e41fc2f9b3",
            "name": "Nanfang Hospital, Southern Medical University",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "38",
            "organizationId": "020ba8d7-59b8-4be8-ab45-0d88c66aa47c",
            "country": "China"
          },
          {
            "id": "23d1d94c-e1f3-4ae8-8372-0b6457f7eebf",
            "name": "Sun Yet-sen University Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "39",
            "organizationId": "2dcdca3e-1ddc-44bf-a28f-3bf59b02f183",
            "country": "China"
          },
          {
            "id": "639aedc3-5c7f-4ec1-9983-a67e79fafd96",
            "name": "The First Affiliated Hospital of College of Medicine, Zhejiang University",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "40",
            "organizationId": "e893a8fc-982f-493c-abf6-9734e32ad543",
            "country": "China"
          },
          {
            "id": "34a45a92-5570-444b-996b-84f7b183c548",
            "name": "Sir Run Run Shaw Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "41",
            "organizationId": "44932624-6910-4c24-a3df-35c185f1fae6",
            "country": "China"
          },
          {
            "id": "dfcc5c99-2db7-452f-8a9d-4a59035e6ecd",
            "name": "Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "42",
            "organizationId": "0659e78c-08ab-475a-a1c1-4225abba63ee",
            "country": "China"
          },
          {
            "id": "4a3d200f-1498-4e1e-97bc-dea0ce078b83",
            "name": "Harbin Medical University Cancer Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "43",
            "organizationId": "9f6873cf-3d5e-4b29-9f1c-df674849bd58",
            "country": "China"
          },
          {
            "id": "b02699c9-f48a-4dda-af4e-246baeaa166b",
            "name": "The First Affiliated Hospital of Anhui Medical University",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "44",
            "organizationId": "320becb0-4ca6-4fc0-84e2-26e813f42890",
            "country": "China"
          },
          {
            "id": "6f3fb3ac-c843-48a7-b2ea-4cedaca8613c",
            "name": "Anhui Province Cancer Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "45",
            "organizationId": "786ba484-bff9-47a2-91db-e68b2080a3cc",
            "country": "China"
          },
          {
            "id": "8f29ecaa-b254-4d54-a489-79fe270118f1",
            "name": "General Hospital of Jinan Military Command of PLA",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "46",
            "organizationId": "3a1d7221-f5b5-4abe-867d-22769eff1df9",
            "country": "China"
          },
          {
            "id": "21e2d9bd-0116-4f8d-a443-efaa610e10a7",
            "name": "The 81st Hospital of P.L.A.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "47",
            "organizationId": "cf0647d1-25c5-4995-97e7-6f6b297b7c27",
            "country": "China"
          },
          {
            "id": "0389405c-e00b-43c8-8ac5-d84eca6b3bbd",
            "name": "Zhongshan Hospital Fudan University",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "48",
            "organizationId": "39a4ad9c-4253-4798-a3a4-58a867eb6d43",
            "country": "China"
          },
          {
            "id": "1f5a40f4-8a56-400a-a709-1e7bd2b0a52b",
            "name": "Fudan University Shanghai Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "49",
            "organizationId": "80cadcc6-d21b-4f0d-9a97-f55173742c21",
            "country": "China"
          },
          {
            "id": "8ee54c1c-9fef-4061-a2e2-3b074e299bd3",
            "name": "Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "50",
            "organizationId": "9b7d0700-1fb8-4504-a4cf-02786cdd1c3c",
            "country": "China"
          },
          {
            "id": "f5ddd6cc-8524-4772-b5f1-18a1f79bd610",
            "name": "Masarykuv onkologicky ustav",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "51",
            "organizationId": "dd2d1952-3380-4aba-acf0-dd54b6bacf4b",
            "country": "Czechia"
          },
          {
            "id": "7fbdd7a6-5c6b-4201-abde-3ca71e49a131",
            "name": "Fakultni nemocnice Olomouc; Onkologicka klinika",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "52",
            "organizationId": "b575fa80-af9a-4705-80e4-65efff94aab2",
            "country": "Czechia"
          },
          {
            "id": "d5cb7886-29a5-44c9-b6e2-05e31f47f6de",
            "name": "Hopital Claude Huriez;Gastro Enterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "53",
            "organizationId": "f8e65450-a52f-4dbf-8068-d05a520bdd78",
            "country": "France"
          },
          {
            "id": "6b909bc1-2ca5-4ec1-96cf-df9b55134f51",
            "name": "Hopital De La Croix Rousse; Hepatologie Gastro Enterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "54",
            "organizationId": "cd4993b2-12f9-498c-926a-12d5b745cf61",
            "country": "France"
          },
          {
            "id": "adcac051-355a-46e0-864a-0bed4a09125c",
            "name": "Hopital Timone Adultes; Gastro Enterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "55",
            "organizationId": "7e81ab51-931e-4b8d-9080-68c672bb1906",
            "country": "France"
          },
          {
            "id": "d8ae1c31-169f-41c7-a4ea-9dad38af2a8d",
            "name": "Hopital Saint-Eloi; Hepatologie-Gastro-Enterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "56",
            "organizationId": "365f4304-de98-4285-a5d8-3dc3e76c899d",
            "country": "France"
          },
          {
            "id": "033e4bd7-da47-4738-8a86-14e3fa17a35a",
            "name": "Hopital Hotel Dieu Et Hme; Hepatologie Gastro Enterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "57",
            "organizationId": "cf3613b5-a5fa-403e-9c37-23a7c2a95caf",
            "country": "France"
          },
          {
            "id": "377eb321-066e-4e0f-99bf-eac6ee6449af",
            "name": "CHU Nice - Hpital de l'Archet 2; service Hepato gastro enterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "58",
            "organizationId": "fce25f12-b94e-41c0-87c3-cf1d263132b2",
            "country": "France"
          },
          {
            "id": "6c615960-173f-4ce6-880a-ece9a668e711",
            "name": "Hopital Charles Nicolle; Gastroenterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "59",
            "organizationId": "f9b5af83-998a-4b27-99cd-f72ca3c796b6",
            "country": "France"
          },
          {
            "id": "252a24b8-ab61-4bae-a4b3-d23c33713675",
            "name": "Hopital Hautepierre; Gastro Enterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "60",
            "organizationId": "6a5c3846-300d-4eb9-9e50-88aa63d4ce54",
            "country": "France"
          },
          {
            "id": "ac80cc86-106a-4ec8-a21b-c0732da3446c",
            "name": "Hpital d'Adultes; Service hpato-gastro-entrologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "61",
            "organizationId": "f9c18b84-360e-4222-b3bf-bdcf9ffc160c",
            "country": "France"
          },
          {
            "id": "e88c4ff0-745b-472c-b623-a2b925c0a8c2",
            "name": "Institut Gustave Roussy; Gastro-Enterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "62",
            "organizationId": "0b5716eb-a5fb-4051-a148-5e9b9447c9f8",
            "country": "France"
          },
          {
            "id": "f53434f6-e010-4402-b5f4-db033540db5a",
            "name": "Campus Virchow-Klinikum Charit Centrum 13; Medizinische Klinik; Abt.Hepatologie u.Gastroenterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "63",
            "organizationId": "af3d512b-acf5-41e9-b7f6-1b594dffb693",
            "country": "Germany"
          },
          {
            "id": "7097c323-d64b-42d2-a622-5aec93a8a6a8",
            "name": "Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "64",
            "organizationId": "f6ab42c3-74c7-4e59-831d-bb8d6d438bfb",
            "country": "Germany"
          },
          {
            "id": "df03c0f5-dad1-4a4d-a023-09106016c5c0",
            "name": "Universitaetsklinikum Hamburg-Eppendorf; I. Medizinische Klinik - Gastroenterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "65",
            "organizationId": "27de2049-d125-4298-b33c-5d4f5610b8ab",
            "country": "Germany"
          },
          {
            "id": "2f90c302-6691-473c-8dbf-5547faed1ec8",
            "name": "Med. Hochschule Hannover; Gastroenterologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "66",
            "organizationId": "b2786822-53f6-4c0a-a422-e6e87f54f401",
            "country": "Germany"
          },
          {
            "id": "5ae645cb-62ae-46cb-b890-e07ca111ee26",
            "name": "Universittsklinikum Leipzig Medizinische Klinik II Gastroenterolog. u. Hepatolog.",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "67",
            "organizationId": "c639dc2e-c7e8-4015-93f1-08b3668c7a11",
            "country": "Germany"
          },
          {
            "id": "90d34f00-5c60-419a-a98e-5c2ffccb1a9d",
            "name": "Uniklinik Mainz; I. Medizinische Klinik",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "68",
            "organizationId": "81cc24e8-575d-46cc-aaea-8187859c51b7",
            "country": "Germany"
          },
          {
            "id": "f21df892-9546-40c6-b023-22a0ccbe8c6f",
            "name": "Klinikum der Uni Regensburg; Klinik f.Innere Medizin I Abt. Hmatologie und Internistische Onkologie",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "69",
            "organizationId": "3af83173-a155-4b79-99de-b6f8b95bee86",
            "country": "Germany"
          },
          {
            "id": "e9c3d2f0-e7ed-41a9-9f54-be8c2db17359",
            "name": "Queen Mary Hospital; Dept. Of Haematology & Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "70",
            "organizationId": "5f3a246b-a7c3-4a00-b079-1e49b035fee7",
            "country": "Hong Kong"
          },
          {
            "id": "77b92975-fcf9-46b9-9903-e919a7b6decd",
            "name": "Prince of Wales Hosp; Dept. Of Clinical Onc",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "71",
            "organizationId": "eec246cb-4130-44e1-8789-8a4667707978",
            "country": "Hong Kong"
          },
          {
            "id": "9286d81b-a453-4fd1-8b25-c9c8bdddc45d",
            "name": "Az. Osp. Rummo; Oncologia Medica",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "72",
            "organizationId": "0b34c4e6-ee94-46c0-acd7-d3a8b37b5fad",
            "country": "Italy"
          },
          {
            "id": "17736269-aa22-4daf-9339-08b8d1e9697d",
            "name": "IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "73",
            "organizationId": "5e163c50-984c-465d-a533-97d54ab3c7a2",
            "country": "Italy"
          },
          {
            "id": "f4c4cc68-615e-4f4c-8f23-317f6d6197c4",
            "name": "Az. Osp. S. Luigi Gonzaga; Divisione Di Oncologia Medica",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "74",
            "organizationId": "cdc46449-b9c2-4a3c-8111-f287e2b40f7a",
            "country": "Italy"
          },
          {
            "id": "8494c8c9-1837-4b87-b386-46928728cfa6",
            "name": "A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "75",
            "organizationId": "720ae52d-bed6-4357-a56a-c94f16e105cb",
            "country": "Italy"
          },
          {
            "id": "87f41acd-41a2-4b33-954e-7a1fcee65f24",
            "name": "Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria ? Polo Oncologico",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "76",
            "organizationId": "9b23e35f-548f-4e72-8a4e-bd79872f846c",
            "country": "Italy"
          },
          {
            "id": "dcd7df29-12b4-4554-a814-498de58325d3",
            "name": "IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "77",
            "organizationId": "c0820725-2d26-4e4e-8c65-8e80b7202fc4",
            "country": "Italy"
          },
          {
            "id": "3763ba2b-d77f-4c62-a29f-a2f59db8f89b",
            "name": "Chiba University Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "78",
            "organizationId": "6d7f6ab8-7bcf-4151-8112-886dc672861a",
            "country": "Japan"
          },
          {
            "id": "8d52e675-19b9-4acf-97bd-771686037405",
            "name": "National Cancer Center Hospital East",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "79",
            "organizationId": "f50c6d98-e732-4b71-9cef-ac226c6ab24b",
            "country": "Japan"
          },
          {
            "id": "d9442b58-e16d-4c0e-8b95-508e8aab063b",
            "name": "Kurume University Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "80",
            "organizationId": "6a83b7b7-6969-4c38-b5f6-895a0d82b720",
            "country": "Japan"
          },
          {
            "id": "460650e5-7055-47b7-a1b2-e0a56e7ccc33",
            "name": "Sapporo Kosei Genaral Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "81",
            "organizationId": "184ea649-9805-4590-9ace-b297f1d985ed",
            "country": "Japan"
          },
          {
            "id": "b6e2f498-2454-4c5a-b1b1-03969d552052",
            "name": "Hokkaido University Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "82",
            "organizationId": "c9966309-cef9-464c-a956-593eb25e39da",
            "country": "Japan"
          },
          {
            "id": "3d253f74-5383-4598-bfab-7f07b6cf79a2",
            "name": "Kanazawa University Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "83",
            "organizationId": "828ba241-0f6c-40eb-81d5-9e710d80abe5",
            "country": "Japan"
          },
          {
            "id": "0ff3b9a9-ebf1-480d-b750-7747692efada",
            "name": "Kitasato University Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "84",
            "organizationId": "c9b3c774-17ee-48ce-8cdd-f07e35c9c589",
            "country": "Japan"
          },
          {
            "id": "6abca5cc-9dc5-4bbb-97cb-51b8505e7607",
            "name": "Kumamoto University Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "85",
            "organizationId": "0f03b5c5-448a-4c79-ac26-7c5b3d09c9e1",
            "country": "Japan"
          },
          {
            "id": "15d82072-782f-4f62-b134-7d1e9daaefd2",
            "name": "Osaka Metropolitan University Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "86",
            "organizationId": "75c8749f-3cc1-477a-962e-1ad35ba999e3",
            "country": "Japan"
          },
          {
            "id": "e8a7bf5f-d228-4c9e-ade4-049de492fcb3",
            "name": "Kindai University Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "87",
            "organizationId": "fe660a29-d160-4f59-a7d3-656000a823a6",
            "country": "Japan"
          },
          {
            "id": "00eab02f-7a27-44a2-a022-737ca9c910ff",
            "name": "Saga-ken Medical Centre Koseikan",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "88",
            "organizationId": "ea1eb071-c4c6-4215-a96a-fb910fa12a25",
            "country": "Japan"
          },
          {
            "id": "f380e07e-76bb-4649-886c-dbf8a0cd0efa",
            "name": "Shizuoka Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "89",
            "organizationId": "748bdc8c-faac-4671-aff2-e688fd102f8e",
            "country": "Japan"
          },
          {
            "id": "629916c9-d4b8-4a0d-85e4-d2a0338f6339",
            "name": "Japanese Red Cross Musashino Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "90",
            "organizationId": "b236d452-b8aa-4c48-bd32-688bc6d36d41",
            "country": "Japan"
          },
          {
            "id": "58d8b344-6045-4986-9a9b-ce72d9689c81",
            "name": "Copernicus Podmiot Medyczny Sp. z o.o. Wojewodzkie Centrum Onkologii",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "91",
            "organizationId": "4d400187-4916-44ca-86c0-637c3c269f68",
            "country": "Poland"
          },
          {
            "id": "1698f7e9-9bc8-4bd9-97de-753d83a68518",
            "name": "ID Clinic",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "92",
            "organizationId": "5dd69e30-bbf1-415d-86a6-0107d959428a",
            "country": "Poland"
          },
          {
            "id": "d126e1e7-4d9e-47b8-930a-4cb5613c73ad",
            "name": "SP ZOZ MSWiA z WARMINSKO-MAZURSKIM CENTRUM ONKOLOGII; CLINICAL ONCOLOGY, CLINICAL IMMUNOLOGY",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "93",
            "organizationId": "e3e9590e-ffda-4ae6-8f18-5bf56f2098f6",
            "country": "Poland"
          },
          {
            "id": "013bc4bb-74d3-4fd3-911d-6018306902b7",
            "name": "Narodowy Instytut Onkologii im. Marii Sk?odowskiej-Curie - Pa?stwowy Instytut Badawczy",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "94",
            "organizationId": "308956f2-7d83-4afc-a56e-40ae8d642f2a",
            "country": "Poland"
          },
          {
            "id": "1559a02c-651c-49f5-b12a-f8466cdf3ac3",
            "name": "Dolno?l?skie Centrum Onkologii; Oddzia? Onkologii Klinicznej i Chemioterapii",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "95",
            "organizationId": "54411576-ef65-4094-971c-1760a524b6d9",
            "country": "Poland"
          },
          {
            "id": "17d9ba7b-d8e6-4281-a424-27c20fa664f1",
            "name": "FSBI \"National Medical Research Center of Oncology N.N. Blokhin?; Clinical Biotechnologies",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "96",
            "organizationId": "21b3f2ef-47ce-401f-8d89-48f75f360695",
            "country": "Russia"
          },
          {
            "id": "7b4203f4-5825-4f7e-aceb-3aad08e93b85",
            "name": "GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "97",
            "organizationId": "ee4ef1d6-abd9-43c1-9ff9-c6bbc588c538",
            "country": "Russia"
          },
          {
            "id": "8cc4ffef-6915-4a29-8abe-ab8fa4aa3bb8",
            "name": "National Cancer Centre",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "98",
            "organizationId": "96a416df-2c97-4ec7-9980-2fcdc154e4b1",
            "country": "Singapore"
          },
          {
            "id": "6f48e0a1-4f12-4cee-8a32-d96be00a1bfa",
            "name": "Tan Tock Seng Hospital; Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "99",
            "organizationId": "36d4a223-f38b-44f4-8c9e-1972559ef62f",
            "country": "Singapore"
          },
          {
            "id": "5494c8f9-228e-4e7f-a0c4-3292a92b28d4",
            "name": "Chonnam National University Hwasun Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "100",
            "organizationId": "7a945c64-4077-4448-aced-41bba8697f36",
            "country": "South Korea"
          },
          {
            "id": "e19b2600-7d28-4f28-98a4-76d00f667788",
            "name": "Seoul National University Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "101",
            "organizationId": "b4e692e7-667a-4b4b-abc1-4e720f1f853d",
            "country": "South Korea"
          },
          {
            "id": "aa081a02-a8f1-4ea3-9841-894469caaa51",
            "name": "Severance Hospital, Yonsei University Health System",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "102",
            "organizationId": "f25be671-0e64-48de-a26a-d42d832ca503",
            "country": "South Korea"
          },
          {
            "id": "b5439c47-3f07-46d8-a10a-fa309e21911f",
            "name": "Asan Medical Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "103",
            "organizationId": "a69d8367-574b-4e12-9f69-fb9a21b29de7",
            "country": "South Korea"
          },
          {
            "id": "fc4bf6eb-0855-4afe-872b-96122010ca28",
            "name": "Samsung Medical Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "104",
            "organizationId": "45715435-60e3-4043-91c8-591d029bbae8",
            "country": "South Korea"
          },
          {
            "id": "741947e7-9629-4d26-b343-25c9e6baf4cc",
            "name": "Ulsan University Hosiptal",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "105",
            "organizationId": "33945e80-e42a-45f9-88af-12d6b45361a1",
            "country": "South Korea"
          },
          {
            "id": "da12e43c-7f15-4642-af1a-971d37d29e92",
            "name": "Hospital Universitari Vall d'Hebron; Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "106",
            "organizationId": "23748e5f-f6aa-4f2f-9dda-b6a6a19b402d",
            "country": "Spain"
          },
          {
            "id": "655e13fa-cea6-4d9b-802a-07dd9f21c572",
            "name": "Hospital Clinico San Carlos; Servicio de Oncologia",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "107",
            "organizationId": "438a760f-141d-49d6-a2ec-13c960c9321a",
            "country": "Spain"
          },
          {
            "id": "052a32e7-1a8c-4228-8358-94f77afb41cc",
            "name": "Hospital Universitario La Paz; Servicio de Oncologia",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "108",
            "organizationId": "a3032da6-943a-42f4-866c-71ab7db02b46",
            "country": "Spain"
          },
          {
            "id": "65583c76-7990-4f5f-b179-3a90621f0566",
            "name": "Centro Integral Oncologico Clara Campal; Servicio de Oncologa",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "109",
            "organizationId": "e4c80eb7-4a64-49bf-92b8-fe145e8e5e97",
            "country": "Spain"
          },
          {
            "id": "860076af-0a0b-4beb-8baa-3cee9f94d7ae",
            "name": "Hospital Universitario Miguel Servet; Servicio de Oncologia Medica",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "110",
            "organizationId": "7a71e546-3505-48ae-b4bf-1480a319b2cf",
            "country": "Spain"
          },
          {
            "id": "e21fd37e-6f52-486a-8dd7-317a0c308ee5",
            "name": "National Cheng Kung University Hospital; Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "111",
            "organizationId": "0d851b26-e109-4037-9f80-cd9b1ed2302d",
            "country": "Taiwan"
          },
          {
            "id": "b1ae4b3e-c2e4-4c86-a990-21fb3a68a26c",
            "name": "Chi-Mei Medical Centre; Hematology & Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "112",
            "organizationId": "59e831c6-882e-4672-8a81-5c79e483b536",
            "country": "Taiwan"
          },
          {
            "id": "2d5a708b-7195-4eef-807e-6f1fdf04a7d7",
            "name": "Veterans General Hospital; Cancer Center",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "113",
            "organizationId": "802a86d9-4ccf-4f78-b38a-4205cc380af0",
            "country": "Taiwan"
          },
          {
            "id": "7152b60a-c9e4-441c-b18b-c91f49f1423f",
            "name": "National Taiwan Uni Hospital; Dept of Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "114",
            "organizationId": "65044fcd-8c83-4387-b746-b923e0b4595f",
            "country": "Taiwan"
          },
          {
            "id": "d0fabdf7-6ab9-46ec-a318-2c61901fd599",
            "name": "Chang Gung Memorial Hospital-Linkou; Dept of Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "115",
            "organizationId": "7a0f2096-b7d0-4880-9de7-f9fd9cf2113b",
            "country": "Taiwan"
          },
          {
            "id": "07945e6f-19c4-489d-b157-b5e0f3890676",
            "name": "Beatson West of Scotland Cancer Centre",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "116",
            "organizationId": "a5f087be-a9c9-4770-a512-750acf1f3167",
            "country": "United Kingdom"
          },
          {
            "id": "9e9303db-d4f7-47b9-b06e-25ef06af942a",
            "name": "Royal Free Hospital; Dept of Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "117",
            "organizationId": "bec7dd56-9000-40aa-af49-896a5f1854fc",
            "country": "United Kingdom"
          },
          {
            "id": "21dffb22-b5b7-410c-b246-56613aedf62f",
            "name": "King'S College Hospital",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "118",
            "organizationId": "7f1e175c-e265-4495-89fa-2448b62e46ea",
            "country": "United Kingdom"
          },
          {
            "id": "433e9f5f-02ca-40e7-be73-d41814d97a8c",
            "name": "Christie Hospital Nhs Trust; Medical Oncology",
            "status": "Completed",
            "instanceType": "StudySite",
            "siteNumber": "119",
            "organizationId": "d993914f-a7b4-4c7f-b3bc-cc278e8c527f",
            "country": "United Kingdom"
          }
        ],
        "administrations": [
          {
            "id": "390ffdd1-663c-4df6-bdfa-084973579f61",
            "name": "Administration of Atezolizumab",
            "description": "RouteOfAdministration.ORAL DosingFrequency.TWICE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "6e30a430-03c0-4420-99d6-b2feb463624a",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "efcd809f-cfd6-4a40-ac57-aa1bc86df138",
            "name": "Administration of Sorafenib",
            "description": "RouteOfAdministration.ORAL DosingFrequency.TWICE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "0fc9d163-4c7e-4764-80f0-b50ea40bba2b",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "bd3683af-4172-42e8-a6d2-23742cf12d98",
            "name": "Administration of Patients received",
            "description": "RouteOfAdministration.ORAL DosingFrequency.EVERY_THREE_WEEKS",
            "instanceType": "Administration",
            "route": {
              "id": "e8230cbd-b7b2-4cb1-8b1b-89dc1982a8f4",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "2963953f-047a-445c-954d-89e320f0307a",
            "name": "Administration of Bevacizumab",
            "description": "RouteOfAdministration.INTRAVENOUS DosingFrequency.EVERY_THREE_WEEKS",
            "instanceType": "Administration",
            "route": {
              "id": "b5ea78c0-4312-4b8d-aa13-d217fffd5db6",
              "code": "C38276",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Intravenous",
              "instanceType": "Code"
            }
          }
        ],
        "rationale": "Protocol version"
      }
    ],
    "name": "A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA"
  },
  "administrations": [
    {
      "id": "4089673c-4b0e-40d3-b514-f4304e3f835f",
      "name": "Arm A: Atezolizumab",
      "instanceType": "Administration",
      "dose": "1200 mg",
      "doseFrequency": "Every 3 weeks (Q3W)",
      "route": {
        "id": "13d71e02-9ca2-4b74-bb05-b34ea7b5f596",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Until unacceptable toxicity or loss of clinical benefit"
    },
    {
      "id": "118fc8d8-0dd6-4002-9cc1-fcd65138e68a",
      "name": "Arm A: Bevacizumab",
      "instanceType": "Administration",
      "dose": "15 mg/kg",
      "doseFrequency": "Every 3 weeks (Q3W)",
      "route": {
        "id": "5f8fe32f-b4f0-4018-9355-378f3775e67d",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Until unacceptable toxicity or loss of clinical benefit"
    },
    {
      "id": "06ccd58b-4217-4ea7-baea-202fc733d349",
      "name": "Arm B: Sorafenib",
      "instanceType": "Administration",
      "dose": "400 mg",
      "doseFrequency": "Twice a day (BID)",
      "route": {
        "id": "ce2e6495-624c-42d9-aff0-520ecb43a850",
        "code": "Oral",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Oral",
        "instanceType": "Code"
      },
      "duration": "Continuously until unacceptable toxicity or loss of clinical benefit"
    }
  ],
  "substances": [
    {
      "id": "7ea56a21-406e-4ad1-aee8-b75529654a77",
      "name": "Atezolizumab",
      "instanceType": "Substance",
      "description": "Anti-PD-L1 monoclonal antibody"
    },
    {
      "id": "ddad6715-11a5-4cf8-a6dd-75d2cdb8f6d3",
      "name": "Bevacizumab",
      "instanceType": "Substance",
      "description": "Anti-VEGF monoclonal antibody"
    },
    {
      "id": "a0980589-6d28-40f4-8502-74081b77c892",
      "name": "Sorafenib",
      "instanceType": "Substance",
      "description": "Multi-kinase inhibitor"
    }
  ],
  "studyDefinitionDocument": {
    "id": "6845a41f-5fcc-4a0c-9913-f97ac01c833f",
    "name": "A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "6",
    "contentIds": [
      "5799633c-82cb-49f2-a096-d3a2406f945b",
      "664ee37a-964f-4d18-b887-1afbde9bf25e",
      "308ed2ad-0d85-447c-8563-d6ae77a54dac",
      "56461abe-a3c2-4f5b-917a-bcfdba2927ae",
      "8e4046f3-4de9-45ca-aac6-0a4735d2e96e",
      "197546be-9acc-44fa-844a-8a019de1fb35",
      "ef0a2561-e1b4-49c5-9889-b9ae4601fc6d",
      "1f9ebf83-6eca-4ac0-b30a-46c2db7a55ec",
      "0227efa1-5fdc-4d6b-9d4c-ba10bd402f9b",
      "24d86042-ef93-4660-971c-e030c91bbe33",
      "eefc5e6e-a7ac-49a6-ae44-8e9e7bc87cf7",
      "b052ce3a-bcc7-4ea4-bb3f-cb155c991fee",
      "28309b80-75b6-4fd8-b83b-9c90b8dae06b",
      "460f19e5-d188-46f1-9e65-16d74a6640c3",
      "3fba2bdf-f390-4d6c-8a2f-2bfd75e75cea",
      "f5afacc8-b569-4053-b514-ffe11b882dd7",
      "89007ce2-9929-477d-ae9b-85a6b2db9c81"
    ]
  },
  "geographicScope": {
    "id": "0c8b47c5-efec-42f5-a27d-f13f085f80a5",
    "name": "Study Geographic Scope",
    "scopeType": "Global",
    "instanceType": "GeographicScope",
    "countryIds": [
      "554ffed3-3cf7-47ca-a4db-58fd3062f862",
      "c1a63c5f-22ac-44c9-9359-b4ce2ff04109",
      "8a44bdc4-6e78-4194-952d-0c2218160ee9"
    ],
    "regions": [
      "Global",
      "Mainland China"
    ]
  },
  "countries": [
    {
      "id": "554ffed3-3cf7-47ca-a4db-58fd3062f862",
      "name": "Switzerland",
      "instanceType": "Country",
      "code": "CH"
    },
    {
      "id": "c1a63c5f-22ac-44c9-9359-b4ce2ff04109",
      "name": "United States",
      "instanceType": "Country",
      "code": "US"
    },
    {
      "id": "8a44bdc4-6e78-4194-952d-0c2218160ee9",
      "name": "China",
      "instanceType": "Country",
      "code": "CN"
    }
  ],
  "ingredients": [
    {
      "id": "9cc90494-ddfe-4dd9-8db0-2f1f4de6488e",
      "name": "Atezolizumab",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "49e991d6-70f1-4432-976b-4ddb189bd7e4"
    },
    {
      "id": "5ab98a25-1695-4b20-9897-e067829addda",
      "name": "Bevacizumab",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "b6e18eab-9256-4667-b1cb-cecb49f3bfb3"
    },
    {
      "id": "e0e09912-7ab3-423f-90a6-4ae9c4c4e389",
      "name": "Sorafenib",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "0bfd68d2-6e4d-4bcb-bbf2-b9331de3625b"
    },
    {
      "id": "6a3d28c1-ee62-4a0e-b4af-2be7e9f87a78",
      "name": "Chinese hamster ovary cell products",
      "role": "Inactive",
      "instanceType": "Ingredient",
      "substanceId": "7558c807-02d4-4f32-82ce-04fc3365fd40"
    }
  ],
  "strengths": [
    {
      "id": "9ce3a4ec-4135-445e-8b07-0c810c36f88b",
      "instanceType": "Strength",
      "value": 1200,
      "unit": "mg",
      "numerator": {
        "value": 1200,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "dose"
      }
    },
    {
      "id": "3537abf1-4d62-4cda-9a57-38c8382e26e7",
      "instanceType": "Strength",
      "value": 15,
      "unit": "mg/kg",
      "numerator": {
        "value": 15,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "kg"
      }
    },
    {
      "id": "448de39f-b81b-4d31-ac87-baef8ea71c86",
      "instanceType": "Strength",
      "value": 400,
      "unit": "mg",
      "numerator": {
        "value": 400,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "dose"
      }
    }
  ],
  "transitionRules": [
    {
      "id": "618c9b68-d956-4f62-b53c-05d6e5291e3a",
      "name": "Screening to Randomization",
      "instanceType": "TransitionRule",
      "transitionType": "Epoch Transition",
      "fromElementId": "9532f11c-b073-4095-8285-752ac6e6acbc",
      "toElementId": "84d31fe4-ff74-4826-9db7-fdb4efc463ec",
      "text": "Must meet all inclusion/exclusion criteria including laboratory and performance status within 7 days of randomization."
    },
    {
      "id": "d61d7b16-3931-40e5-bd03-2033dcf95135",
      "name": "Treatment Discontinuation",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Treatment until unacceptable toxicity or loss of clinical benefit as determined by investigator."
    }
  ],
  "documentContentReferences": [
    {
      "id": "85534d50-6bcf-47fd-affb-fe2a8eddf9f1",
      "name": "OS Analysis Clarification",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "6.1, 6.4.1.1, 6.10",
      "sectionTitle": "Statistical Analysis Sections",
      "description": "Clarification of descriptive and optional nature of subsequent overall survival analyses"
    },
    {
      "id": "8d8e5e7d-11c3-4b45-ad92-129c5ff7b5d4",
      "name": "Safety Plan Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.1.1",
      "sectionTitle": "Atezolizumab Risks",
      "description": "Reference to Severe Cutaneous Adverse Reactions added as a risk"
    },
    {
      "id": "a2a13ac1-97c5-4678-bff7-50b963c533f8",
      "name": "COVID-19 Considerations",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "1.6.3",
      "sectionTitle": "COVID-19 Considerations",
      "description": "New section added to describe COVID-19-related risks"
    },
    {
      "id": "b053c222-8edb-4e30-86ec-d20b37ff9516",
      "name": "Exclusion Criteria Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "4.1.2",
      "sectionTitle": "Exclusion Criteria",
      "description": "Updated criteria regarding severe infection and investigator opinion"
    },
    {
      "id": "1faa365a-c639-4893-b308-9403ba982608",
      "name": "Safety Plan COVID Update",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.1",
      "sectionTitle": "Safety Plan",
      "description": "Inclusion of COVID-19 risk language regarding active infection"
    },
    {
      "id": "0bef995c-81d0-48f2-b66d-62ac956e7d37",
      "name": "Tumor Assessment Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "4.5.5",
      "sectionTitle": "Tumor and Response Evaluations",
      "description": "Reference for tumor assessment intervals"
    },
    {
      "id": "21055f4f-980c-4f78-bf67-c1e076ccf246",
      "name": "Schedule of Activities Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 1",
      "sectionTitle": "Schedule of Activities",
      "description": "Reference for timing of study assessments and procedures"
    },
    {
      "id": "335a5bb0-87c2-46ee-bd43-4c92164f30e5",
      "name": "Study Design Schema",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Figure 1",
      "sectionTitle": "Study Schema",
      "description": "Visual overview of the study design"
    },
    {
      "id": "75ff40d7-0329-4f1d-b417-04349e9bcee8",
      "name": "AASLD Criteria Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "Appendix 13",
      "sectionTitle": "Algorithm for Investigation of Small Nodules",
      "description": "Criteria for HCC diagnosis in cirrhotic patients"
    }
  ],
  "commentAnnotations": [
    {
      "id": "bcdc476c-d318-46ab-9b34-d2594374970c",
      "text": "Caution should be used in patients who have previously experienced a severe or life-threatening atezolizumab skin adverse reaction",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Appendix 8",
      "pageNumber": 2
    },
    {
      "id": "112d803e-082c-4859-8454-dd7b494ce7e8",
      "text": "Substantive new information appears in italics.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Rationale for Amendment",
      "pageNumber": 2
    },
    {
      "id": "6ac91df9-96c0-4875-8b21-054610cd6a69",
      "text": "Patients may be transfused to meet this criterion (Hemoglobin >= 90 g/L).",
      "annotationType": "Footnote",
      "instanceType": "CommentAnnotation",
      "sourceSection": "4.1.1 Inclusion Criteria",
      "pageNumber": 52
    },
    {
      "id": "3f25ab8a-acfb-4890-85cc-7a3cb6953a6e",
      "text": "Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 5 minutes between dosing.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Table 2: Study Treatment Regimens",
      "pageNumber": 60
    }
  ],
  "studyDefinitionDocumentVersions": [
    {
      "id": "6028b34e-33a5-483c-a4c6-f6cb6da4f8d0",
      "versionNumber": "1",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2017-10-18",
      "description": "Initial Protocol",
      "amendmentNumber": "Original"
    },
    {
      "id": "95d77dec-ec6b-4d71-a31a-9983bd26cf3e",
      "versionNumber": "6",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2021-02-01",
      "description": "Primary alignment with Atezolizumab Investigators Brochure Version 17 and COVID-19 updates",
      "amendmentNumber": "Amendment 6"
    }
  ],
  "studyAmendmentImpacts": [
    {
      "id": "eb91d788-712c-4076-80a2-7ef9571c493c",
      "amendmentId": "d95d6126-38ad-45e7-9f7a-c4390a7ab70b",
      "affectedSection": "Section 6.1, 6.4.1.1, 6.10",
      "impactLevel": "Minor",
      "instanceType": "StudyAmendmentImpact",
      "description": "Clarified the descriptive and optional nature of subsequent overall survival (OS) analyses after statistical significance is reached."
    },
    {
      "id": "5426bca4-daa6-46fb-ad8a-8187eee60e7a",
      "amendmentId": "d95d6126-38ad-45e7-9f7a-c4390a7ab70b",
      "affectedSection": "Section 5.1.1, Appendix 8",
      "impactLevel": "Major",
      "instanceType": "StudyAmendmentImpact",
      "description": "Added Severe Cutaneous Adverse Reactions (SCARs) as a risk associated with atezolizumab."
    },
    {
      "id": "8c134ce7-6f0e-45a2-85a0-878b4034ba19",
      "amendmentId": "d95d6126-38ad-45e7-9f7a-c4390a7ab70b",
      "affectedSection": "Section 1.6.3, 5.1, Appendix 12",
      "impactLevel": "Major",
      "instanceType": "StudyAmendmentImpact",
      "description": "Integration of COVID-19 risk considerations and management guidelines."
    },
    {
      "id": "6e344dd0-afd4-416f-b7ba-b423a469d28c",
      "amendmentId": "d95d6126-38ad-45e7-9f7a-c4390a7ab70b",
      "affectedSection": "Section 4.1.2 - Exclusion Criteria",
      "impactLevel": "Minor",
      "instanceType": "StudyAmendmentImpact",
      "description": "Expanded exclusion criteria for severe infections to include investigator discretion regarding patient safety."
    }
  ],
  "studyAmendmentReasons": [
    {
      "id": "1320000f-27e4-438a-8cb0-141356025845",
      "amendmentId": "d95d6126-38ad-45e7-9f7a-c4390a7ab70b",
      "reasonText": "Align with updates in the Atezolizumab Investigators Brochure, Version 17.",
      "category": "Scientific",
      "isPrimary": true,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "8949d5c1-f60e-4c2c-8f05-fcb4b1dc4c66",
      "amendmentId": "d95d6126-38ad-45e7-9f7a-c4390a7ab70b",
      "reasonText": "Address risks and operational considerations related to the COVID-19 pandemic.",
      "category": "Safety",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "b4419bb4-dd6c-498a-b475-0fba3ad07a0a",
      "amendmentId": "d95d6126-38ad-45e7-9f7a-c4390a7ab70b",
      "reasonText": "Improve clarity and consistency of the protocol document.",
      "category": "Administrative",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    }
  ],
  "studyChanges": [
    {
      "id": "2f919c1e-ede9-43c5-9978-572a38160afa",
      "amendmentId": "d95d6126-38ad-45e7-9f7a-c4390a7ab70b",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "1.6.3",
      "afterText": "Section 1.6.3, COVID-19 Considerations, has been added to describe COVID-19-related risks",
      "summary": "New section added to address pandemic-related risks."
    },
    {
      "id": "b4fc2bcc-d19d-4423-a7eb-733e33b66291",
      "amendmentId": "d95d6126-38ad-45e7-9f7a-c4390a7ab70b",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "4.1.2",
      "beforeText": "Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia",
      "afterText": "Severe infection within 4 weeks... updated to include any active infection that, the opinion of the investigator, could impact patient safety",
      "summary": "Broadened exclusion criteria for infections based on investigator judgment."
    },
    {
      "id": "f0faa78d-495b-4822-87a9-fc3dfa4a5180",
      "amendmentId": "d95d6126-38ad-45e7-9f7a-c4390a7ab70b",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "Appendix 12",
      "beforeText": "Management Guidelines for Dermatologic Events",
      "afterText": "Updated management guidelines for Grade 3 dermatologic events and new guidelines for Stevens-Johnson syndrome or toxic epidermal necrolysis of any grade",
      "summary": "Updated safety management protocols for severe skin reactions."
    },
    {
      "id": "0da58cae-90f5-4364-8a1d-9a7888ef9735",
      "amendmentId": "d95d6126-38ad-45e7-9f7a-c4390a7ab70b",
      "changeType": "Clarification",
      "instanceType": "StudyChange",
      "sectionNumber": "6.1",
      "beforeText": "Pre-planned interim analyses of OS",
      "afterText": "Descriptive and optional nature of subsequent OS analyses once statistical significance is reached",
      "summary": "Clarified statistical approach for OS following positive interim results."
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "complete"
  }
}